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Abstract 
Malaria, caused by apicomplexan parasites of the Plasmodium species, is 
one of the deadliest infectious diseases worldwide. Despite the urgent need to 
identify new drug targets and vaccine candidates, a large proportion of the 
Plasmodium genes are uncharacterized, as tools to study gene function are 
limited. In many eukaryotes, genes can be silenced via RNA interference (RNAi) 
using artificial short hairpin RNAs (shRNAs). However, Plasmodium parasites 
lack the machinery required for RNAi. In this study, I therefore engineered a 
non-canonical RNAi machinery into the rodent parasite Plasmodium berghei 
(P. berghei). 
To this end, I exploited a non-canonical RNAi pathway which requires only 
a single protein, Argonaute 2 (Ago2), and a specifically designed shRNA, a so-
called AgoshRNA, for gene silencing. I generated a P. berghei line constitutively 
expressing Ago2, named PbAgo2, and demonstrated that this parasite can 
complete its life cycle through the mammalian and insect host, despite 
exhibiting a reduced growth in blood and mosquito stages.  Expression of 
AgoshRNAs targeting the mRNA of the green fluorescent protein GFP 
(constitutively expressed by PbAgo2) induced a potent knockdown of GFP both 
in blood and in non-erythrocytic stages. As different AgoshRNAs mediated gene 
silencing to various levels, target gene expression could be fine-tuned. 
AgoshRNA-mediated gene knockdown was also possible for endogenous genes, 
and the knockdown of a non-essential gene phenocopied the full knockout. 
Additionally, the expression of a blood-stage-essential gene was reduced using 
RNAi. The analysis of the transcriptome of PbAgo2 by RNA sequencing 
suggested a possible interaction between Ago2 and a Plasmodium mRNA 
storage protein as a putative reason for the growth impairment. To further 
increase the potential applications of the RNAi-competent parasite, Ago2 
expression was restricted to the liver stage using a stage-specific promoter. 
This transgenic line behavee indistinguishable from wild type and the 
expression of an AgoshRNA targeting GFP silenced fluorescence exclusively in 
late liver stages.   
In summary, PbAgo2 is a potent tool to modulate gene expression without 
the need to alter the genetic locus. In contrast to existing tools, PbAgo2 
provides the option to target genes exclusively in a single life cycle stage, to 
multiplex different AgoshRNAs enabling the simultaneous knockdown of 
multiple genes, or to screen for phenotypes using a library of AgoshRNAs.  This 
novel, RNAi-competent parasite line opens a wealth of new options to annotate 
genes in Plasmodium. 
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Zusammenfassung 
Malaria, verursacht von Plasmodium-Parasiten, ist eine der tödlichsten 
Infektionskrankheiten weltweit. Die Funktion vieler Plasmodium-Gene ist 
unbekannt, obwohl dieses Wissen für die Entwicklung neuer Medikamente und 
Impfstoffe unabdingbar ist. Ein Grund dafür ist, dass nur wenige Technologien 
eine gezielte Manipulation der Genexpression ermöglichen. In vielen 
Eukaryoten nutzt man RNA-Interferenz (RNAi) zur Unterdrückung der 
Genexpression mittels kurzer RNA-Moleküle (short hairpin RNAs, shRNAs). 
Plasmodium-Parasiten haben diesen RNAi Mechanismus jedoch nicht. In der 
vorliegenden Arbeit wurde RNAi deshalb in den murinen Erreger Plasmodium 
berghei (P. berghei) eingeführt. 
Dazu habe ich einen alternativen RNAi-Mechanismus genutzt, in dem das 
Protein Argonaute 2 (Ago2) und eine spezielle shRNA, eine sogenannte 
AgoshRNA, ausreichend sind, um Genexpression zu inhibieren. Die in dieser 
Arbeit entwickelte P. berghei-Linie PbAgo2, die Ago2 sowie das grün 
fluoreszierende Protein GFP konstitutiv exprimiert, durchlief trotz eines 
Wachstumsdefekts in Blut- und Mosquitostadien den Lebenszyklus vollständig. 
Die Expression von AgoshRNAs gegen die mRNA von GFP reduzierte die 
Fluoreszenz von Parasiten in allen Stadien und unterschiedliche AgoshRNAs 
modulierten die Stärke dieser Genrepression. Auch endogene Gene konnten 
mittels RNAi inhibiert werden, und die Inhibition eines nicht-essentiellen Gens 
hatte den gleichen Phänotyp wie die vollständige Abschaltung des Gens. Die 
Analyse des Transkriptoms von PbAgo2 mittels RNA-Sequenzierung deutet 
darauf hin, dass Ago2 mit einem Plasmodium mRNA-Speicherprotein 
interagieren könnte und so möglicherweise den Wachstumsdefekt verursacht. 
Um die Anwendungsmöglichkeiten des RNAi-kompetenten Parasiten zu 
erweitern, wurde in einer zweiten transgenen Linie Ago2 spezifisch in 
Leberstadien exprimiert. Diese Linie hat keinen Wachstumsdefekt und 
ermöglichte es, GFP Expression ausschließlich in Leberstadien zu inhibieren.  
Zusammengefasst bietet der PbAgo2-Parasit eine vielseitige Technologie, 
um Gene in Plasmodium zu regulieren ohne dafür den genetischen Lokus zu 
modifizieren. Im Gegensatz zu aktuellen Technologien ermöglicht es PbAgo2, 
ein Gen nur in einem spezifischen Stadium des Lebenszyklus zu inhibieren, 
mehrere Gene parallel durch Expression mehrerer AgoshRNAs zu regulieren, 
oder Screenings durchzuführen. Dieser neuartige RNAi-kompetente Parasit 
eröffnet somit neue Möglichkeiten, Genfunktionen in Plasmodium zu 
erforschen.  
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 Introduction 
1.1 MALARIA, A DEADLY DISEASE  
“I was still hesitating whether these elements were parasites, when on 
November 6th, 1880, on examining the pigmented spherical bodies mentioned 
above, I observed […] moveable filaments or flagella, whose extremely rapid and 
varied movements left no doubt as to their nature.”1 
~ Charles Louis Alphonse Laveran (1845-1922)  
Malaria, caused by parasites of the Plasmodium genus, continues to be a 
devastating disease. In 2015, an estimated 214 million people worldwide were 
infected with malaria, and about 438,000 people died due to the infection3. 
Years of intense research have yielded potent anti-malarial drugs such as the 
artemisinin combination therapy (ACT), which is now the recommended 
therapy for Plasmodium infection4, and even resulted in the development of a 
vaccine against malaria, RTS,S5. However, the rapid rise of drug resistance in 
malaria parasites remains problematic, and there are already first studies 
reporting ACT-resistant parasites6–8. The RTS,S vaccine, on the other hand, has 
a relatively low efficacy ranging from 25 % to 55 %, which further decreases 
over time5,9. Therefore, the use of insecticide-treated bed nets is still the most 
effective method to prevent morbidity and mortality caused by malaria3.  
There are more than 200 Plasmodium species known, all of which have a 
vertebrate host (mammals, birds or reptiles) and an invertebrate host 
(mosquitoes). Five Plasmodium species, Plasmodium falciparum (P. falciparum), 
P. vivax, P. malariae, P. ovale and P. knowlesi, are known to infect humans. All of 
them are transmitted by biting mosquitoes of the Anopheles genus. With the 
exception of P. knowlesi, which is zoonotic, there are no animal reservoirs of 
Plasmodium, making the eradication of malaria, in theory, feasible. However, 
more basic research is required to understand the biology of the parasites, in 
turn enabling the identification of new drug targets and vaccine candidates.  
Rodent-infecting malaria species, such as P. berghei, P. chabaudi or P. yoelii, 
have proven to be of tremendous value for malaria research, as these species 
allow to study malaria infection in mouse models and to maintain the complete 
life cycle of Plasmodium under laboratory conditions. Many findings of rodent 
parasites, although not all, could later be validated in human Plasmodium 
species11,12. 
 
Malaria comes from the 
Italian term mala aria, 
bad air, and refers to the 
initial assumption that 
the disease is transmitted 
by the air of swampy 
regions2.  
 
 
The name Anopheles 
comes from the Greek αν, 
an, (“not”), and όφελος, 
óphelos, (“benefit”), and 
translates to “useless”10.  
1 
2 INTRODUCTION  
 
1.2 THE MALARIA LIFE CYCLE 
This Section will give a general overview of the life cycle of Plasmodium 
parasites through the mammalian and mosquito host. A summary is depicted in 
in Figure 1. 
 
FIGURE 1: Life cycle of human malaria parasites. Sporozoites are transmitted into the 
skin of the mammalian host by the bite of an infected mosquito. After entering the 
bloodstream, they reach the liver where they establish an infection within hepatocytes. 
Liver stages mature into thousands of merozoites, which are released into the 
bloodstream to invade erythrocytes. Within the erythrocytes, parasites undergo 
multiple rounds of asexual replication, yielding more merozoites to invade more red 
blood cells. Occasionally, parasites differentiate into female and male gametocytes. 
When these are taken up by another mosquito bite, they will fertilize and develop into a 
motile ookinete. The ookinete then traverses the midgut and forms an oocyst just 
outside of the midgut wall. Within the oocyst, sporozoites develop (sporogeny), that 
upon rupture of the oocysts, are released into the hemolymph from where they invade 
the salivary glands. There, sporozoites await the transmission to the next mammalian 
host by another mosquito bite. Image modified from www.euvaccine.eu/vaccines-
diseases/diseases-of-poverty/malaria.  
1.2.1 ESTABLISHING AN INFECTION 
Infection of the mammalian host begins with the bite of a Plasmodium-
infected mosquito, through which so-called sporozoites are injected into the 
skin of the new host. These banana-shaped, motile parasite stages move 
through the skin in search of a blood vessel to invade. Only a third of the 
transmitted sporozoites actually penetrate a capillary13 and are subsequently 
carried away with the bloodstream until they reach the liver. In the liver 
sinusoids, sporozoites interact with heparin sulfate proteoglycans (HSPGs)14 as 
well as additional receptors. They then attach to the endothelium and penetrate 
it by traversing through either Kupffer cells or liver sinusoidal endothelial cells 
(LSECs)15–17. After transmigration of several hepatocytes, sporozoites establish 
a persistent infection within a hepatocyte17,18. The latter occurs by invagination 
of the hepatocyte membrane, forming a parasitophorous vacuole (PV) around 
the parasite that physically shields it from the host cytoplasm.  
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1.2.2 THE LIVER STAGE 
Once inside the hepatocyte, sporozoites de-differentiate and develop into a 
so-called liver stage, or extra-erythrocytic form (EEF). The parasites scavenge 
nutrients from the host, such as apolipoprotein H (ApoH)19 and 
phosphatidylcholine20, to support their massive growth, and exploit host 
pathways such autophagy (reviewed by Graewe et al., 201121 and Kaushansky 
and Kappe, 201522). Despite highly dynamic host-parasite interactions at this 
stage, liver stage infections are clinically silent and do not cause disease 
symptoms. This is partially due to the fact that, in general, the liver is an 
immune privileged organ23. Additionally, only a very low number of liver stages 
result from a single infection, and the parasites effectively hide within their PV. 
Nevertheless, the host mounts an innate immune response to hepatic 
infection24. Arresting parasite development at this stage of the life cycle, e. g. by 
disrupting a gene essential for liver stage development, elicits a robust and 
protective immune response. This liver-stage attenuation is the basis of all 
vaccine candidates that induce sterile protection in human clinical trials, such 
as radiation-attenuated sporozoites (RAS)25,26, genetically attenuated parasites 
(GAP)27 or sporozoite infection under drug cover28 (reviewed e. g. by Bijker et 
al., 201529).  
Parasites complete their intrahepatic development with a massive 
proliferation, during which thousands of daughter cells, so-called merozoites, 
are formed in a single liver stage. For this enormous asexual replication, the 
parasite undergoes several rounds of DNA replication and nuclear division 
without a subsequent cytokinesis, yielding a large syncytium, the 
multinucleated schizont. Then, daughter cells are formed by invagination of the 
plasma membrane that separates the nuclei from each other, resulting in up to 
30,000 individual merozoites21. After merozoite formation is completed, the 
parasitophorous vacuolar membrane (PVM) is dissociated, while the host cell 
membrane stays intact, triggering the death of the host cell30,31.  
From the infected hepatocytes, merosomes (membrane-enclosed vesicles 
containing thousands of merozoites) bud off into the bloodstream30,32. Through 
the circulation, they reach the pulmonary capillaries of the lung, where the 
merosomes rupture and the freed merozoites can infect the red blood cells 
(RBCs) surrounding them33. Invasion of RBCs occurs in a sequential manner 
(reviewed by Koch and Baum, 201634). Parasites attach through one of several 
possible receptor-ligand interactions to the erythrocyte membrane and re-
orient themselves such that their apical tips face the erythrocyte membrane. 
The subsequent release of the content of micronemes and rhoptries 
(specialized secretory organelles of apicomplexan parasites) causes the 
formation of a tight junction through which parasites pull themselves actively 
into the RBC. As in hepatocytes, the parasite surrounds itself with a PV to shield 
it from the host cytoplasm. 
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1.2.3 THE BLOOD STAGE 
In the erythrocyte, the parasite initiates a cycle of asexual replication, 
leading to the formation of new merozoites. Initially, the merozoite establishes 
itself in the RBC as a ring stage, which grows substantially and develops into a 
trophozoite. The trophozoite undergoes schizogeny, yielding a schizont 
containing about 8 to 32 daughter merozoites. Upon rupture of the erythrocyte, 
the merozoites are released into the blood and invade new RBCs. This asexual 
replication step is the phase of infection causing the clinical symptoms of 
malaria, including recurrent fever and anemia resulting from the loss of 
erythrocytes.  
Plasmodium parasites extensively remodel their erythrocyte surrounding 
(reviewed by Gilson et al., 201735). Through an export machinery named PTEX 
(Plasmodium translocon of exported proteins), parasites export a wide variety 
of their own proteins into the RBC cytoplasm36. Many of these proteins serve to 
modify the erythrocyte allowing the transport of virulence factors to the 
parasite surface. One of the most important virulence factors in P. falciparum is 
P. falciparum erythrocyte membrane protein 1 (PfEMP1), which is exported to 
knob-like structures on the surface of the erythrocytes37–39. There, PfEMP1 
interacts with receptors on the blood vessel endothelium, causing the parasites 
to cytoadhere in the vessels and thus avoid clearance by the spleen40. PfEMP1 is 
expressed in a mutually exclusive manner from a large multigene family called 
var genes, and antigenic variation by switching var gene expression is a major 
part of the immune evasion of Plasmodium41–43. The cytoadherence of parasites 
leads to the clotting of vessels, especially in the brain microvasculature, and an 
inflammatory response44. Both contribute to cerebral malaria, one of the most 
severe forms of malaria, which often results in coma and death44. Cerebral 
malaria is often modeled by infecting C57BL/6 mice with the P. berghei ANKA 
strain45, although not all mechanisms seem to be conserved11.  
Most blood-stage parasites continue the cycle of asexual replication, 
formation of merozoites and invasion of new red blood cells. However, some 
parasites will develop into sexual stages, the female and male gametocytes of 
the parasite. Factors that trigger gametocyte formation remain unknown, but 
parasite-derived microvesicles have been proposed to play a role46,47. These 
gametocytes initially leave the blood stream and hide in the bone marrow from 
the immune system until they are fully matured48,49. Then, they return to the 
blood, from which they are eventually taken up by a mosquito during its blood 
meal.  
1.2.4 THE MOSQUITO INFECTION 
Once in the mosquito midgut, gametocytes sense the change in the 
environment, indicated by a drop in temperature from 37 °C to 20 °C, an 
increase in pH and the presence of the mosquito molecule xanthurenic acid50. 
 
 
 
 
 
 
 
 
 
The validity of the 
experimental cerebral 
malaria (ECM) mouse 
model has been 
extensively debated in the 
past11. 
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Male gametocytes then undergo several rounds of mitosis to develop into eight 
male gametes. These gametes are flagellated and highly motile, and, in a 
process called exflagellation, they rupture the PVM and the erythrocyte 
membrane to search for female gametocytes (reviewed by Bennink et al., 
201651). In the mosquito midgut, male and female gametocytes mate and form a 
zygote, which further develops into an ookinete, another motile stage of the 
Plasmodium parasite.  
The ookinete traverses the midgut wall of the mosquito to establish an 
infection just outside of the midgut at the basal lamina. There, the ookinete 
transforms into a so-called oocyst, encapsulating itself into a cyst wall 
(reviewed by Aly et al., 200952). Within the cyst, the parasite replicates again, 
forming thousands of sporozoites. These are already motile within the oocyst53, 
and upon maturation, rupture the cyst wall to enter the hemolymph of the 
mosquito. From there, they are passively transported to the salivary glands of 
the mosquito, which they subsequently invade54. In the salivary glands, 
sporozoites await their transmission to the next vertebrate host by a mosquito 
bite, completing the life cycle.  
1.3 GENETIC TOOLS FOR PLASMODIUM RESEARCH 
With such a complex life cycle involving various hosts and tissues, the 
malaria parasite is a difficult organism to study. To identify new drug targets 
and vaccine candidates to fight malaria, deciphering the function of individual 
parasite genes in the various parts of the life cycle is essential. In 2002, the 
genome sequence of P. falciparum was published, revealing around 5300 genes 
in this parasite, of which about 60 % have no homology to known genes in 
other organisms55. These “orphan” genes are attractive drug candidates as 
inhibitors might not cause unintended side effects in the host. However, the 
lack of homologs renders the identification of the biological role of these 
Plasmodium-unique genes difficult. Therefore, a whole plethora of genetic tools 
has been developed to study Plasmodium genes, allowing the manipulation of 
gene expression, with the aim to infer the biological function from the resulting 
phenotype (reviewed e. g. by de Koning-Ward et al., 201556 or Shaw et al., 
201757). This section will summarize currently available technologies and 
discuss their advantages and disadvantages.  
1.3.1 GENE KNOCKOUT AND GENE EDITING 
Gene knockout, meaning the disruption of a gene of interest (GOI) on the 
DNA level, has been used in Plasmodium parasites since the mid-90s, when the 
development of efficient transfection protocols enabled the introduction of 
exogenous DNA to Plasmodium blood stages58–61. Exogenous DNA that 
comprises regions homologous to a Plasmodium sequence can integrate into the 
parasite genome via homologous recombination59,61. The presence of a single 
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homologous sequence on a circular plasmid results in a single crossover event 
by which the entire exogenous DNA sequence is inserted into the genome at 
this locus. If a sequence is flanked by two homologous arms, it can insert via 
double crossover, thereby replacing the Plasmodium DNA between the 
homologous regions62. As integration events resulting from single crossover 
can revert to wild type, most genetic modifications are now performed using 
double cross-over strategies.  
Traditionally, gene knockout is achieved by allelic replacement of the target 
gene with a selection cassette that confers drug resistance to transgenic 
parasites (Figure 2 A). Among the first genes disrupted by allelic replacement 
with a selection marker were the circumsporozoite protein in P. berghei63 and 
the knob-associated histidine-rich protein in P. falciparum64, followed by many 
more. It is now estimated that about 500 Plasmodium genes (almost 10 % of all 
genes) have been successfully disrupted using this strategy56. Recently, even a 
genome-wide knockout screen was performed in P. berghei, using integration 
vectors with very long homology arms that have a high integration frequency65. 
These vectors, produced during the Plasmodium Genetic Modification Project 
(PlasmoGEM)66, all carry an individual barcode, which allows for the parallel 
transfection of multiple knockout vectors. The growth phenotype of the 
individual knockout is then assessed by next generation sequencing of the pool 
of transfectants. This way, the effect of each knockout of all roughly 5700 
P. berghei genes on blood-stage growth is now characterized65.  
A      Classical knockout 
 
B   Gene editing using nucleases 
 
FIGURE 2: Gene knockout and gene editing. DNA segments in the Plasmodium genome 
can be replaced by exogenous DNA via double-crossover homologous recombination. 
(A) Conventional gene disruption relies on replacing the GOI ① with a drug-selectable 
marker ②. Drug selection (positive selection) yields parasites that have the selection 
marker integrated ③. If the selection marker also encodes yFCU and is flanked by 
homologous sequences, negative selection can select for marker-free parasites ④. 
(B) Nucleases such as Cas9, directed by gRNAs, sequence-specifically cleave the GOI ①. 
This cleavage event greatly increases the rate of homologous recombination, so that the 
GOI is efficiently replaced by a co-transfected repair template ②, yielding a marker-free, 
mutated GOI ③. This strategy requires the transfection of two plasmids, one encoding 
the repair template and the gRNA ② and the other encoding the Cas9 ④. This image 
has been created using elements from Servier Medical Art (www.servier.de)          
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The relatively low efficiency of homologous recombination especially in 
P. falciparum renders gene knockout very laborious. The introduction of a DNA 
double-strand break (DSB) at the target locus substantially increases the 
frequency of homology-directed recombination. Not surprisingly, this approach 
has been applied to Plasmodium. The first strategy to site-specifically cleave a 
gene in Plasmodium was the expression of zinc-finger nucleases (ZFN), artificial 
enzymes that can be engineered to target a specific locus on the DNA67. The 
parasite uses a repair template provided in parallel to restore the integrity of 
the genome. This repair is highly efficient, as the alternative repair pathway via 
non-homologous end-joining (NHEJ) is absent in Plasmodium species68,69. Thus, 
transgenic parasites can be obtained without the need to integrate a selectable 
marker, facilitating construct design and marker-free introductions of point 
mutations at the target site68,70,71.  
One major disadvantage of ZFNs is that proteins binding a specific target 
site are challenging and laborious to generate. Recently, a much simpler tool to 
achieve targeted DSBs has been introduced to Plasmodium: The CRISPR 
(clustered regulatory interspaced short palindromic repeats)-Cas9 (CRISPR-
associated protein 9) system (Figure 2 B)72,73. In this system, a guide RNA 
(gRNA) targets the endonuclease Cas9 to the genomic locus of interest. Cas9 
then cleaves the DNA at this locus, which is subsequently repaired by 
homologous recombination, provided a homologous template is present 
(reviewed e. g. by Wang et al., 201674). Target specificity is solely determined 
by the sequence of the 20 nt-long gRNA, rendering CRISPR-Cas9 a versatile and 
easily adaptable system that even enables genomic-wide screens. Such a 
genome-wide CRISPR-Cas9-mediated knockout screen has already been 
successfully performed in Toxoplasma gondii (T. gondii), a close relative of 
Plasmodium75. CRISPR-Cas9-mediated genome editing in P. falciparum is highly 
efficient and easily adaptable to any desired target sequence, making it the 
current standard procedure for gene targeting. While it was also successfully 
applied to P. yoelii76, there are no reports of its application in P. berghei. 
Gene knockout and gene editing have been invaluable to study the 
biological role of individual genes. Recent advances in the efficiency of these 
technologies are expected to further extend this knowledge, especially for the 
1900 genes (P. berghei) or 2075 genes (P. falciparum) that are currently 
annotated as having unknown functions (www.plasmodb.org, April 2017). 
However, all these systems have a major drawback in common: as transfection 
and gene editing occurs in the blood stages of Plasmodium, any genes that are 
essential for this stage cannot be targeted since their knockout is lethal to the 
parasite. Conditional systems permitting inducible gene knockout are thus 
necessary to study the function of blood-stage essential genes. These will be 
discussed in the next section.    
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1.3.2 CONDITIONAL GENE KNOCKOUT 
One approach to control the timing of gene deletion is the use of 
recombinases. These proteins will excise DNA segments that are flanked by 
recombinase recognition sites from the genome. Two systems have been 
adapted for Plasmodium: the flippase FLP, which binds to FLP recognition sites 
(frt)77, and the Cre protein that binds to loxP sites78. The frt or loxP sites are 
very short nucleotide sequences (about 30 bp long) and flanking a gene with 
these sequences (referred to as flirting or floxing) should not interfere with 
normal gene function. Upon expression of the corresponding recombinase, 
however, the gene flanked by the recognition sites is rapidly excised and 
removed from the genome. The deletion of the gene is entirely dependent on 
the expression of the recombinase, which thus must be tightly controlled.  
Recombinase-mediated knockout 
 
FIGURE 3: Recombinase-mediated knockout. Here, the regulatable DiCre System is 
depicted exemplarily. The GOI ① is replaced with a version of the GOI that is flanked by 
recombinase recognition sites (here loxP sites) ②. A selection marker is included to 
allow for the selection of double-crossover recombination events ③. In the resulting 
line, a plasmid is transfected which encodes the two fragments of the split Cre 
recombinase: Cre1-FKBP and Cre2-FBP ④. Upon addition of rapamycin, the two parts 
dimerize, and the active Cre recombinase mediates the recombination of the loxP sites, 
resulting in the deletion of the GOI ⑤. This image has been created using elements from 
Servier Medical Art (www.servier.de)          
In P. falciparum, Cre recombinase has been shown to be more efficient than 
the FLP/frt system79. The expression of Cre can be controlled using a 
tetracycline (Tet) regulatable promoter (discussed in detail below). Thus, the 
knockout of a floxed GOI can be precisely timed by the addition of 
anhydrotetracycline (aTc) to the culture medium79. A more recent strategy, 
called the DiCre System, uses a split Cre protein in which one part is fused to a 
human FK506-binding protein 12 (FKBP12) and the other to the binding 
domain of the FKBP12-rapamycin-associated protein (FRB) (Figure 3)80,81. 
While the split Cre is inactive, addition of the small ligand rapamycin triggers 
heterodimerization and thus activation of Cre. Akin to the Tet-controlled Cre, 
this allows for a timed and inducible gene knockout, e. g. of the blood-stage 
essential apical membrane antigen 1 (AMA1)82. As recombinase-mediated gene 
excision is not 100 % efficient and single parasites can evade the gene deletion, 
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the DiCre system has been combined with a reporter gene whose expression is 
only turned on after recombination81. Reporter gene expression can thus be 
used to identify positive recombinants. 
A major drawback of the recombinase-mediated gene knockout is that 
flirting or floxing large target genes can be very laborious, as it requires either 
cloning the whole gene or sequential transfection of integration constructs to 
insert both recognition sites. The use of a short synthetic intron carrying a loxP 
site (loxPint), which can be integrated close to the 5’end of the GOI, facilitates 
floxing83. However, although the loxPint has been used to ablate expression of 
several genes, it is unclear if this artificial intron is correctly spliced in all 
genetic contexts. Another disadvantage is the minor antimalarial activity of 
rapamycin (IC50: 2.7 µM)82, and side effects of the treatment have to be 
considered. Additionally, the DiCre system is not applicable in mammalian 
hosts, due to immune-modulatory effects of rapamycin in mice84. 
In P. berghei, the expression of recombinases is thus not controlled by small 
ligands, but by exploiting stage-specific promoters85,86. In this manner, FLP has 
been expressed under the TRAP (thrombospondin-related anonymous protein) 
promoter or the UIS4 (upregulated in infectious sporozoites 4) promoter, to 
express FLP only in mosquito stages85,87. Genes flanked with frt sites are 
unaffected in blood stages, but excised upon transmission of the parasites to 
mosquitoes. Using this strategy, the blood-stage essential merozoite surface 
protein 1 (MSP1) was deleted in liver stages, which revealed that this protein is 
essential for the correct formation of merozoites in the intrahepatic 
development85.  
In summary, recombinases are useful tools to target genes for which a 
conventional knockout strategy is not possible. Due to the rapid gene deletion, 
there is no selection of evasion mutants as can happen during the long 
procedure of generating traditional knockouts. Conditional gene knockouts are 
“all-or-nothing”, and do not allow for intermediate expression levels. Other 
systems have been developed to regulate and tune gene expression to 
investigate “dose-dependent” phenotypes and will be discussed in the following 
Section.  
1.3.3 KNOCKDOWN OF GENE EXPRESSION 
Expression of a GOI can be altered not only by removal, i. e. knockout, but 
also by modulating gene expression at the transcriptional, post-transcriptional 
or post-translational level. For all these steps, tools have been developed in 
Plasmodium. These knockdown strategies have in common that they are not 
100 % efficient, which can be a disadvantage when low levels of gene 
expression are sufficient for gene function. On a positive note, knockdown 
strategies allow for the investigation of intermediate phenotypes.  
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Regulation of gene expression on a transcriptional level is achieved 
through modifying the promoter. In P. berghei, a “promoter swap”, i. e. the 
replacement of the endogenous promoter by a different promoter, is a widely 
used method to alter the gene expression profile across the life cycle88. If the 
GOI is e. g. expressed across the life cycle, but essential in blood stages, the 
promoter of said gene can be exchanged with a blood-stage-specific promoter. 
This promoter swap should not affect blood stage development but ablate gene 
expression in other stages, resulting in loss-of-function phenotypes there. 
However, this method changes the overall expression pattern of the gene and is 
not inducible or reversible. It also does not permit to study essential genes in 
blood stages. Additionally, many promoters are leaky and at least weakly 
expressed in all life cycle stages, confounding phenotypic analysis89,90.  
Alternatively, the promoter of a GOI can be replaced by an inducible 
promoter. In both P. berghei and P. falciparum, the “Tet-OFF” system has been 
used (Figure 4 A)91,92. Here, the promoter of the GOI is replaced with a 
promoter containing tetracycline operator (TetO) sites. Transcriptional 
transactivator domains (TRAD) bind to these TetO sites and trigger expression 
of the gene. Upon addition of the tetracycline analog aTc, TRAD binds to aTc 
instead of the TetO. Thus, gene expression is silenced. In P. falciparum, this 
system can regulate gene expression from episomes, but not endogenous genes, 
likely due to low activation of transcription by the TRAD proteins56,91. In 
P. berghei, TRAD activity has been improved by using endogenous 
transactivator domains92,93. This improved Tet-OFF system was used to 
regulate the expression of various genes, including some that are essential for 
blood-stages92,94, and could also downregulate a reporter gene in in vitro liver 
stages92. The dynamic range of the knockdown is somewhat limited, yielding 
knockdown efficiencies of around three to four-fold94.  
Several tools to mediate gene knockdown act on the mRNA of the GOI. In 
many eukaryotic organisms, RNA interference is the method of choice to silence 
genes by cleaving the mRNA (discussed in detail in Section 1.4). Unfortunately, 
Plasmodium parasites lack the required machinery, rendering this potent tool 
unavailable for malaria research95. One alternative that has been employed 
with limited success in P. falciparum are small chemical molecules that bind in 
an antisense manner to the RNA of interest and thereby inhibit translation 
(Figure 4 B). For example, synthetic peptide nucleic acids (PNAs), 
oligonucleotides with uncharged backbones, bind in vivo to complementary 
RNA and prevent translation96–98. Similarly, vivo morpholinos, which are 
phosphorodiamidate morpholino oligomers (PMOs) conjugated to octa-
guanidinium dendrimers to improve cellular uptake, have been shown to 
inhibit splicing and translation by binding to the corresponding RNA99. PMOs 
can also be conjugated to peptides (PPMO), and these can be designed in such a 
way that they mimic the natural substrate of RNaseP, triggering target cleavage 
by the Plasmodium RNaseP100,101. These inhibitors have been shown to reduce 
gene expression by up to four-fold. However, as this requires very high 
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amounts of the inhibitors, off-target effects are frequently observed that 
confound the phenotypic analysis. 
A                   Tet-OFF System 
 
B    Morpholinos 
 
C                                             GlmS-Ribozyme System 
 
D                                                Tet-Aptamer System 
 
FIGURE 4: Transcriptional and post-transcriptional repression. (A) For the Tet-OFF-
system, the promoter of the GOI ① is replaced by a cassette encoding TRAD, a selection 
marker, and an inducible promoter ②. TRAD is expressed and triggers the transcription 
of the GOI. Upon addition of aTc, TRAD is sequestered from the inducible promoter, and 
gene transcription is inhibited ③. (B) Morpholinos are synthetic RNA molecules binding 
to the mRNA of the GOI ② and preventing translation. The genetic locus is unaffected 
①. (C) For the glmS-ribozyme system, the 3’UTR of the GOI ① is replaced with a 
ribozyme-containing UTR ② via single crossover ③. Upon addition of GlcN-6P, the 
ribozyme is activated and cleaves the mRNA, triggering degradation ④. (D) In the Tet-
aptamer system, the 3’UTR of the GOI ① is modified by single crossover to include an 
aptamer sequence ②. At the same time, a gene encoding the TetR fused to DOZI is 
introduced ②. The TetR-DOZI is constitutively expressed ③ and prevents gene 
translation by binding to the aptameric sequence and initiating storage. Upon addition 
of aTc, the TetR-DOZI is sequestered, and the gene can be translated. This image has 
been created using elements from Servier Medical Art (www.servier.de)          
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Other strategies to regulate mRNAs act in cis, as regulatory elements are 
introduced to the mRNA itself by genetic modification. Widely used are self-
cleaving ribozymes, such as the 5’ cis-regulatory element in the glucosamine-6-
phosphate synthase (glmS) gene of bacteria102. This glmS element can be placed 
in the 3’UTR of the GOI and, upon induction with glucosamine-6-phosphate 
(GlcN-6P), cleaves the mRNA, reducing its translation (Figure 4 C)103. Cleavage 
commonly results in a roughly three-fold reduction on the RNA level, which 
translates into an about 10-fold reduction of protein levels103. The introduction 
of the glmS element requires only a single 3’ replacement strategy and does not 
interfere with normal protein expression, making it an attractive and easy tool 
for inducible gene knockdown. As GlcN-6P is toxic to Plasmodium, the precursor 
glucosamine (GlcN) is used to trigger knockdown and is converted in the 
parasite to GlcN-6P57,103. However, also GlcN affects parasite growth at higher 
concentrations103. Thus, when the level of knockdown that can be achieved with 
non-toxic GlcN concentrations is not sufficient to detect a phenotype, the use of 
the glmS system is limited. In P. berghei, only a single publication reports the 
successful application of the glmS system to regulate gene expression, and the 
knockdown was restricted to in vitro cultures104. 
Tet-responsive aptamers are an alternative to ribozymes. In vitro selection 
revealed small artificial RNA aptamers that bind to the Tet repressor (TetR)105. 
If such an aptamer is introduced close to the translation initiation site, the TetR 
binds the mRNA and prevents translation. Upon addition of aTc, the interaction 
is blocked, and protein expression is induced. This system is rapid, stable and 
reversible, yielding up to about five-fold knockdown106. It has recently been 
refined by coupling TetR to the DOZI (development of zygote inhibited) protein 
(Figure 4 D)107. This protein mediates storage of mRNA in processing bodies of 
the gametocyte until the parasite reaches the mosquito108. Binding of TetR-
DOZI to the target mRNA thus inhibits its translation and targets it for storage, 
greatly improving the knockdown capacity to up to 300-fold for a luciferase 
reporter.  
The tools discussed so far modify mRNA levels by either controlling 
transcription, inhibiting translation or degrading the mRNA. Another option to 
regulate gene expression is the direct modification of protein levels. Here, 
transcription and translation of the GOI are unaffected, but the protein is either 
degraded or mislocalized to prevent its function.  
One of the most widely used strategies for post-translational regulation is 
the fusion of the protein of interest to a degron (Figure 5 A). Degrons are small 
protein domains that are structurally unstable and promote their own 
ubiquitination. Fusion of these to the protein of interest thus results in 
proteasomal degradation of the whole protein. This degradation can be 
prevented by small ligands which, when added to the medium, bind to the 
degron and stabilize it. Two degrons have been used in Plasmodium: the FKBP-
based destabilization domain (DD), which is stabilized by the small ligand 
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Shield-1109,110, and the Escherichia coli (E. coli) DHFR destabilizing domain 
(DDD), which is stabilized by trimethoprim111. The latter can only be applied in 
parasites expressing hDHFR, which mediates resistance against the 
antimalarial trimethoprim111. As it is a ligand-on system, meaning that the 
ligand has to be supplied to ensure protein stability, DD- or DDD-are especially 
well suited for the regulation of dominant negative genes112 or auto-regulatory 
protein domains113. Yet, DD- or DDD-based knockdowns are restricted to 
proteins that tolerate tagging, and that are accessible to the proteasomal 
degradation system. The knockdown efficiency appears to depend on the gene 
context but is typically around four-fold for the DD system114. In some cases, 
stabilization by Shield-1 was insufficient to restore protein expression to its full 
extent114, and in others, the knockdown was not strong enough to observe a 
phenotype113. Additionally, Shield-1 has slightly anti-malarial activity at high 
concentrations114.  Only a single report exists that describes the application of 
the DD system in P. berghei, and only a moderate knockdown without 
corresponding phenotype was observed115.  
Another degron system that has been applied to both P. falciparum116 and 
P. berghei117 acts as ligand-off system: the auxin-inducible degron (AID) (Figure 
5 B)118. Here, parasite lines are used that express an auxin-responsive F-box 
protein (transport inhibitor response 1 from the rice plant Oryzae sativa 
(OsTIR1)). This F-box protein interacts with the Plasmodium proteins to form 
the Skp1, Cullin1, F box protein ubiquitin ligase (SCF) complex. The GOI is fused 
to the AID domain. In the presence of auxin, OsTIR1 interacts with AID, recruits 
the SCF complex and ubiquitylates the protein, targeting it for degradation.  
This way, protein levels could be reduced by up to 30-fold118. However, high 
amounts of the inducer are needed to achieve this knockdown, and although 
auxin is not toxic to the parasite, this requirement limits the application in 
mice. In P. berghei, a knockdown was thus only realized in in vitro cultures117. 
As for the DD or DDD systems, the knockdown efficiency likely depends on the 
protein target.  
Other strategies perturb protein function not by degradation, but by 
conditional aggregation or conditional mislocalization of the protein. The first 
has been realized by fusion of a protein to a conditional aggregation domain 
(CAD)119. CAD causes self-aggregation of the protein in the ER, which is 
reversible upon addition of the compound AP12998. This strategy is only 
applicable for secreted proteins and publications reporting its use are sparse. 
Recently, a conditional mislocalization system (knock sideways) has been 
adapted to Plasmodium (Figure 5 C)120,121. Here, the GOI is fused to an FKBP 
domain which, upon addition of rapamycin binds to an FRB domain that 
localizes differently, e. g. in the nucleus. As the GOI is thereby detargeted from 
its regular locus, e. g. the cytoplasm, it can no longer perform its function, 
essentially resulting in a loss-of-function phenotype. Successful inducible 
protein displacement has been demonstrated for P. falciparum blood stages in 
vitro120 and for P. berghei blood stages and mosquito stages in vivo121.  
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A                                              DD-System 
 
B                      Auxin-inducible Degron (AID) 
 
C                                                Knock sideways 
 
FIGURE 5: Post-translational modification of protein activity. (A) To control protein 
degradation, the GOI ① is tagged C-terminally with a degron domain (DD) using a single 
crossover strategy ②. From the modified locus ③ the gene is translated. The DD 
domain fused to the GOI will destabilize the protein, resulting in its degradation, unless 
the stabilizing molecule Shield-1 is present ④. (B) A similar strategy utilizes the auxin-
inducible degron AID. Fusion of the GOI ① to AID by double crossover ② yields 
expression of a fusion protein ③. From a different locus, the OsTir is expressed that 
forms the SCF complex with endogenous Plasmodium proteins ④. Upon addition of 
auxin, the SCF is recruited to the AID and ubiquitylates the protein (Ub), targeting it for 
degradation ⑤. (C) Knock sideways is a different approach in which the GOI ① is fused 
to an FKBP domain ②. The protein is expressed from its genomic locus ③ and exerts its 
function in the cytoplasm. In parallel, an FRB fused to an nuclear localization signal 
(NLS) is expressed ④. Upon addition of the rapamycin analogue rapalog, the FRB and 
the FKBP-domain dimerize, sequestering the protein from its regular localization into 
the nucleus. This image has been created using elements from Servier Medical Art 
(www.servier.de)          
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Despite many advances in recent years, the technologies available to study 
Plasmodium gene function are still limited, and several challenges remain 
unsolved. Tunability is one of these issues, as there are only limited options to 
modulate or fine-tune gene expression in order to observe intermediate 
phenotypes. Also, many genetic tools only act on the asexual blood stage of 
P. falciparum. Manipulation of P. berghei gene expression in vivo, especially in 
mosquito or liver stages, is still difficult. Finally, as most tools require the 
manipulation of the genetic locus of the GOI, which is often labor- and time-
intensive, high-throughput screens remain out of reach.  
1.4 RNA INTERFERENCE 
“RNA interference has proven to be a quite reliable mechanism for turning 
genes off in a whole variety of different plants and animals.” 
~ Craig Cameron Mello (*1960) 
RNA interference (RNAi) is a widespread mechanism to regulate gene 
expression posttranscriptionally. Almost all eukaryotes, including plants, 
animals, and protozoa such as trypanosomes use RNAi to control gene 
expression. RNAi is based on short RNA molecules, so-called microRNAs 
(miRNAs), which bind complementary target mRNA sequences and induce their 
cleavage, translational repression and/or degradation. In humans, more than 
60 % of all protein-coding genes are predicted to be controlled by miRNAs123, 
demonstrating the importance of RNAi. It is thus surprising that Plasmodium 
parasites have lost all components of the RNAi machinery95. This is particularly 
unfortunate for research, as RNAi can be easily exploited for targeted gene 
knockdown by introducing short hairpin RNAs (shRNAs) or short interfering 
RNAs (siRNAs). The following Sections will briefly delineate the mechanism of 
canonical RNAi in animals and introduce the various non-canonical RNAi 
pathways that have been described recently.  
1.4.1 CANONICAL RNAI PATHWAY  
RNAi in animals is executed by small RNA molecules, the miRNAs, which 
can be encoded by separate genes or within introns of protein-coding 
genes124,125. Their generation is a multistep process requiring several proteins 
(Figure 6, reviewed e. g. by Ha and Kim, 2014126). MiRNAs are transcribed by 
RNA polymerase II as primary (pri)-miRNAs and processed akin to protein-
coding mRNAs by splicing, capping, and polyadenylation127,128. The typically 
over 1 kb long transcripts contain one or more hairpin structures128, which are 
processed by an RNase III family enzyme called Drosha129–132. Drosha acts in 
conjunction with the protein DGCR8 (DiGeorge syndrome critical region gene 
8), forming a complex called microprocessor133–136. The microprocessor cleaves 
the flanking sequences from the hairpin structures, yielding precursor (pre)-
miRNAs. These are exported from the nucleus by Exportin 5 (XPO5)137–139.  
RNAi has been discovered 
for the first time in the 
nematode Caenorhabditis 
elegans, with lin-4 being 
the first miRNA 
described122  
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Once in the cytoplasm, pre-miRNAs are further processed by the 
endonuclease Dicer, which cleaves the loop of the hairpin structure and 
releases the mature miRNA duplex141–144. Dicer requires the association with 
another RNA binding protein. In humans, this is often the Tar RNA binding 
protein (TRBP), although the protein PACT can also associate with Dicer145–148. 
After Dicer/TRBP-mediated processing, the miRNA-duplex is loaded into a 
protein of the Argonaute (Ago) family, forming the RNA-induced silencing 
complex (RISC)149–151. Humans have four different Ago proteins (Ago1-4), 
which all participate in miRNA-mediated gene silencing, but only one, Ago2, has 
a catalytically active RNaseH domain and can cleave targeted mRNAs in a 
process called slicing152–154. Within RISC, one strand of the miRNA duplex, the 
so-called guide strand is selected, while the other, the star or passenger strand, 
is removed. Strand selection is mainly determined by the thermodynamic 
stability of the 5’ terminus: the strand with the lesser stability is preferred as  
guide strand155,156. Removal occurs either by cleavage and degradation of the 
star strand (in the case of Ago2 and a perfect complementarity between the two 
strands of the duplex)157–161 or by helicase-assisted unwinding (for non-slicing 
Ago proteins and if there are mismatches between the guide and star 
strand)162–168. While the guide strand is generally preferentially loaded 
into RISC, next generation sequencing showed that for almost all 
miRNAs, the passenger strand is infrequently selected as well169. 
After one strand is removed, mature RISC then binds to the target mRNA 
based on its complementarity to the miRNA. Target selection is mainly 
determined by the nucleotides 2-8, which constitute the seed region of the 
miRNA171–175. Target mRNAs are then silenced depending on the extent of base 
pairing between miRNA and mRNA and the Ago protein within RISC (reviewed 
e. g. by Wilczynska and Bushell, 2014176). Ago2 cleaves the mRNA if there is 
perfect complementarity in the central region of the miRNA177,178. In animal 
cells, the base pairing between miRNA and mRNA is usually imperfect, which 
triggers translational repression through inhibition of translation initiation179–
186, followed by deadenylation and degradation of the mRNA. Both processes 
are mediated by effector proteins binding to Ago2, first and foremost the 
glycine-tryptophan-rich protein GW182187–189. GW182 binds to Ago2 and 
recruits additional effector proteins, such as the poly(A) binding protein PABP 
and the CCR4-NOT deadenylase complex190–192. Also, the DEAD-box RNA 
helicase DDX6/Rck-p54 is directly or indirectly recruited to Ago2 and essential 
for miRNA-mediated gene silencing, possibly also by recruiting the CCR4-NOT 
complex193–196. Decapping and removal of the poly(A) tail finally target the 
mRNA for rapid degradation. Both GW182 and DDX6/Rck-p54 target RISC to 
processing (P-) bodies, cytoplasmic foci of mRNA storage and degradation, 
although miRNA-mediated knockdown also occurs in the absence of 
P-bodies187,193,197,198.   
 
 
PACT stands for protein 
activator of the 
interferon-induced 
protein kinase as it has 
first been implicated in 
the immune response to 
viral infections140. 
 
 
 
 
 
 
 
 
 
 
 
In humans, there are three 
different GW182 proteins: 
TNRC6 A, B and C 
 
 
Only about 1 % of all 
Ago2 localizes to P-bodies, 
while the majority of 
miRNA-mediated 
silencing happens in the 
cytoplasm170.  
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FIGURE 6: The canonical RNAi pathway. MiRNAs are transcribed in the nucleus as pri-
miRNAs ①, which are processed by Drosha and DGCR8 to pre-miRNAs ②. XPO5 is then 
responsible for their translocation into the cytoplasm ③, where the pre-miRNAs are 
further processed by Dicer with the help of an RNA-binding protein such as TRBP ④. 
Then, the mature miRNA is incorporated into the pre-RISC complex by binding to an Ago 
protein ⑤. Note that loading of Ago likely involves additional proteins, and that the free 
miRNA is depicted here only for simplicity. One strand of the miRNA is selected as guide 
strand, yielding the mature RISC, while the other strand is degraded. The RISC then 
binds to its mRNA target complementary to the miRNA sequence. In the case of perfect 
complementarity and if RISC contains Ago2, Ago2 will slice the mRNA, resulting in its 
degradation ⑥. More commonly, however, miRNA binding is imperfect, and additional 
proteins such as the GW182 are recruited to RISC, mediating translational repression 
and mRNA destabilization ⑦. RNAi can be artificially induced by introducing either 
genetically encoded shRNAs ⑧ or short RNA duplexes (siRNAs) ⑨. This image has 
been created using elements from Servier Medical Art (www.servier.de)          
The endogenous RNAi pathway can easily be exploited to artificially induce 
gene silencing205 (Figure 6). For example, synthetic siRNAs, small RNA duplexes 
that can be introduced into cells e. g. by transfection, act directly as Ago2 
substrate199. These siRNAs are typically designed to be perfectly 
complementary to the target mRNA and thereby induce target cleavage through 
the slicing activity of Ago2. In contrast, shRNAs are DNA-encoded small RNAs 
that upon transcription form a hairpin, which is subject to XPO5 export and 
Dicer processing before entering RISC200.  As target specificity is solely 
determined by the 20-21 nt long sequence of the si- or shRNA, RNAi-mediated 
knockdown can be easily adapted to a target of choice, and genome-wide 
screening approaches using shRNA/siRNA libraries have yielded a plethora of 
new information about gene function in RNAi-competent organisms201–203. 
1.4.2 NON-CANONICAL RNAI PATHWAY 
Besides the canonical RNAi-pathway, by which 99 % of all miRNAs are 
processed, various alternative, non-canonical mechanisms exist that generate 
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active RISCs204,205 (Figure 7). Several different short RNA species have been 
reported to serve as Drosha-independent precursors for active miRNAs, 
including tRNAs or tRNA- like precursors206–209, small nucleolar RNAs 
(snoRNAs)210–212, or naturally occurring dsRNA transcripts that give rise to 
endo-siRNAs or endo-shRNAs213–216. A prominent class of non-canonical RNAi 
mediators are miRtrons, which are miRNAs derived from introns during 
splicing217–220. They bypass Drosha, as the small introns form hairpins which 
are further processed by the lariat-debranching enzyme to a pre-miRNA217–219. 
The pre-miRNAs then enter the canonical RNAi pathway by XPO5-mediated 
export and Dicer-processing prior to Ago2 loading. A subclass of miRtrons, so-
called agotrons, not only circumvent Drosha- but also Dicer-mediated 
processing, and are directly loaded into Ago2. The biological function of these 
agotrons is however unclear221.  
 
FIGURE 7: Non-canonical processing of Ago-associated RNAs. (A) MiR-451 is 
processed by Drosha and DGCR8 ① and exported by XPO5 ② akin to canonical 
miRNAs. Instead of Dicer processing, this miRNA is loaded directly into Ago2 ③. 
Cleavage of the passenger strand then activates RISC for target knockdown ⑤. (B, C) 
Introns ① can also serve as a substrate for Ago2 loading. They are processed by the 
lariat-debranching enzyme ② and exported into the cytoplasm ③. (B) MiRtrons are 
processed by Dicer and TRBP, following the canonical RNAi pathway. (C) Agotrons are 
directly loaded into Ago2, but their biological function is unclear. (D) Also, other small 
RNAs are processed by Dicer, including tRNAs ①, endo-siRNAs ②, endo-shRNAs ③ 
and snoRNAs ④. This image has been created using elements from Servier Medical Art 
(www.servier.de)          
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Other small RNAs are a substrate of Drosha, but bypass Dicer-mediated 
processing. A prime example is miR-451, which is an unconventional miRNA 
that is abundant in red blood cells and important for erythropoiesis222–227. 
Drosha-processing of the pri-miR-451 yields a very short hairpin with a stem 
length of only 17 nt, which is no longer recognized by Dicer as substrate228–230. 
Instead, it is directly incorporated into Ago2, which slices the 3’ strand of the 
miRNA in its center, resulting in a 30 nt-long intermediate RNA. This precursor 
is then further trimmed at the 3’ end by the Poly(A)-specific ribonuclease 
PARN, yielding the about 23 nt-long mature miR-451231. This trimming is, 
however, not essential for the function of miR-451231.  
As for the canonical RNAi pathway, also non-canonical pathways can be 
exploited for targeted gene silencing. This is exemplified by shRNAs that mimic 
the Dicer-independent miR-451, so-called AgoshRNAs232,233. These AgoshRNAs 
are characterized by shortened stems of 16-19 nt, a mismatch at the bottom of 
the stem and a small loop, all of which prevents the processing by Dicer232–237. 
Instead, they are directly bound by Ago2, which, similar to miR-451 processing, 
will cleave the 3’ strand, yielding a roughly 30 nt long mature AgoshRNA232,238. 
AgoshRNAs tend to be less active than their shRNA counterparts236 but they 
have other advantages. Because their biogenesis involves no passenger strand 
(which could participate in RNAi silencing236), AgoshRNAs are proposed to 
have reduced off-targeting effects. They also are less toxic to cells as their 
overexpression does not saturate the endogenous RNAi machinery233,236, in 
contrast to conventional sh- or siRNAs239. Additionally, these AgoshRNAs rely 
solely on Ago2 and can thus also be used in cells that lack Dicer, such as 
monocytes240.  
1.5 PLASMODIUM AND RNAI 
1.5.1 INTERACTION OF PLASMODIUM WITH HOST MIRNAS 
Plasmodium interacts in many ways with its host during infection, and it is 
thus not surprising that this interaction also involves the hosts RNAi pathway. 
Investigation of the miRNAs of Plasmodium-infected RBCs showed that miR-
451 is the predominant miRNA241,242 and implied that it has both beneficial as 
well as inhibitory effects for the parasite. During blood-stage infection, infected 
red blood cells were reported to shed extracellular vesicles which parasites use 
for cell-to-cell communication46,47. Among other host and parasite proteins, 
these vesicles also contain functional Ago2-miR-451 complexes that are 
transferred to endothelial cells243. In these cells, miR-451 silences Caveolin-1 
and Activating Transcription Factor 2. As silencing of these genes stimulate the 
expression of cellular receptors on the endothelial cells, it enhances the binding 
and sequestration of the infected RBC243. While miR-451 is favorable for 
parasite infection in this case, this effect seems to be reverted when miR-451 
expression is greatly increased, e. g. in sickle cell disease244. Apparently, miR-
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451, along with the miRNA let-7i, translocates to the parasite cytoplasm. There, 
it integrates into essential parasite mRNAs, which prevents translation by 
impairing ribosomal loading245. In normal blood cells, this effect is minor and 
does not impede parasite growth. In contrast, the increased miRNA levels in 
sickle cell disease significantly affect parasite growth, contributing to the 
known resistance of sickle cell erythrocytes to malaria infection245,246. However, 
trans-splicing of erythrocyte miRNAs into parasite mRNAs has not been 
reported previously, and independent validation of these data is still lacking.  
Besides miR-451, other host miRNAs also affect Plasmodium growth. We 
and others have previously shown that Plasmodium liver stage infection alters 
the miRNA profile of the host247,248. In particular, miR-155 was significantly 
upregulated upon infection with wild type or genetically attenuated parasites 
(GAP). Importantly, ectopic upregulation of miR-155 using adeno-associated 
viral (AAV) vectors improved the experimental immunization of mice with 
GAPs by reducing the number of vaccinations needed for sterile protection. A 
differential miRNA profile was also observed between mice susceptible to ECM 
and those that are resistant249,250. Again, miR-155 was described as a key player 
and found to be upregulated in P. berghei-infected mice that are susceptible to 
cerebral malaria250. Vice versa, miR-155-deficient mice were less susceptible to 
cerebral malaria. A possible explanation is that miR-155 increases 
inflammation and aggravates blood-brain-barrier dysfunction. This example 
demonstrates that the same miRNA can have very different effects on 
Plasmodium infection depending on context and expression level. While it is 
clear that host miRNAs impact Plasmodium infection, there is less evidence for 
the presence of Plasmodium-endogenous miRNAs, as the following Section 
shows.  
1.5.2 RNAI IN PROTOZOAN PARASITES  
The discovery of RNAi and miRNAs as a universal strategy to regulate gene 
expression raised hopes that protozoan parasites would also be equipped with 
this machinery and that this could be exploited as a tool to study gene function. 
Indeed, the RNAi machinery was readily identified in the kinetoplast parasite 
Trypanosoma brucei (T. brucei)251, the causative agent of sleeping sickness. 
With two Dicer-like homologs252,253 and one Ago protein254,255, T. brucei 
possesses proteins for the canonical RNAi pathway, and this has been exploited 
for genome-wide screens201,256. A subspecies of the kinetoplast Leishmania, 
L. Vienna braziliensis, is also capable of RNAi-mediated gene silencing257. In the 
evolution of kinetoplasts, however, the RNAi pathway has been lost twice: Both 
T. cruzii and the Old world Leishmania species lack functional RNAi258,259. In 
apicomplexans, only T. gondii has proteins of the RNAi machinery260, and the 
existence of miRNAs has been shown261262. In line with this, several 
publications reported a downregulation of gene expression using 
dsRNA261,263,264. However, it seems to be difficult to reproduce these results, and 
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the existence of a canonical RNAi pathway is debated265. Consequently, RNAi is 
not a popular tool to study this parasite.  
A few studies also report gene silencing in Plasmodium upon expression of 
dsRNA. The first work targeted the dihydroorotate dehydrogenase (DHODH) of 
P. falciparum using dsRNA, causing a growth defect266. In a second study, the P. 
falciparum cysteine proteases falcipain 1 and 2 were targeted by dsRNA, 
yielding a moderate growth defect along with enlarged food vacuoles267. 
Surprisingly, later gene disruption studies revealed that only falcipain 2 has an 
important role in blood stages, while the knockout of falcipain 1 had no 
phenotype in the erythrocyte development268–270. Two studies also report 
dsRNA-mediated gene silencing in P. berghei: in one, the Plasmodium 
berghepains were targeted by injecting corresponding siRNAs into infected 
mice271, while in the second study, a downregulation of eukaryotic initiation 
factor 5A (eIF-5A) and Deoxyhypusine synthase (DHS) was observed upon 
transfection of P. berghei with shRNAs against these genes272. Both studies, 
however, determine mRNA and protein knockdown only semi-quantitatively.   
Despite these promising first studies, several publications argue against the 
activity of dsRNA in Plasmodium via a canonical RNAi pathway. First and 
foremost, a study using bioinformatical as well as experimental methods 
demonstrated the absence of Ago- and Dicer-homologs in Plasmodium as well 
as the failure to downregulate gene expression with dsRNA delivered by 
various approaches95. Secondly, two studies that investigated miRNAs isolated 
from P. falciparum-infected red blood cells found only human miRNAs241,242. In 
conclusion, it is now commonly accepted that Plasmodium lacks an endogenous 
miRNA pathway. The initially reported effects of dsRNA on Plasmodium were 
thus either due to non-specific effects of dsRNA on parasite growth or to a non-
canonical mechanism of gene silencing in Plasmodium that has yet to be 
elucidated. Therefore, it is not possible to study gene function in Plasmodium 
using canonical RNAi-mediated gene silencing. The aim of the present thesis 
was to overcome this bottleneck by introducing an artificial, non-canonical 
RNAi pathway into P. berghei.  
 Aim of the Thesis 
For a long time, the absence of the RNAi machinery has been hampering 
gene annotation efforts in Plasmodium. While the canonical RNAi pathway is 
complex and involves the interplay of many different proteins, newly adapted 
non-canonical RNAi pathways are much simpler. This is best exemplified by 
AgoshRNAs, which rely only on Ago2 for processing and gene silencing. In this 
thesis, I aimed to test the hypothesis that expression of the protein Ago2 along 
with a target-specific AgoshRNA is sufficient to mediate gene silencing in 
P. berghei. 
 
FIGURE 8: Introduction of non-canonical RNAi into Plasmodium. A cassette encoding 
Ago2 along with a selection marker ② is integrated into a silent intergenic locus ①. 
Positive ③ and negative selection ④ yield a marker-free transgenic line expressing 
Ago2. A second transfection introduces an expression cassette for an AgoshRNA against 
the GOI ⑤. The AgoshRNA is processed by Ago2 ⑥, and the minimal RISC can target the 
mRNA of a GOI⑦ for degradation ⑧. This image has been created using elements from 
Servier Medical Art (www.servier.de)          
To this end, I planned to first stably integrate an Ago2 expression cassette 
into P. berghei and to then investigate whether Ago2 expression in the resulting 
line PbAgo2 impacts parasite development. In parallel, I wanted to design and 
test Dicer-independent AgoshRNAs against a proof-of-principle target (GFP). 
These AgoshRNAs, when expressed in PbAgo2, should reduce GFP levels 
significantly in blood stages, as well as in mosquito and liver stages. In case of 
promising results from the proof-of-concept study, I aimed to target 
endogenous GOI for AgoshRNA-mediated knockdown. If likewise successful, the 
RNAi-competent P. berghei could serve as a new tool to study gene function in 
the Plasmodium parasite (Figure 8). 
 
2 
 Results 
 “The first principle is that you must not fool yourself, and you are the easiest 
person to fool.”273 
~ Richard Feynman (1918 – 1988) 
3.1 IN VITRO TEST OF DICER-INDEPENDENT 
AGOSHRNAS 
The introduction of a minimal, functional RNAi machinery in Plasmodium is 
based on two premises: First, the parasite needs to express the protein Ago2. 
Second, an AgoshRNA against the gene of interest is required, which can induce 
Dicer-independent knockdown of said target gene. As AgoshRNAs are a fairly 
recent development, their optimal structure was not yet determined at the 
beginning of this work, and only a few requirements were known that render 
them Dicer-independent. The first Section of the Results Chapter thus presents 
the optimization of AgoshRNA design, with the aim to identify potent 
AgoshRNAs that only need Ago2 for processing and target knockdown.   
3.1.1 OPTIMIZATION OF THE AGOSHRNA DESIGN 
As a proof-of-principle target for AgoshRNA-mediated knockdown in 
Plasmodium I selected GFP, which the parasite line PbGFPcon expresses 
constitutively in all stages of the life cycle274. To be able to compare different 
AgoshRNA designs to conventional shRNAs, I first performed GFP knockdown 
experiments in cell culture. To this end, shRNAs and AgoshRNAs were cloned 
under the U6 promoter into an expression plasmid which also encodes 
mCherry as a marker for successful transfection. In parallel, I subcloned the 
GFP gene into a mammalian expression plasmid under the Cytomegalovirus 
(CMV) promoter. Human embryonic kidney (HEK) 293T cells were co-
transfected with these two plasmids and, two days later, the median GFP 
fluorescence of mCherry-positive (i. e. transfected) cells was measured by flow 
cytometry. The knockdown efficiency of a given shRNA or AgoshRNA was 
calculated by normalizing the GFP median fluorescence of cells expressing this 
particular RNA to the GFP median fluorescence of cells transfected with an 
empty vector (mCherry-plasmid lacking the U6-expression cassette).  
 
 
The testing of AgoshRNAs 
by flow cytometry was 
performed in part by 
Daria Krzikalla during 
her Master thesis.  
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FIGURE 9: GFP knockdown mediated by three different GFP-shRNAs. HEK293T cells 
were co-transfected with a GFP expression plasmid and one of three shRNAs targeting 
GFP (GFP-shR1a to 3a). A scrambled shRNA (scr) served as positive control. Two days 
after transfection, GFP median fluorescence of mCherry-positive cells was measured by 
flow cytometry and normalized to that of cells transfected with an empty vector 
(indicated by the dashed line at 1). Shown is the mean +/- SEM of three independent 
experiments. Statistical analysis: One-way ANOVA followed by Dunnett’s test. 
*** p<0.001. 
In this way, I tested three different shRNAs that were designed using an 
online tool (siRNA wizard, www.invivogen.com/sirnawizard). A scrambled 
shRNA served as negative control. Out of the three tested shRNAs, GFP-shR1a 
performed best and reduced GFP fluorescence to approximately 8 % (Figure 9). 
Interestingly, also the expression of the scrambled shRNA negatively affected 
the GFP fluorescence, reducing it to 71 % of the empty vector control. The 
presence of an active U6 promoter thus appears to influence the expression 
from a CMV promoter, potentially by competing for the same transcription 
factors.  
AgoshRNAs have to meet certain structural requirements in order to be 
recognized by Ago2 directly and to mediate a potent knockdown independent 
of Dicer. In contrast to well-established shRNAs, there are no tools available yet 
to select the target sequence and to design functional AgoshRNAs. The first 
publication describing Dicer-independent AgoshRNAs listed three main design 
rules that should prevent recognition of the hairpin by Dicer and facilitate 
Ago2-mediated processing232:  
1) With only 19 nt, the length of the target sequence is shorter than 
that of conventional shRNAs (20-21 nt). 
2) The loop size is reduced from 7 nt to 3 nt. 
3) The sense strand of the AgoshRNA is located at the 3’ end, while 
shRNAs start with the sense strand at the 5’ end. 
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FIGURE 10: Optimization of the AgoshRNA design. (A), (C) and (E) depict the structure 
of the AgoshRNAs based on design rules a, b and c, respectively. The antisense strand 
that is complementary to the target mRNA sequence is indicated in orange. (B), (D) and 
(F) show the relative GFP fluorescence (measured by flow cytometry) of HEK293T cells 
co-transfected with a GFP-expression plasmid and one of three or four AgoshRNAs 
targeting GFP based on (B) design a, (C) design b or (F) design c. A previously validated 
shRNA, GFP-shR1a, served as positive control, a non-targeting shRNA (Ren-shR1, (B) 
and (D)), or a scrambled AgoshRNA (scr, (F)) as a negative control. Shown is the median 
GFP fluorescence intensity normalized to control cells transfected with an empty vector 
(indicated by a dashed line at 1). (B) and (D) Mean +/- SD of a single experiment. 
(F) Mean +/- SEM of three independent experiments. Statistical analysis: One-way 
ANOVA followed by Dunnett’s test. * p<0.05; **  p<0.01. 
Based on these criteria, I designed a set of three different AgoshRNAs 
against GFP (GFP-AgoshR1-3a, Figure 10 A). The knockdown efficiency of 
these three AgoshRNAs was assessed by flow cytometry of transfected 
HEK293T cells as described above. The GFP-shR1a served as positive control, 
and a non-targeting shRNA against Renilla (Ren-shR1) served as negative 
control. While the GFP-shR1a silenced GFP expression to about 3 % 
fluorescence intensity, the knockdown mediated by the AgoshRNAs was much 
less pronounced and not statistically significant different from that with the 
shR-Ren1. Thus, it was necessary to improve the AgoshRNA design. 
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As the U6 promoter used 
for expression of shRNAs 
requires a G or A as first 
nucleotide275, target 
sequences ending on C 
were selected, so that the 
AgoshRNA antisense 
strand starts with a G. 
28 RESULTS  
 
 GFP mCherry merge 
A
g
o
sh
R
sc
r 
   

G
F
P
-s
h
R
1
a
 
   

G
F
P
-A
g
o
sh
R
1
c 
   

G
F
P
-A
g
o
sh
R
2
c 
   

G
F
P
-A
g
o
sh
R
3
c 
   

G
F
P
-A
g
o
sh
R
4
c
   
E
m
p
ty
 V
e
ct
o
r 
   
FIGURE 11: Microscopy images of HEK293T cells co-transfected with GFP and sh- or 
AgoshRNAs. HEK293T cells were co-transfected with a GFP-expression plasmid and a 
plasmid encoding mCherry and one of four GFP-AgoshRNAs (GFP-AgoshR1c to 4c). 
The previously validated GFP-shR1a served as positive control, and a scrambled 
AgoshRNA (AgoshRscr) and an empty vector not encoding any short RNA as two 
negative controls. Cells were imaged two days after transfection. One representative 
image of three per condition is shown. Pictures were taken with identical settings with a 
wide-field fluorescence microscope and are all processed alike. The scale bar indicates 
200 nm.  
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In the meantime, additional optimizations regarding the design of 
AgoshRNAs were published234. Taking these new data into account, I designed a 
second set of four different GFP-AgoshRNAs with a loop length of 5 nt and a 
terminal G-U mismatch (GFP-AgoshR1-4b, Figure 10 C). Additionally, target 
sequences were extended across the loop, to maximize base pairing of 
AgoshRNA and mRNA. However, flow cytometry of cells transfected with these 
AgoshRNAs again revealed no significant knockdown of GFP (Figure 10 D).   
Based on personal communication with Ben Berkhout and newly published 
data276, I again modified the AgoshRNA design to include an initial A-G 
mismatch (GFP-AgoshR1-4c, Figure 10 E). As a more appropriate negative 
control, I replaced the non-targeting shRNA with a scrambled AgoshRNA 
(AgoshRscr). Of the four AgoshRNAs in this set, GFP-AgoshR2c significantly 
reduced GFP fluorescence to about 29 % compared to AgoshRscr (Figure 10 F). 
Microscopical analysis of the cells further confirmed the reduction of GFP 
fluorescence (Figure 11).  
 
FIGURE 12: GFP mRNA expression after expression of sh- or AgoshRNAs. HEK293T 
cells were transfected with a GFP-expression plasmid and the shR1a (positive control) 
or one of the four GFP-AgoshRNAs of set c. A scrambled AgoshRNA (scr) served as 
negative control. Two days post-transfection, RNA was isolated from the cells and GFP 
mRNA levels were determined by qRT-PCR. mCherry, which is also encoded on the sh-
/AgoshRNA expression plasmids, served as a housekeeper to account for transfection 
variability. Results were normalized to cells transfected with an empty vector instead of 
an sh- or AgoshRNA-expression plasmid (indicated by the dashed line). Mean +/- SEM of 
three independent experiments. Statistical analysis: One-way ANOVA followed by 
Dunnett’s test. * p<0.05; *** p<0.001. 
To assess whether the decreased GFP fluorescence is due to mRNA 
cleavage by Ago2 or rather due to translational inhibition, I performed 
quantitative reverse-transcription PCR (qRT-PCR) on RNA isolated from 
transfected HEK293T cells. As expected, the level of GFP mRNA was 
significantly reduced to about 33 % in cells expressing the GFP-shR1a. 
Importantly, also AgoshRNAs led to mRNA degradation, as seen by the 
approximately twofold reduction of GFP mRNA in cells co-transfected with 
GFP-AgoshR2c or GFP-AgoshR3c (Figure 12). The optimization of the 
AgoshRNA design thus yielded an GFP-AgoshRNA that silences GFP in RNAi-
competent cells by means of mRNA degradation.  
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3.1.2 KNOCKDOWN EFFICIENCY IN DICER-DEFICIENT CELLS 
HEK293T cells possess all proteins required for RNAi. It is thus conceivable 
that GFP-AgoshR2c is processed by Dicer and exerts the knock down via the 
conventional RNAi pathway, although the short stem of 18 nt should prevent 
recognition by Dicer. To evaluate if the AgoshRNAs of set c truly act 
independently of Dicer, they were tested in mouse embryonic fibroblast (MEF) 
cells lacking Dicer (Dicer-/- MEF)278, along with the most potent shRNA GFP-
shR1a. As a control, the same experiment was performed in RNAi-competent 
MEF cells that still express Dicer. As MEF cells are hard to transfect, I employed 
recombinant AAVs that packaged GFP or sh/AgoshRNA expression vectors to 
transduce these cells, followed by flow cytometry to measure GFP fluorescence 
four days after transduction.  
A 
 
B
 
FIGURE 13: GFP knockdown in Dicer-deficient cells. (A) Wild type or (B) Dicer-/- MEF 
cells were co-transduced with AAVs encoding GFP and either the shR1a or one of the 
four GFP-AgoshRNAs. A scrambled AgoshRNA (scr) served as negative control. Four 
days after transduction, GFP fluorescence of cells was analyzed via flow cytometry, and 
results were normalized to cells transduced with the scrambled AgoshRNA (dashed 
line). Mean +/- SEM of three independent experiments performed with independent 
AAV productions. Statistical analysis: One-way ANOVA followed by Dunnett’s test. 
ns: not significant. * p<0.05; **  p<0.01; *** p<0.001. 
In RNAi-competent MEF cells, I observed a GFP knockdown pattern 
comparable to that measured in HEK293T cells, albeit the absolute knockdown 
efficiencies were lower in the MEF cells. The GFP-shR1a exerted the most 
potent knockdown to about 60 %, and out of the four AgoshRNAs, only GFP-
AgoshR2c significantly reduced GFP fluorescence to about 73 % (Figure 13 A). 
As expected, the GFP-shR1a is not functional in MEF cells lacking Dicer. 
Importantly, in contrast to the shRNA, GFP-AgoshR2c retains its knockdown 
capacity in Dicer-/- MEF cells, reducing the GFP fluorescence to about 53 % 
(Figure 13 B). Interestingly, also the other AgoshRNAs 1c, 3c, and 4c silence 
GFP in Dicer-/- MEFs (Figure 13 B). Possibly, AgoshRNAs are more potent in 
Dicer-deficient cells as they do not compete with endogenous miRNAs for Ago2, 
an observation that has been made before235.  
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The vectors were 
packaged in AAV-DJ277, a 
capsid that transduces 
MEF cells very efficiently.  
 
 
 
 
Presumably, Dicer-/- MEFs 
express miRNA genes to 
the same level as wild type 
MEFs. However, as Dicer 
does not further process 
the pre-miRNAs, they 
might be no substrate for 
Ago2.   
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Alltogether, the data support the successful generation of AgoshRNAs that 
act independently of Dicer. This is a first essential step towards the 
establishment of the non-canonical RNAi pathway in P. berghei. The following 
Section addresses the next important step, namely, the expression of Ago2 in 
P. berghei.  
3.2 GENERATION OF PBAGO2 
3.2.1 INTEGRATION OF AN AGO2-EXPRESSION CASSETTE 
In order to generate a P. berghei line expressing Ago2 constitutively across 
the life cycle, it is necessary to integrate an Ago2-expression cassette into the 
genome. Previously, a silent intergenic locus on chromosome 6 (SIL6) has been 
published, along with vectors that can be used for integration of DNA sequences 
into this locus without affecting the expression of any endogenous neighboring 
genes of P. berghei279. Here, I used one of these published vectors to integrate 
the Ago2 cDNA into the GFP-positive P. berghei ANKA line PbGFPcon. Figure 14 
shows a schematic representation of the integration strategy.  
 
FIGURE 14: Strategy to integrate Ago2 into the PbGFPcon genome. A 5’HSP70-
promoter-driven human (h)Ago2 expression cassette (red) together with a selection 
marker (blue) for positive and negative selection (hDHFR-yFCU) is placed between two 
DNA segments that are homologous to a genomic sequence on chromosome 6 of 
P. berghei (yellow). After transfection, the vector integrates via double homologous 
crossover into the genome and parasites positive for this integration can be enriched by 
pyrimethamine drug pressure. As the resistance cassette is flanked by homologous 
sequences owing to a duplication of the 3’DHFR-TS UTR (light blue), parasites can 
remove the resistance cassette by recombination. Application of the prodrug 5-FC 
selects for this event, resulting in a marker-free insertion of the 5’HSP70-hAgo2 
expression cassette into the chromosome 6 of P. berghei. The arrows indicate the 
location of the primers used for diagnostic PCR to verify integration and recombination 
events (see also Figure 15 and Figure 16).  
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5-Fluorocytosine
Selection markerhAgo25‘HSP70
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In short, the human Ago2 coding sequence fused to a FLAG- and an HA-tag 
was cloned into the vector pBAT-SIL6 behind the Plasmodium HSP70 promoter, 
a strong and ubiquitously active promoter. Transfection of PbGFPcon parasites 
with a linearized plasmid allowed for the integration of the Ago2 expression 
cassette as well as a drug-selectable marker (hDHFR-yFCU) via double 
homologous crossover into the SIL6. Parasites positive for integration were 
selected by administering pyrimethamine to the drinking water. A subsequent 
limiting dilution allowed the selection of a single clone that only carries the 
integration and was devoid of wild type parasites. As homologous regions 
flanked the drug-selectable marker, parasites could remove the cassette by 
recombination, and negative selection using 5-FC selected for variants that 
have done so. This recycling of the selectable marker is of particular 
importance for this project, as additional pyrimethamine selection is required 
when these parasites are transfected with AgoshRNA-expression vectors (see 
e. g. Section 3.3.) A final limiting dilution gave rise to a single clone of the 
parasite line PbAgo2.  
A 
 
B 
 
FIGURE 15: Diagnostic PCR of PbAgo2 clone 4.3. (A) Genotyping of clones obtained after 
positive selection. After transfection with pBAT-SIL6-Ago2, parasites were put under 
positive selection pressure using pyrimethamine. Limiting dilution (intravenous 
injection of a single parasite per mouse) yielded four clones (3, 4, 9 and 10). DNA 
isolated from these was subject to diagnostic PCR using primers described in Figure 14, 
which demonstrated successful 3’ and 5’ integration of the vector as well as the absence 
of wild type in three out of four clones. (B) Genotyping of clones obtained after negative 
selection. PbAgo2 clone 4 was injected into a donor mouse and subject to negative 
selection pressure with 5-FC. After limiting dilutions, three clones (4.1, 4.3 and 4.4) were 
obtained. Diagnostic PCR using primers described in Figure 14 confirmed the complete 
recycling of the selection marker (absence of 3’ integration band and the presence of a 
band in neg sel PCR) as well as the continued presence of the 5’ integration site.  WT: 
wild type; 5’Int: 5’ Integration; 3’Int: 3’ Integration; Neg Sel; Locus obtained after 
negative selection. D: Donor used for limiting dilution.   
During the generation of this line, all steps were verified by diagnostic PCR 
using different sets of primers binding outside of the integration site as well as 
within the vector (Figure 15, primer binding sites depicted in Figure 14). 
Parasites appeared within one to two weeks after transfection, and four clones 
were obtained after limiting dilution (Figure 15 A). From the clone PbAgo2 4, 
the selection cassette was recycled by negative selection, and the resulting 
parasite population was subjected to another limiting dilution, yielding three 
marker-free clones (Figure 15 B). In this work, all further experiments were 
performed with clone PbAgo2 4.3. In order to obtain two independent clones, 
the transfection and selection procedure was repeated a second time, yielding 
5‘Int 
                    clone 4        h                        
  WT   D     4.1   4.3   4.4      
WT 
5‘Int 
3‘Int 
3‘Int 
                    clone         h 
 WT   D    3    4    9    10      
Neg Sel 
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the second clone PbAgo2 3.2. Figure 16 shows the final diagnostic PCR of these 
two clones which confirmed correct integration of the vector, the recycling of 
the resistance marker and the absence of wild type in both clones. The next two 
Sections delineate the experiments that were performed to further characterize 
these two clones of PbAgo2 regarding the expression of Ago2 and their growth 
behavior across the life cycle.  
 
FIGURE 16: Diagnostic PCR of the final clones PbAgo2 3.2 and 4.3. Genotyping of 
PbGFPcon (wild type, WT) and two independently generated clones of PbAgo2, clone 3.2 
and clone 4.3. Primers used amplified the wild type locus, the 5’ integration site, and the 
3’ integration site as well as the locus following recycling of the selection cassette 
(negative selection) and are indicated as arrows. Their respective binding site is 
depicted in Figure 14. WT: PbGFPcon; Ø: no-template control; PbAgo2 4: Clone prior to 
negative selection, served as a positive control for the 3’ integration PCR.  
 
3.2.2 EXPRESSION OF AGO2 ACROSS THE LIFE CYCLE 
The promoter of HSP70 is a strong promoter and ubiquitously active across 
all life cycle stages of Plasmodium280. I performed Western blotting of mixed 
blood stages of PbGFPcon and PbAgo2 to analyze if this promoter also drives 
Ago2 expression. Probing with an anti-Ago2 antibody revealed a band 
corresponding to the size of Ago2 in both PbAgo2 clones, as well as in the 
positive control (cell lysate of HEK293T cells overexpressing Ago2) (Figure 17). 
Notably, this band is absent from the PbGFPcon sample, even though the HSP70 
loading control indicates that the amount of protein in this sample is 
comparable to the PbAgo2 samples.  
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FIGURE 17: Ago2 expression in mixed blood stages. Western blots of protein lysates of 
PbGFPcon or PbAgo2 mixed blood stages were probed for Ago2 with an anti-hAgo2 
antibody (upper blot). Lysate of HEK293T cells transfected with an Ago2 expression 
construct served as positive control. Probing with an anti-HSP70 antibody served as a 
loading control for the parasite samples (lower blot). 
In addition to blood stages, I also analyzed expression of Ago2 in liver 
stages by immunofluorescence. To this end, I infected human hepatoma cells 
(HuH7 cells) with PbGFPcon or PbAgo2 sporozoites and fixed the developing 
liver stages 48 h later. Staining of the samples with an anti-FLAG antibody 
against the tagged hAgo2 verified expression of Ago2 in late liver stages of 
PbAgo2 3.2 and 4.3, while no signal above background was detected in 
PbGFPcon liver stages (Figure 18).  
 
FIGURE 18: Expression of Ago2 in liver stages. Immunofluorescence staining of liver 
stages 48 h post-infection of HuH7 cells with either PbGFPcon or PbAgo2 sporozoites. 
Cells were incubated with Hoechst to stain the nuclei of parasites and host cells (first 
column), an antibody against the FLAG-tag of Ago2 (second column), and an antibody 
against the PVM protein exported protein 1 (EXP1) (third column). One representative 
image of ten per condition is shown. Pictures were taken with identical settings with a 
confocal microscope and are all processed alike. Scale bars indicate 10 µm.  
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3.2.3 CHARACTERIZATION OF PBAGO2  
In eukaryotic cells, Ago2 is not only a key player in RNAi but has been 
implicated in a wide range of additional functions, including roles in 
transcriptional silencing or splicing281. For some functions, the interaction of 
Ago2 with a short non-coding RNA is required, while others rely on direct 
protein-protein interaction between Ago2 and additional partners. Plasmodium 
parasites encode a large variety of non-coding RNAs, whose functions remain 
mostly unknown282. Although P. berghei does not express miRNAs95, it is 
conceivable that exogenously expressed Ago2 in this parasite interferes with 
the endogenous non-coding RNAs and thus may affect parasite development 
and growth. To evaluate any such unspecific effects, I assessed the life cycle 
progression of PbAgo2 and compared it to the parental line PbGFPcon.  
A
 
B 
 
C 
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FIGURE 19: Growth of PbAgo2 blood stages. (A, B) Inbred C57BL/6J mice or (C, D) 
outbred NMRI mice were intravenously infected with 1000 iRBC of either PbGFPcon, 
PbAgo2 3.2 or PbAgo2 4.3. (A, C) Parasitemia was monitored from day 3 to day 14/15 
post-infection via Giemsa-stained thin blood smears. The number of mice (n) for each 
group is indicated in the legend. Shown is the mean parasitemia +/-SEM. (B, D) Survival 
of the infected mice. Mice were observed until day 20 post-infection for signs of (B) 
experimental cerebral malaria or (B, D) severe disease symptoms and sacrificed 
accordingly. d.p.i: days post-infection.  
In order to compare the growth rate of PbAgo2 to PbGFPcon, inbred 
C57BL/6J mice were intravenously injected with 1000 iRBCs, and parasitemia 
was determined by daily blood smears from day 3 to day 14/15 post-infection 
(Figure 19 A). The growth of PbAgo2 during the first six days of infection was 
comparable to that of PbGFPcon. The parasitemia of PbGFPcon-infected mice 
then continued to increase until it reached a plateau at approximately 5 % on 
day 8 to 10. Around this time, these mice developed signs of ECM and 
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succumbed to the infection (Figure 19 B), as it is expected for PbANKA-infected 
C57BL/6 mice283. In contrast to wild type, PbAgo2 parasites grew significantly 
slower, with a declining parasitemia on days 8 to 10 post infection followed by 
resurgence two weeks post-infection. The reduced growth rate was 
accompanied by an increased survival of PbAgo2-infected mice, with only a 
subpopulation succumbing to the disease in the 20 days following infection. 
To assess if this growth impairment is mouse strain specific or a general 
feature of PbAgo2, I repeated the experiment in outbred NMRI mice (Figure 
19 C, D). In this strain, the parasitemia of PbGFPcon increased rather steadily 
over the course of infection, reaching a peak of 15 % at day 14 after infection. 
Early after infection, the parasitemia of PbAgo2-infected mice was even higher 
than in the wild type-infected mice. However, as observed for the C57BL/6 
mice, it then dropped on day 8 to 10 post-infection. This reduction is followed 
by another increase, reaching a peak parasitemia of 10 to 15 %. In contrast to 
C57BL/6 mice, NMRI mice do not develop cerebral symptoms but rather die 
due to hyperparasitemia and anemia. Interestingly, the survival of NMRI mice is 
not different between PbGFPcon- and PbAgo2-infected animals. In conclusion, 
while the expression of Ago2 affects the blood-stage growth rate, the 
differences of PbAgo2 to PbGFPcon are much less pronounced in NMRI mice 
than in C57BL/6 mice.  
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FIGURE 20: Mosquito stage development. Mosquitoes were infected by blood meal on 
parasite-infected mice. (A) Midguts were isolated 12 to 14 days after blood mean from 
10 to 15 mosquitoes per cage, and the number of oocysts per midgut was scored by 
microscopic examination. Depicted is the percentage of midguts (+/-SEM) belonging to 
one of five groups: No oocysts, 1 to 10 oocysts, 11 to 30 oocysts, 31 to 100 oocysts, >100 
oocysts per midgut. Data is the mean of four to five independent feedings per strain. 
(B) Salivary gland sporozoites were isolated 18 days post-feeding from at least 25 
female mosquitoes per cage and counted. Depicted is the average number of sporozoites 
per female mosquito. Each dot represents an individual cage (independent feeding). 
Statistics: One-way ANOVA followed by Dunnett’s test. * p<0.05. 
Within oocysts, sporozoites develop, which are released into the 
hemolymph of the mosquito to invade the salivary glands. On day 18 after 
infectious blood meal, I dissected salivary glands from mosquitoes and 
determined the average number of sporozoites per mosquito. The infectivity of 
PbAgo2-infected mosquitoes (on average 1500 to 3000 sporozoites per 
mosquito) was significantly lower than that of PbGFPcon-infected mosquitoes 
(on average 10000 sporozoites per mosquito) (Figure 20 B). The reduced 
number of salivary gland sporozoites is likely a direct consequence of the lower 
infection rate of PbAgo2- compared to PbGFPcon-infected mosquitoes and does 
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not necessarily mean that PbAgo2 forms fewer infectious sporozoites than the 
wild type. To conclude at which stages the development of PbAgo2 in the 
mosquito is impaired, one could quantify the mosquito infection rate more 
precisely regarding oocyst numbers as well as midgut sporozoite numbers per 
mosquito. Nevertheless, for the purpose of this work a general estimation of 
mosquito infectivity of PbAgo2 is sufficient. 
Sporozoites are transmitted to the mammalian host by the bite of an 
infected mosquito and, after entering the blood-stream, they subsequently 
infect hepatocytes to undergo the first round of asexual replication. This liver 
stage development can be monitored in vitro by adding a defined amount of 
sporozoites to human hepatoma (HuH7) cells and detecting the number and 
size of liver stages at various time points post infection by 
immunofluorescence. In Figure 21 A and B, numbers and sizes of PbAgo2 liver 
stages 48 h after infection are compared to those of PbGFPcon. Interestingly, in 
contrast to blood stages and mosquito stages, the expression of Ago2 does not 
have a significant impact on liver stage development in vitro.  
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FIGURE 21: Liver stage development in vitro and in vivo. (A, B) HuH7 cells were 
infected with 104 sporozoites per well and incubated for 48 h prior to fixing and staining 
with an anti-HSP70 antibody. (A) Numbers of liver stages per well and (B) sizes of at 
least 50 randomly selected liver stages per experiment were determined by 
fluorescence microscopy and results were normalized to PbGFPcon wild type liver 
stages analyzed in parallel. Shown is the merged data (A) as bar graph +/- SEM or (B) as 
whisker plots with 10-90 percentile of three independent experiments comprising 4-8 
technical replicates each. Statistics: One-Way-ANOVA followed by Dunnett’s test. ns: 
non-significant. (C, D) C57BL/6J mice were i. v. infected with 104 sporozoites. (C) 
Parasitemia was determined from daily blood smears from 3 to 14/15 days after 
infection. (D) Survival of mice. Mice were observed until day 20 post-infection for signs 
of ECM or severe disease and sacrificed accordingly.  
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To test if PbAgo2 also completes liver stage development in vivo, I infected 
C57BL/6 mice i.v. with sporozoites and monitored parasitemia over the course 
of the infection. PbAgo2-infected mice had a one day delay in prepatency when 
compared to PbGFPcon-infected mice, and lower overall parasitemia (Figure 21 
C). In concordance with the phenotype observed after iRBC inoculation, the 
survival of PbAgo2-infected mice was increased, while PbGFPcon-infected mice 
succumbed to ECM 7 days post-infection (Figure 21 D). Taking into account that 
the liver stage development is not impaired in vitro, the delay in prepatency 
and the reduced growth can most likely be attributed to the decreased growth 
rate in the blood stages. Importantly, despite a growth defect in blood and 
mosquito stages, PbAgo2 can complete the whole life cycle.  
3.3 KNOCKDOWN OF GFP IN BLOOD STAGES  
The previous two Sections described the basic ingredients required for 
using the non-canonical RNAi machinery in Plasmodium: An AgoshRNA that 
targets GFP independently of Dicer, and a parasite line that expresses Ago2. The 
following Section summarizes how these two parts were subsequently 
combined to target GFP for Ago2-mediated downregulation in P. berghei.  
3.3.1 KNOCKDOWN OF GFP IN PBAGO2 
To begin to elucidate whether PbAgo2 is indeed capable of executing RNAi, 
I selected the most potent AgoshRNA against GFP, GFP-AgoshR2c and 
designed a vector to express this AgoshRNA in PbAgo2. AgoshRscr was 
included as negative control. P. berghei blood stages are known to maintain 
circular plasmid DNA as episomes and amplify these along with the genomic 
DNA60,285. Transfection of plasmids as episomes instead of a stable integration 
of the DNA allows for a quick assessment of the effect of the specific AgoshRNA, 
without the need to select individual clones via limited dilution.  
The first challenge was the identification of a promoter driving AgoshRNA 
expression in P. berghei. In contrast to protein-coding mRNAs, which are 
transcribed from a polymerase II promoter, many short non-coding RNAs are 
transcribed by polymerase III (Pol III)286. Only few Pol III-transcripts are well 
described in apicomplexan species, among these are spliceosomal RNAs such as 
the U6 snRNA287. With the introduction of the CRISPR/Cas9 technology to 
Plasmodium and Toxoplasma research, however, Pol III promoters were needed 
to transcribe the gRNAs that target the Cas9 protein to the DNA. Both for 
P. falciparum as well as for T. gondii, the expression of gRNAs has been achieved 
by using the 5’ region of the spliceosomal U6 snRNA288–290, however, no 
application of the P. berghei U6 promoter has been reported.  
 
 
 
The mechanism by which 
Plasmodium amplifies 
these episomes is still 
unknown, but there is 
apparently no need for a 
specific sequence to serve 
as origin of replication284. 
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Based on homology to the P. falciparum U6 promoter, I chose 500 bp 
upstream of the P. berghei U6 snRNA gene to drive expression of AgoshRNAs. 
Additionally, I added a stretch of five adenosines at the 3’ end of the AgoshRNA 
to serve as a termination signal for the polymerase III286.  The vector that I 
designed for episomal expression consisted of three main components:  
1) A pyrimethamine marker to permit selection for transfectants.
2) An mCherry fluorescence reporter driven by an HSP70 promoter to 
distinguish between parasites carrying the episome and parasites that 
spontaneously became pyrimethamine resistant.
3) An expression cassette for the AgoshRNA. 
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FIGURE 22: GFP knockdown in blood stages. PbGFPcon or PbAgo2 3.2 parasites were 
transfected with episomal vectors carrying mCherry and either GFP-AgoshR2c or 
AgoshRscr. Upon appearance in the blood, parasites were imaged with a wide-field 
fluorescence microscope. Shown are representative images taken using the same 
settings. Only parasites that exhibited mCherry fluorescence were chosen for 
quantification of the GFP signal (Figure 23). The white arrows in the first row of images 
specify a parasite that does not carry the episome as indicated by a lack of mCherry 
fluorescence and which was thus excluded from the analysis. The scale bars indicate 
10 µm.  
Transfection of PbAgo2 3.2, PbAgo2 4.3 or PbGFPcon parasites with such 
plasmids encoding either GFP-AgoshR2c or AgoshRscr yielded 
pyrimethamine-resistant parasites in the usual time frame of one to three 
weeks. In almost all cases, 90-100 % of parasites were also mCherry-positive, 
indicating that they carry the episome (Figure 22). For quantification of the GFP 
fluorescence, only those parasites were considered that expressed mCherry, 
and parasites that lacked mCherry fluorescence were excluded from further 
analysis (an example is highlighted with an arrow in the upper lane of Figure 
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22). Parasite populations with less than 90 % mCherry-positive blood stages 
occurred in about 5 % of all transfections, suggesting that a subpopulation of 
parasites spontaneously acquired resistance to pyrimethamine and outgrew 
the parasites maintaining the episome. In this case, these parasites were 
discarded and the transfection was repeated.  
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FIGURE 23: Quantification of GFP fluorescence in blood stages. PbGFPcon, PbAgo2 3.2 
or PbAgo2 4.3 were transfected with episomes encoding either AgoshRscr (scr) or the 
GFP-AgoshR2c (GFP2c) and selected with pyrimethamine drug pressure. After the 
appearance of pyrimethamine-resistant parasites, blood stages were imaged with a 
wide-field fluorescence microscope with constant settings across all samples. The 
integrated GFP fluorescence intensity of individual parasites was determined using the 
software ImageJ. Depicted is the integrated GFP fluorescence intensity for individual 
(A) ring stages, (B) early trophozoites, (C) late trophozoites and (D) gametocytes as 
whisker plots with 10-90 percentile. Data is merged from three independent 
experiments (based on independent transfections), and the number below each bar 
indicates the total number of individual parasites quantified. Statistics: Kruskal-Wallis-
Test followed by Dunn’s test. ns: not significant; *** p<0.001; au: arbitrary units.  
While imaging the transfected parasites, I noted that the GFP fluorescence 
of PbAgo2 parasites transfected with GFP-AgoshR2c was greatly diminished 
compared to PbGFPcon parasites or PbAgo2 parasites transfected with 
AgoshRscr (Figure 22). Quantification of the GFP signal of individual parasites 
revealed that the GFP fluorescence of all PbAgo2 blood stages (ring stages, early 
trophozoites, late trophozoites, and gametocytes) decreased significantly upon 
expression of GFP-AgoshR2c as compared to AgoshRscr (Figure 23). Western 
blot analysis of schizont-enriched blood stages further supported a reduction of 
GFP on the protein level in PbAgo2 upon expression of GFP-AgoshR2 (Figure 
24). Importantly, in PbGFPcon parasites, GFP-AgoshRNA did not alter GFP 
fluorescence or protein level (Figure 22-24). This observation further 
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corroborates that wild type P. berghei is devoid of any RNAi machinery and 
suggests that the detected reduction of GFP is indeed due to Ago2-mediated 
RNAi in PbAgo2. 
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FIGURE 24: GFP protein levels upon expression of GFP-AgoshR2c. Schizont-enriched 
protein samples of PbGFPcon, PbAgo2 3.2 or PbAgo2 4.3 transfected with AgoshRscr or 
GFP-AgoshR2c were analyzed by Western blotting. The blots were probed with an 
antibody against GFP or HSP70. (A) and (B) show representative blots from samples 
obtained from independent transfections (biological replicate). Each blot was done in 
technical duplicates. 
It is notable that the GFP-AgoshR2c-mediated knockdown of GFP is much 
more pronounced in PbAgo2 (about 40-fold reduction of fluorescence in late 
trophozoites) than in vitro (about 2-fold reduction of GFP fluorescence) 
(compare Figure 10 F to Figure 23 C). Possible explanations for this will be 
discussed in detail in Chapter 4. The strength of the GFP knockdown prompted 
me to test also the other AgoshRNAs, which had shown only a limited effect 
against GFP in vitro, in PbAgo2.  
3.3.2 FINE-TUNING OF GFP EXPRESSION 
To this end, I transfected PbAgo2 3.2 with vectors encoding the other three 
GFP-AgoshRNAs, namely GFP-AgoshR1c, -AgoshR3c and -AgoshR4c, and 
performed the same microscopic analysis of blood stages as in the first 
experiment (see Section 3.3.1). Indeed, all AgoshRNAs were found to be active 
against GFP and significantly reduced the fluorescence of transgenic parasites. 
The extent of the knockdown varied between the individual AgoshRNAs, and 
ranged, for late trophozoites, from 5-fold (GFP-AgoshR4c) to 13-fold 
reduction (GFP-AgoshR3c) (Figure 25). 
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FIGURE 25: Quantification of GFP fluorescence after expression of different 
AgoshRNAs. PbAgo2 3.2 was transfected with episomes encoding one of the GFP-
AgoshRNAs 1c, 3c or 4c. (GFP1c, GFP3c, or GFP4c, respectively), and selected with 
pyrimethamine drug pressure. After the appearance of pyrimethamine-resistant 
parasites, blood stages were imaged with a wide-field fluorescence microscope with 
constant settings across all samples. The integrated GFP fluorescence intensity of 
individual parasites was determined using the software ImageJ. Depicted is the 
integrated GFP fluorescence intensity for individual (A) ring stages, (B) early 
trophozoites, (C) late trophozoites and (D) gametocytes as whisker plots with 10-90 
percentile. Data is merged from two independent experiments (based on independent 
transfections), and the number below each bar indicates the total number of individual 
parasites quantified. Note that the data for PbAgo2 3.2 transfected with AgoshRscr and 
AgoshR2c is taken from Figure 23 and plotted here again for comparison. Statistics: 
Kruskal-Wallis-Test followed by Dunn’s test. ns: not significant; * p<0.05; ** p<0.01; 
*** p<0.001; au: arbitrary units.  
A Western blot analysis of schizont-enriched blood stages yielded the same 
pattern, with GFP-AgoshR2 inducing the strongest reduction of GFP, followed 
by the GFP-AgoshR3c, AgoshR1c, and AgoshR4c, in this order (Figure 26). 
Interestingly, this observation parallels the results in Dicer-deficient MEF cells 
(see Section 3.1.2, Figure 13 B). This implies that the cell culture assays are a 
good indicator of the relative activity of individual AgoshRNAs against a given 
target, albeit they may not accurately predict the strength of the knockdown 
that can be observed in vivo. 
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FIGURE 26: GFP protein levels in PbAgo2 expressing different GFP-AgoshRNAs. 
Schizont-enriched protein samples of PbAgo2 3.2 transfected with AgoshRscr or one of 
the four GFP-AgoshRNAs were analyzed by Western blotting. The blots were probed 
with an antibody against GFP or HSP70. (A) and (B) show representative blots from 
samples obtained from independent transfections (biological replicate). Each blot was 
done in technical duplicates. (C) Relative amount of GFP as compared to AgoshRscr-
transfected samples. Protein amount was determined with ImageJ using the HSP70 band 
to normalize for input. Each dot represents an individual technical replicate and dots of 
the same shade (dark or light) belong to the same biological replicate. Note that while 
there is a high technical variation between blots, the overall trend is in line with 
previous quantifications of GFP fluorescence intensity (compare Figure 25).  
3.4 KNOCKDOWN OF AN ENDOGENOUS TARGET IN 
BLOOD STAGES 
Having confirmed that a knock down of GFP using AgoshRNAs is possible, 
the next step was to silence the expression of an endogenous gene. The target I 
chose for the first knockdown experiment was required to fulfill three main 
criteria: 
1) It must not be essential for blood stage development, as it was not clear 
at this point whether RNAi-mediated knockdown would be possible for 
this group of genes. 
2) The phenotype of the knockout of this gene should be published, to 
permit an assessment whether the knockdown phenocopies the 
knockout.  
3) The phenotype should appear in blood stages, where episomally 
expressed AgoshRNAs would induce a knockdown, and should be easy 
to quantify.  
Using these three criteria, I searched the literature and selected the gene 
encoding the Plasmodium perforin-like protein 2 (PPLP2), whose knockout has 
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been published both for P. berghei and P. falciparum291,292. This protein is 
important for the exflagellation of the male gametocytes, which occurs when 
gametocytes enter the mosquito midgut. The concurrent drop in temperature 
and increase of pH, as well as the presence of xanthurenic acid, induces a 
cascade of events in which the male gametocyte replicates its nucleus three 
times and forms eight flagellated gametes. These gametes then emerge from the 
red blood cell and actively search for a female gametocyte to fertilize51. Since 
PPLP2 is required for the lysis of the RBC membrane during the emergence of 
the gametes, the gametocytes are trapped within the erythrocyte if PPLP2 is 
missing. Instead of eight individual flagella, they form a single large 
“superflagellum” within the erythrocyte membrane, which can be easily 
distinguished under the microscope291.  
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FIGURE 27: Knockdown of PPLP2 phenocopies the pplp2(-) parasite. PbAgo2 3.2 
parasites were transfected with AgoshRscr, GFP-AgoshR4c (both black), or one of three 
PPLP2-AgoshRNAs (2, 3 or 4, turquoise). To enrich for gametocytes, mice were 
pretreated with phenylhydrazine prior to i.v. infection with 106 iRBC. (A) Four days after 
infection, blood was collected and PPLP2 mRNA levels were determined by qRT-PCR. 
The gametocyte-specific gene PSOP1 (putative secreted ookinete protein, 
PBANKA_0619200) served as housekeeper293. Results were normalized to PbAgo2 + 
AgoshRscr.  Each dot represents parasites isolated from an individual mouse. Statistics: 
One-way-ANOVA followed by Dunnett’s test. * p<0.05; ** p<0.01. (B) Exflagellation 
events were microscopically examined four days after infection and scored as either 
normal (black) with the formation of eight individual flagella or abnormal (turquoise) 
with the formation of a single large superflagellum. Numbers of individual 
exflagellations assessed are indicated at the bottom of the bars. (C) Representative 
picture of a normally exflagellating gametocyte. Note that the individual flagella are 
difficult to image due to their thin nature. The scale bar indicates 10 µm. (D) 
Representative picture of a gametocyte forming a superflagellum due to the lack of 
PPLP2. The scale bar indicates 10 µm. 
To address whether an AgoshRNA-mediated knockdown of PPLP2 could 
phenocopy this effect, I designed four different AgoshRNAs against PPLP2 
(PPLP2-AgoshR1 to 4) based on the design rules outlined in section 3.1.1, and 
transfected these AgoshRNAs as episomes into PbAgo2 3.2. Parasites positive 
for mCherry fluorescence appeared readily at one to two weeks after 
transfection. Surprisingly, sequencing of the four parasite lines revealed that 
the parasite line that should have been transfected with the PPLP2-AgoshR1 
episome instead carried the GFP-AgoshR4c episome. It remains unclear at 
which point this mix-up occurred. Nevertheless, I included this line in all 
subsequent analyses as an additional non-targeting AgoshRNA. The other 
parasite lines obtained all carried the correct episome.  
0.1
1
10
PbAgo2 3.2
GFP 4c PPLP2 3
     scr PPLP2 2 PPLP2 4
*
**
R
e
la
ti
ve
 P
P
LP
2
 e
xp
re
ss
io
n
0
20
40
60
80
100
Normal
Abnormal
587       735        114        91        588
%
 E
xf
la
g
e
lla
ti
o
n
PbAgo2 3.2
GFP 4c PPLP2 3
     scr PPLP2 2 PPLP2 4
KNOCKDOWN OF AN ENDOGENOUS TARGET IN BLOOD STAGES 45 
 
As PPLP2 is only expressed in gametocytes, I performed all experiments in 
conditions that promote gametocytogenesis. To this end, I pretreated mice 
prior to parasite infection with phenylhydrazine, a substance that induces 
reticulocytosis, which is known to foster the development of gametocytes294. 
Quantification of the PPLP2 mRNA by qRT-PCR of these gametocyte-enriched 
samples revealed a robust knockdown of PPLP2 for two out of three 
AgoshRNAs (PPLP2-AgoshR2 and -AgoshR3), while PPLP2 mRNA levels 
remained unchanged in parasites expressing GFP-AgoshR4c or PPLP2-
AgoshR4 (Figure 27 A). I then examined exflagellation of these transfected 
parasites. Parasites expressing AgoshRscr, GFP-AgoshR4c or PPLP2-
AgoshR4, which all do not silence PPLP2, predominantly exflagellated normally 
by forming eight separate flagella (Figure 27 B, C). In contrast, a subpopulation 
of parasites that expressed PPLP2-AgoshR2 or -AgoshR3 showed the 
previously described phenotype of a superflagellum (Figure 27 B, D). In 
conclusion, a knockdown of PPLP2 can induce the same phenotype as a full 
knockout291,292. 
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FIGURE 28: PPLP2 knockdown is accompanied by a reduced exflagellation 
frequency. (A) Four days prior to the analysis, phenylhydrazine-pretreated mice were 
i.v. infected with 2x106 iRBCs of PbAgo2 3.2 carrying AgoshRscr, GFP-AgoshR4c (both 
black), or one of three PPLP2-AgoshRNAs (turquoise). A drop of tail blood was 
transferred to a glass slide, and exflagellation was induced with xanthurenic acid. 
Twelve min after induction, exflagellation events and field of views (FOV) were counted 
for 2.5 min. Shown are the exflagellation events per FOV normalized to the scr control 
quantified in parallel. Statistics: One-way ANOVA with Dunnett’s multiple comparisons. 
*** p<0.001.  (B) Absolute and (C) relative parasitemia and gametocytaemia of the mice 
were determined in parallel from Giemsa-stained thin blood smears.  
While assessing the phenotype of the PPLP2-AgoshRNAs, I noticed that 
parasites that expressed either PPLP2-AgoshR2 or -AgoshR3 seemed to 
exflagellate less frequently than the others. I thus quantified the exflagellation 
rate in gametocyte-enriched parasite populations. Interestingly, there was a 
sharp and significant drop in the exflagellation rate of PbAgo2 parasites 
expressing an active PPLP2-AgoshRNA versus those expressing a scrambled 
AgoshRNA or the non-active PPLP2-AgoshR3 (Figure 28 A). Although there 
was also a slight reduction of the overall parasitemia in these groups (Figure 
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28 B), its extent was not sufficient to explain the reduced exflagellation rate. 
PPLP2 inhibition did not influence the formation of gametocytes, as their in all 
iRBCs remained constant, irrespective of the AgoshRNA expressed (Figure 
28 C). Additionally, the gametocytaemia of individual mice did not correlate 
with the exflagellation frequency (data not shown). The observation that a 
knockdown of PPLP2 reduces the rate of exflagellation contrasts the published 
phenotype of PPLP2-deficient P. berghei parasites, which presumably 
exflagellate at the same rate291. However, such a loss of exflagellation is 
reported for a PPLP2 knockout in P. falciparum292.  
3.5 STABLE INTEGRATION OF AGOSHRNAS 
As demonstrated in the previous Sections, episomal AgoshRNA expression 
can lead to a potent knockdown of a target of interest in blood stages. However, 
episomes are no suitable tool for target knockdown in the mosquito stages, as 
the plasmids are not evenly distributed to daughter cells during asexual 
replication. Therefore, constant drug selection is required to retain the 
episome, which is not possible in the mosquito stages285,295. Hence, the 
episomal plasmid is lost during the asexual replication within the mosquito 
midgut. To study whether RNAi is also functional in non-erythrocytic stages of 
PbAgo2, it is thus necessary to stably integrate the AgoshRNAs into the genome. 
This is the subject of the following Section.  
3.5.1 INTEGRATION STRATEGY 
Akin to the initial experiment in blood stages, GFP served as a proof-of-
principle target for a knockdown in mosquito- and liver stages. Accordingly, I 
designed a construct to integrate the potent GFP-AgoshR2c as well as the 
AgoshRscr as a negative control into the PbAgo2 genome directly behind the 
Ago2 expression cassette. A scheme of the construct design and the integration 
strategy is depicted in Figure 29 A.  
The integration vector was designed in such a way that the 3’UTR of Ago2 
and the 3’ region of SIL6 serve as homology regions for double homologous 
integration (Figure 29 A). In PbAgo2, these two parts border the part of the 
selection marker that remained after recycling of the cassette by homologous 
recombination, i. e. the duplicate region of the 3’DHFR-TS site (see also Section 
3.2.1, Figure 14). Inadvertently, this site was also present in the integration 
vector for the AgoshRNAs. Therefore, parasites could use the duplicate 3’DHFR-
TS region as homology arm to integrate the selection marker only, without the 
5’PbU6-AgoshRNA cassette (depicted as red dashed lines in Figure 29). 
Consequently, the transfection of PbAgo2 3.2 with this initial set of constructs 
resulted in a mixed population of parasites that either had the full selection 
marker and 5’PbU6-AgoshRNA cassette incorporated into the genome or only 
integrated the resistance cassette. Still, a single clone of each line 
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PbAgo2.GFP2c and PbAgo2.scr could be obtained after limiting dilution which 
had the 5’PbU6-AgoshRNA cassette integrated as intended. Diagnostic PCR of 
the parental locus and the 3’ integration site verified the absence of the PbAgo2 
parental line and of parasites with only the selection marker integrated (Figure 
29 B, C).  
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B              PbAgo2 3.2          h 
            3.2      .scr   .GFP2c  Ø 
 
                   Parental  
C               PbAgo2 3.2          h 
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FIGURE 29: Integration strategy and genotyping of PbAgo2.scr and PbAgo2.GFP2c. 
(A) Strategy to integrate the AgoshRNA under the 5’PbU6 promoter (5’PbU6-AgoshRNA) 
along with a selection marker for pyrimethamine resistance (hDHFR-yFCU) into the 
genome of PbAgo2. The red dashed lines indicate an alternative 3’ homology region that 
can lead to the insertion of the selection cassette only. (B, C) Diagnostic PCR of 
PbAgo2.scr and PbAgo2.GFP2c clonal lines. PbAgo2 3.2 (first lane) served as a control 
for the parental line. Ø: No-template control. Colored arrows indicate the respective 
primer pairs used for amplification in (A). (B) PCR amplifying the parental locus. 
Amplification of the parental locus yields a fragment of 1.3 kb which is visible for 
PbAgo2 3.2, but absent in PbAgo2.scr and PbAgo2.GFP2c. Note the larger amplicons in 
the lanes PbAgo2.scr and PbAgo2.GFP2c. These indicate that a subpopulation of these 
lines has already removed the selection marker by homologous recombination 
(expected amplicon length for this event: 1.7 kb). (C) PCR amplifying the 3 ’integration 
site, yielding an expected amplicon length of 1.9 kb. Note that in the case of an unwanted 
integration event of the selection cassette only, this PCR would result in a shorter 
amplicon of 1.4 kb, which is absent in both clonal lines.  
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3.5.2 GROWTH BEHAVIOR OF PBAGO2.SCR 
Up to this point, it was still unclear what causes the growth impairment of 
PbAgo2. A hypothesis was that in the absence of an AgoshRNA, Ago2 binds in an 
unspecific manner to endogenous non-coding RNAs, resulting in their 
dysregulation. An analogous growth impairment has been observed in T. gondii 
that constitutively express the Cas9 protein. Similar to Ago2, Cas9 requires a 
small RNA to function, and in the absence of a matching gRNA, the 
endonuclease might associate with endogenous small RNAs. A recent study has 
demonstrated that constitutive co-expression of a non-targeting decoy gRNA 
alleviated the growth defect induced by Cas9 expression in T. gondii75. I thus 
hypothesized that the expression of the AgoshRscr might have a similar effect 
and rescue the growth of PbAgo2.  
A 
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FIGURE 30: Blood-stage growth of PbAgo2.scr. Inbred C57BL/6J mice were 
intravenously infected with 1000 iRBC of either PbAgo2 3.2 or PbAgo2.scr. 
(A) Parasitemia was monitored from day 3 to day 14 post-infection via Giemsa-stained 
thin blood smears. The number of mice (n) for each group is indicated in the legend. 
Shown is the mean parasitemia +/-SEM. (B) Survival of the infected mice. Mice were 
observed until day 20 post-infection for signs of ECM or severe disease symptoms and 
sacrificed accordingly. d.p.i: days post-infection.  
To test this hypothesis, I infected C57BL/6J mice with 1000 iRBC of PbAgo2 
or PbAgo2.scr and followed parasitemia and survival over 14 and 20 days, 
respectively (Figure 30). Both lines had a very comparable growth rate and 
survival of mice, which reflects the data observed in the previous experiments 
with PbAgo2 (see Section 3.2.3, Figure 19). Vera Mitesser further analyzed 
these two lines during her master thesis. After feeding the two lines PbAgo2.scr 
and PbAgo2.GFP2c to mosquitoes, she determined the mosquito infectivity of 
these lines by measuring oocyst prevalence and sporozoite numbers (Figure 
31). Similar to the blood-stage growth, a decreased mosquito infectivity in the 
range of previously obtained data for PbAgo2 became apparent (see Section 
3.2.3, Figure 20). In conclusion, in contrast to observations for Cas9 expression 
in T. gondii, the expression of a scrambled AgoshRNA does not rescue the 
growth defect of PbAgo2. The observation that Ago2 toxicity cannot be 
alleviated by the presence of an AgoshRNA indicates that the growth defect 
may not mediated by the RNA binding function of Ago2.   
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FIGURE 31: Mosquito development of PbAgo2.scr and PbAgo2.GFP2c. Mosquitoes 
were infected by blood meal on parasite-infected mice. (A) Midguts were isolated 12 to 
14 days after blood meal from 10 to 15 mosquitoes per cage, and the number of oocysts 
per midgut was scored by microscopic examination. Depicted is the percentage of 
midguts (+/-SEM) belonging to one of five groups: No oocysts, 1-10 oocysts, 11 to 30 
oocysts, 31 to 100 oocysts, >100 oocysts per midgut. Data is the mean of four to five 
independent feedings per strain. (B) Salivary gland sporozoites were isolated 18 days 
after blood meal from at least 25 female mosquitoes per cage and counted. Depicted is 
the average number of salivary gland sporozoites per female mosquito. Each dot 
represents an individual cage (independent feeding). Note that data for the PbGFPcon 
wild type is the same as in Figure 20, and presented here for comparison only.  
3.5.3 KNOCKDOWN OF GFP ACROSS THE LIFE CYCLE 
Importantly, the stable integration of AgoshRNAs into the genome of 
PbAgo2 now allowed to assess whether Ago2-mediated RNAi is also possible in 
the other life cycle stages of the PbAgo2 parasite line. First, however, I analyzed 
the GFP fluorescence of blood stages by microscopy and indeed observed that 
PbAgo2.GFP2c lacks any detectable GFP fluorescence (Figure 32 A). This 
finding was further confirmed by Vera Mitesser when she performed a Western 
blot of schizont-enriched PbAgo2.scr and PbAgo2.GFP2c samples (Figure 
32 B). Subsequently, Vera Mitesser and I both analyzed the non-erythrocytic 
stages of PbAgo2.  
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FIGURE 32: Knock down of GFP in blood stages. (A) Blood stage parasites of PbAgo2.scr 
or PbAgo2.GFP2c were imaged with a fluorescence microscope with equal settings. 
Shown are the DIC and GFP channel, and in the merge additionally Hoechst-stained 
nuclei (blue) to indicate parasites. The scale bars indicate 10 µm. (B) Western blot 
analysis of schizont-enriched cultures of PbAgo2.scr or PbAgo2.GFP2c. Blots were 
revealed with an anti-HSP70 antibody (upper blot) or an anti-GFP antibody (lower blot). 
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The analysis of the GFP 
fluorescence of the lines 
PbAgo2.scr and 
PbAgo2.GFP2c were 
carried out in part by 
Vera Mitesser in the 
course of her master 
thesis.  
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After feeding mosquitoes on PbAgo2.scr or PbAgo2.GFP2c-infected mice, 
we imaged oocysts at day 13. Importantly, we measured a significant reduction 
of GFP fluorescence for PbAgo2.GFP2c compared to PbAgo2.scr oocysts 
(Figure 33 A, B). We also imaged salivary gland sporozoites at day 18 and found 
that PbAgo2.GFP2c sporozoites were clearly less GFP-fluorescent than their 
PbAgo2.scr counterpart (Figure 33 C, D). These findings confirm that both Ago2 
and AgoshRNAs are active in the mosquito stages of PbAgo2.  
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FIGURE 33: Knock down of GFP in mosquito stages. Mosquitoes were fed on 
PbAgo2.scr- or PbAgo2.GFP2c-infected mice. (A) Midgut oocysts (day 13) and (C) 
salivary gland sporozoites (day 18) were imaged with a wide-field microscope. Shown 
are representative pictures of PbAgo2.scr and PbAgo2.GFP2c. The scale bar indicates 
10 µm. GFP fluorescence of (B) oocysts and (D) sporozoites was quantified using ImageJ. 
Depicted is the pooled data of three independent experiments (independent cages) as 
whiskers plot with 5-95 percentile. Numbers below the bars indicate the total number of 
individual parasites. Statistics: Student’s T-test. *** p<0.001. 
Finally, we also analyzed the GFP knockdown in liver stages. As imaging of 
the GFP fluorescence of live liver stages has proven to be difficult, we fixed 
sporozoite-infected liver stages with methanol after 48 h of intrahepatic 
development and stained them with an anti-GFP antibody as well as an 
antibody against HSP70 (Figure 34 A). We quantified the signal of the anti-GFP 
staining from microscopy images and again determined a marked 
downregulation of GFP in PbAgo2.GFP2c- versus PbAgo2.scr-liver stages 
(Figure 34 B). In conclusion, the PbAgo2 parasite strain is capable of RNAi-
mediated target knockdown in all stages of the life cycle. 
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FIGURE 34: Knock down of GFP in liver stages. (A) Liver stages of PbAgo2.scr and 
PbAgo2.GFP2c were fixed 48 h post-invasion and stained with an antibody against 
HSP70 (first column), an antibody against GFP (second column) and Hoechst to stain 
DNA (third column). Shown are representative images. All pictures were taken with a 
wide-field microscope with same settings and processed alike. The scale bars indicate 
10 µm. (B) The GFP signal of liver stages after immunofluorescence staining was 
quantified using ImageJ, and normalized to the mean signal intensity of PbAgo2.scr liver 
stages to control for different staining efficiencies. Shown is the pooled data of two 
independent experiments (independent cages). Numbers below the bars indicate the 
total number of individual parasites quantified. Statistics: Student’s T-test. *** p<0.001.  
3.6 KNOCKDOWN OF EXPORTED PROTEIN 1 
(EXP1) 
As shown in the previous Sections, expression of different AgoshRNAs in 
PbAgo2 induce a target knockdown to various levels. This differential 
knockdown results in intermediate phenotypes, such as the partially reduced 
GFP fluorescence (see Section 3.3.2) or formation of a superflagellum in a part 
of the population when targeting PPLP2 (see Section 3.4). This observation 
prompted the hypothesis that PbAgo2 might permit targeting of a blood-stage 
essential gene, as its partial knockdown might be compatible with parasite 
survival while still yielding a phenotype that allows to study gene function. To 
test this hypothesis, I chose the blood-stage essential gene exported protein 1 
(EXP1) as a target. EXP1 is a dominant antigen in many immune responses and 
a major vaccine candidate296. This protein is located to the PVM of blood-stage 
as well as liver-stage parasites297–299, and its function is not yet clearly 
identified. EXP1 has been refractory to gene deletion, but studies on truncated 
EXP1 have shown that in the liver, the C terminus of EXP1 is involved in the 
uptake of nutrients by directly interacting with the host cell factor ApoH119. In 
blood-stages, EXP1 might act as glutathione transferase300. However, this 
current hypothesis is based on a single study applying computational gene 
analyses and requires further experimental validation.  
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FIGURE 35: EXP1-protein expression in PbAgo2 parasites expressing EXP1-
AgoshRNAs.  (A) Schizont-enriched samples were analyzed by Western blotting probing 
for either EXP1 or HSP70 (as loading control). One representative blot of two technical 
replicates is shown. (B) Quantification of the Western blots. Band intensities were 
determined with ImageJ, and the EXP1 signal was normalized to the HSP70 signal. The 
PbAgo2 3.2 + AgoshRscr sample served as control for normalization and was set to 
100 %. Each dot represents the signal of an individual technical replicate. 
To target this protein, I designed three different AgoshRNAs against EXP1 
and transfected them episomally into PbAgo2 3.2. Mice became blood-stage-
positive one to two weeks after transfection. After confirming that all parasites 
retained the episome (indicated by mCherry fluorescence), I analyzed EXP1 
protein expression of these parasites, as well as a PbAgo2 + AgoshRscr control 
(Figure 35). A Western blot from a single protein preparation was performed in 
technical duplicates (Figure 35 A). Quantification of these blots indicated a 
reduction of EXP1 to about 40-50 % for the EXP1-AgoshR1 and AgoshR2, 
while AgoshR3 did not change EXP1 expression levels (Figure 35 B). As 
Western blot is an inherently error-prone method to quantify protein levels, 
this observation needs to be verified by additional analysis of independent 
protein preparations.  
 
FIGURE 36: Growth of PbAgo2 3.2 parasites expressing EXP1-AgoshRNAs. Female 
C57BL/6J mice (n=4) were intravenously injected with 10³ iRBC of PbAgo2 3.2 
expressing either AgoshRscr or EXP1 AgoshR1 or 2. Pyrimethamine was constantly 
supplied via the drinking water to retain the episome. Parasitemia was monitored from 
day 4 to day 14 post-infection by daily Giemsa-stained thin blood smears.  
To assess whether the moderate knockdown of EXP1 influences parasite 
viability, I analyzed the blood-stage growth of PbAgo2 3.2 parasites expressing 
EXP1-AgoshR1 and 2, and compared that to parasites expressing AgoshRscr 
(Figure 36). After inoculation of 1000 iRBC into C57BL/6 mice, all three lines 
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grew comparably, recapitulating the growth phenotype of PbAgo2 in the 
absence of any AgoshRNA. Thus, the expression of the EXP1 AgoshRNAs does 
not affect the blood-stage growth rate.  
A possible explanation for the relatively weak knockdown and the 
unaffected blood stage growth in parasites expressing EXP1-AgoshRNAs could 
be that parasites with a spontaneous mutation in either the EXP1 locus or the 
AgoshRNA locus outgrew the population. Such a mutation could prevent the 
binding and efficient knockdown of EXP1 and thus be advantageous to the 
parasite. To exclude this possibility, I sequenced the EXP1 and the AgoshRNA 
locus in all PbAgo2 lines, which revealed that no evasion mutations occurred 
which prevented the AgoshRNAs from binding (data not shown).  
It thus remains thus unclear whether EXP1 was truly downregulated, and 
more quantitative measurements such as qRT-PCR should be used to 
unanimously determine successful knockdown. If these confirm a knockdown, 
further studies would be necessary to investigate whether there is a more 
subtle phenotype associated with the EXP1 knockdown.  
3.7 OFF-TARGET ANALYSIS OF AGOSHRNAS VIA 
RNA-SEQ 
The work so far has demonstrated that RNAi can be used in PbAgo2 to 
knock down a gene of interest. To be broadly useful as a genetic tool, not only 
the efficiency of gene silencing is interesting, but also its specificity. Phenotypic 
analysis of a given target knockdown is confounded by side effects if the 
AgoshRNA also downregulates an unknown amount of other genes via so-called 
off-targeting. This is a concern for all technologies in which the target is 
determined by relatively short DNA or RNA sequences, such as shRNA-
mediated knockdown in RNAi-competent organisms or CRISPR/Cas9-mediated 
gene editing173,301. For commonly used technologies, such as shRNA-mediated 
knockdown in human cells, tools exist that predict off-targets of a given shRNA 
sequence, allowing to experimentally test if these targets are indeed affected by 
the shRNA. However, such prediction tools do not yet exist for Plasmodium, in 
which RNAi is absent.  
We therefore took a comprehensive and unbiased experimental approach 
to identify potential off-targets that are affected by AgoshRNA-mediated 
knockdown in PbAgo2. Specifically, we performed whole RNA sequencing 
(RNA-Seq) and quantified the entire transcriptome of PbAgo2 expressing 
AgoshRscr, GFP-AgoshR1c, GFP-AgoshR2c or no AgoshRNA at all (as a 
reference). We also compared PbAgo2 with the parental line PbGFPcon as a 
second reference, hoping to be able to identify a reason for the growth 
impairment of PbAgo2.  
Sabine Fraschka 
performed the RNA-Seq 
work in the group of our 
collaboration partner 
Dr. Richard Bartfaí, 
Nijmegen, Netherlands.  
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FIGURE 37: Stage composition of RNA-Seq samples. Mice with about 1-2 % parasitemia 
were bled and blood was cleared of leukocytes by column filtration. Parasites were then 
cultured for 18 h in vitro before analyzing stage compositions via Giemsa-stained thin 
blood smears. For each sample, at least 100 individual parasites were classified.  
For RNA-Seq, a comparable sample preparation is critical to minimize 
intersample variation. As the various stages in the asexual replication cycle 
have very distinct transcriptional profiles302, mixed blood-stage samples, in 
which the stage composition cannot be controlled, are not suitable for RNA-Seq. 
I thus synchronized the different samples by culturing blood stages overnight. 
As P. berghei schizonts are not able to egress in vitro, the prolonged culture will 
cause an enrichment of this stage and yield comparable stage 
distributions303,304. To ensure that samples were equivalent, I performed blood 
smears of all samples and quantified the stages present. Figure 37 depicts the 
percentage of schizonts, trophozoites, and gametocytes (no ring stages were 
observed) in all samples prepared for RNA-Seq. All samples (two biological 
replicates per sample) had a comparable composition with on average 39 % 
schizonts, 55 % trophozoites and 6 % gametocytes. RNA-Seq was subsequently 
performed by Sabine Fraschka, a PhD student in the laboratory of Richard 
Bartfaí, Nijmegen, the Netherlands.  
We first compared PbAgo2 to its parental line, PbGFPcon, hoping to be able 
to identify differentially regulated transcripts that might explain the growth 
impairment of PbAgo2. Indeed, when comparing the RPKM (reads per kilobase 
per million mapped reads) values for all transcripts between PbAgo2 and 
PbGFPcon, we identified a set of genes that were downregulated in PbAgo2 as 
compared to PbGFPcon. A closer analysis revealed that these genes all belong to 
a group which is translationally repressed in gametocytes through the 
association of their mRNA with the DOZI (development of zygote 
inhibited)/CITH (homolog of worm CAR-I and fly Trailer Hitch) complex305. In 
contrast, male gametocyte-specific genes306, as well as female gametocyte-
specific genes that are part of the DOZI/CITH complex, are not dysregulated 
(Figure 38). This finding is in line with the previous observation that the 
gametocytaemia was comparable in all RNA-Seq samples (Figure 37). Thus, the 
downregulation of a subset of gametocyte-specific genes in PbAgo2 cannot be 
explained by an overall reduction in gametocytaemia. The data instead 
indicates that Ago2 interferes with DOZI/CITH-mediated mRNA storage in 
gametocytes, which will be further discussed in Chapter 4. 
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FIGURE 38: “Ago2 expression results in the downregulation of DOZI/CITH 
dependent transcripts. Scatter plot showing transcript levels (RPKM, log10) in 
PbGFPcon (median of two biological replicates) in comparison to all PbAgo2 samples 
(median of PbAgo2, PbAgo2 + scr, PbAgo2 + GFP2 with two replicates each). Fifty 
proteins previously reported to be abundant in male gametocytes are highlighted in 
dark blue306. Female gametocyte-specific proteins that are part of the DOZI/CITH 
complex are highlighted red305. Transcripts that are significantly downregulated both in 
DOZI and in CITH mutants305 are marked with an orange dot.“ (Hentzschel et al., 2017, 
manuscript in preparation). The figure is provided by Sabine Fraschka, Radboud 
University, Nijmegen, The Netherlands.  
We next compared gene expression in PbAgo2 expressing GFP-AgoshR1c 
or AgoshR2c against PbAgo2 expressing the scrambled AgoshRNA (Figure 
39 A, B). As expected, GFP was downregulated in both samples expressing an 
GFP-AgoshRNA, most pronounced in PbAgo2 expressing GFP-AgoshR2c. 
Most other genes were unaffected by the expression of an GFP-AgoshRNA, 
except a few, low-expressing, genes. These belong to multigene families, such as 
bir and pir genes, and the variation can most likely be largely attributed to 
intersample variation, rather than a specific effect of the AgoshRNA itself.  
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FIGURE 39: Analysis of off-target effects from AgoshRNA expression in PbAgo2. (A, B) 
Scatter plots showing transcript levels of PbAgo2 + scr compared to (A) PbAgo2 + 
GFP1c  or (B) PbAgo2 + GFP2c. Shown is the log10 of the mean RPKM values of two 
biological replicates. In both blots, GFP is indicated in red. Both figures are provided by 
Sabine Fraschka, Radboud University, Nijmegen, The Netherlands. (C) Relative 
transcript levels of GFP and the top 21 genes with the highest sequence identity to 
AgoshRNA GFP2c. Mean RPKM values of two biological replicates per sample were 
normalized to PbAgo2 + scr (indicated by solid full line). The borders of two-fold 
changes (0.5 and 2) are indicated by dashed lines. Note that the data is depicted on a log 
scale.  
To further identify potential AgoshRNA off-targets despite the absence of a 
prediction software, I reasoned that the sequence of an off-target of a given 
AgoshRNA would align to the AgoshRNA sequence. Thus, I identified the 21 
P. berghei genes that had the highest sequence identity with the GFP-
AgoshR2c (11 or 10 nt), and, based on the RNA-Seq data, analyzed their relative 
transcript expression in PbAgo2, PbAgo2 + scr, PbAgo + GFP1c and 
PbAgo2 + GFP2c (Figure 39 C). Importantly, none of these genes were 
significantly deregulated upon expression of the GFP-AgoshR2c, indicating 
that these genes are not off-targets. As sequence identity is not the only 
determinant of off-target activity,  it will be important to further predict and 
study potential off-targets once respective software is available for 
Plasmodium. Until then, the present data indicate that AgoshRNA expression in 
PbAgo2 causes no major off-targeting.   
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3.8 STAGE-SPECIFIC KNOCKDOWN  
3.8.1 GENERATION OF PBLISP2AGO2 
So far I have established that constitutive, high-level expression of Ago2 in 
P. berghei is feasible and allows for AgoshRNA-mediated gene knockdown 
throughout the life cycle, albeit at the expense of parasite viability. For many 
applications, it would be desirable to further control the timing of the 
downregulation of the GOI. For example, a general knockout or knockdown 
might be difficult to achieve for blood-stage essential genes, whereas restricting 
the knockdown to the liver stage might yield valuable information about the 
function of this gene in this particular stage. Such approaches have, for 
instance, been employed to achieve the stage-specific expression of the FRT-
recombinase, enabling the excision a GOI in late mosquito stages, yielding a 
target knockout in liver stages only85. However, this strategy results in a 
permanent loss of the gene, and parasites can no longer progress from the liver 
to blood stages. 
One advantage of the Ago2-mediated knockdown strategy that was 
established here is that it opens up the possibility to control the timing of the 
knockdown by regulating Ago2 expression, e. g. by expressing it under a stage-
specific promoter. As the expression of Ago2 is limited to a single stage only, 
the knockdown is restricted to this stage, and gene function should be 
unaffected in all other stages where Ago2 is not expressed. To test the 
feasibility of such a stage-specific knockdown, Vera Mitesser and I chose to 
express Ago2 under the promoter of the LISP2 (liver-specific protein 2) gene, 
which is expressed in late liver stages only307. 
To generate the parasite line PbLISP2Ago2, Vera Mitesser pursued a strategy 
similar to the one I had already used to produce the line PbAgo2 but she 
replaced the HSP70 5’UTR with the 5’UTR of LISP2 (Figure 40 A). After 
transfecting PbGFPcon with the 5’LISP2-Ago2 construct and limiting dilution, 
she obtained a single clone PbLISP2Ago2 that was positive for integration. 
Further negative selection and another round of limiting dilutions yielded the 
final clone PbLISP2Ago2 1.1. Diagnostic PCR verified the correct insertion of the 
construct and the complete recycling of the selection marker (Figure 40 B-E). 
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C                   PbLISP2Ago2 f 
            WT       1       1.1      Ø 
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FIGURE 40: Generation of PbLISP2Ago2. (A) Scheme of the integration of a 5’LISP2-Ago2 
expression construct into the SIL6. The integration strategy followed the same approach 
as for the PbAgo2 line. (for details, see Figure 14). Proper integration of the construct 
into PbGFPcon was confirmed by diagnostic PCR amplifying the (B) wild type locus, (C) 
5’ integration site, (D) 3’ integration site, or (E) 3’ integration site after negative 
selection. Colored arrows indicate the primers used for each diagnostic PCR as depicted 
in the scheme (A). PbLISP2Ago2 1 is a single clone obtained by limiting dilution after 
positive selection, which was subsequently negatively selected, yielding PbLISP2Ago2 1.1. 
WT: PbGFPcon. Ø: No-template control.  
Vera Mitesser also tested the expression of Ago2 in blood stages via 
Western blotting and in liver stages via immunofluorescence staining. As 
predicted from the activity of the LISP2 promoter, no Ago2 could be detected in 
schizont-enriched blood stages (Figure 41 A), in contrast to a clear signal in the 
liver stages (Figure 41 B). PbLISP2Ago2 should thus allow the targeting of gene 
specifically at the liver stage.  
 
 
 
 
Pyrimethamine 
5-Fluorocytosine
Selection markerhAgo25‘LISP2
1.6 kB
Selection markerhAgo25‘LISP2
2.0 kB 1.2 kB
hAgo25‘LISP2
1.2 kB
Chr 6:524240..525356 bp
Chr 6
Chr 6
Wild type  
5’ Integration  
3’ Integration  
Negative Selection  
[kb] 
2.0 –  
1.7 –  
1.0 – 
  
[kb]
1.7 –  
1.0 – 
  
0.7 –  
[kb] 
2.0 –  
1.7 –  
1.0 –  
[kb] 
2.0 –  
1.7 –  
1.0 – 
STAGE-SPECIFIC KNOCKDOWN 59 
 
 
B Hoechst anti-FLAG anti-EXP1 Merge 
P
b
G
F
P
co
n
 
    
P
b
LI
S
P
2
A
g
o
2
 
    
FIGURE 41: Expression of Ago2 in PbLISP2Ago2. (A) Western blotting analysis of 
schizont-enriched samples of PbGFPcon, PbLISP2Ago2, and PbAgo2. Western blots were 
probed with an antibody against hAgo2 (upper blot) or HSP70 (lower blot). (B) 
Immunofluorescence staining of liver stages 48 h after infection of HuH7 cells with 
either PbGFPcon or PbLISP2Ago2. Liver stages were stained with Hoechst for DNA (first 
column), an antibody against the FLAG tag of Ago2 (second column) or an antibody 
against the PVM protein EXP1 (third column). One representative image of ten per 
condition is shown. Pictures were taken with same settings with a widefield 
fluorescence microscope and are all processed alike. The scale bars indicate 10 µm.  
3.8.2 CHARACTERIZATION OF PBLISP2AGO2 
Constitutive expression of Ago2 in P. berghei has an adverse effect on 
blood-stage growth and mosquito infectivity, but apparently does not 
negatively impact liver stage development of the parasites (see Section 3.2.3). 
We thus hypothesized that limiting the expression of Ago2 to this particular 
stage of the life cycle would result in parasites whose growth is comparable to 
that of wild type parasites.  
To test this, Vera Mitesser injected equal amounts of iRBC of PbLISP2Ago2 
and PbGFPcon into C57BL/6J mice and followed the blood stage growth (Figure 
42 A, B). Indeed, she observed that both lines had a comparable growth, and 
both PbGFPcon, as well as PbLISP2Ago2-infected mice, succumbed to ECM 
between 7 to 11 days post-infection. We also infected mosquitoes with 
PbGFPcon- or PbLISP2Ago2 and assessed oocyst prevalence as well as sporozoite 
numbers. Importantly, we found that PbLISP2Ago2 infects mosquitoes at the 
same rate as PbGFPcon, both in the midgut and in the salivary glands (Figure 42 
C, D). When we subsequently infected HuH7 cells in vitro with sporozoites and 
quantified the number and size of liver stages 48 h post-infection, we detected 
no difference in liver stage infectivity or intrahepatic development between the 
two lines (Figure 42 E, F). Congruent with these findings, also the intravenous 
infection of C57BL/6 mice with sporozoites of either PbGFPcon or PbLISP2Ago2 
yielded comparable blood-stage growth and the majority of infected mice in 
both groups succumbed to ECM around seven days post-infection (Figure 42 G, 
H). In summary, liver-stage-restricted expression of Ago2 does not affect the 
growth of P. berghei. 
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FIGURE 42: Characterization of PbLISP2Ago2. (A, B) Blood-stage growth. C57BL/6J mice 
were i.v. infected with 103 iRBC of PbGFPcon or PbLISP2Ago2. (A) Parasitemia and 
(B) survival of mice were monitored over 14 and 20 days, respectively. (C, D) Mosquito 
infectivity. Mosquitoes were allowed to feed on PbGFPcon- or PbLISP2Ago2-infected mice. 
(C) Oocyst numbers were scored in dissected midguts on day 10 to 14 post-infection. (D) 
Salivary gland sporozoite numbers were quantified at day 18 post feeding. (E, F) Liver 
stage development. HuH7 cells were infected with PbGFPcon- or PbLISP2Ago2-sporozoites 
and liver stages were fixed 48 h post-invasion to determine (E) average numbers and (F) 
sizes of liver stages. Values are normalized to PbGFPcon and result from three 
independent experiments. (G, H) Sporozoite-induced growth. C57BL/6J mice were i.v. 
infected with 103 spz of PbGFPcon or PbLISP2Ago2. (G) Parasitemia and (H) survival of 
mice were monitored over 14 and 20 days, respectively. 
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3.8.3 INTEGRATION OF AGOSHRNAS INTO PBLISP2AGO2 
Restricting Ago2-expression to the liver should permit gene silencing in 
this stage only. As expression is unaffected in blood stages, this strategy would 
be of particular interest for blood-stage essential genes. To test the hypothesis 
that AgoshRNA expression in PbLISP2Ago2 silences gene expression only in the 
liver, we stably integrated expression cassettes for AgoshRscr (as a negative 
control) or AgoshR-GFP2c into the genome. Thereby, any reduction of GFP 
levels across the life cycle, in particular in the liver stage, can be monitored 
using established assays.  
A 
 
 
B                PbLISP2Ago2                   3 
                                                   MSP1             h
           WT       .scr   .GFP2c      1         3         Ø
 
 
C                PbLISP2Ago2                   3 
                                                   MSP1             h
           WT       .scr   .GFP2c      1         3          Ø
 
 
 
FIGURE 43: Integration of AgoshRNAs in PbLISP2Ago2. (A) Integration strategy. The 
strategy resembles the initial approach to integrate AgoshRNAs behind the Ago2 locus 
(depicted in Figure 29). Parasites use the 3’ UTR of the selection cassette and the 
homology region of the SIL6 to integrate the selection marker along with the AgoshRNA 
cassette. Parasites can still recycle the selection marker, using the 3’UTR of the Ago2 
cassette for recombination. (B, C) Diagnostic PCR of the clonal lines of PbLISP2Ago2.scr, 
PbLISP2Ago2.GFP2c, PbLISP2Ago2.MSP1 1, and PbLISP2Ago2.MSP1 3. PbLISP2Ago2 (WT, 
first lane) served as a control for the parental line. Ø: No-template control. Colored 
arrows indicate the location of the respective primer pairs used for amplification in (A). 
(B) PCR amplifying the parental locus which yields the expected amplicon of 1.3 kb in 
the case of for PbLISP2Ago2. For the clones with the AgoshRNA integration, the higher 
amplicon of 1.4 kB indicates a subpopulation that has recycled the selection marker. 
(C) PCR amplifying the 3’ integration site, yielding an expected amplicon length of 1.9 kb. 
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In parallel, we also aimed to integrate three AgoshRNAs targeting the 
cross-stage antigen merozoite surface protein 1 (MSP1). This protein is 
essential in blood stages, where it is required for the egress of the merozoites 
from the schizonts308. However, a conditional deletion of MSP1 in liver stages 
using the FLP/frt system demonstrated that MSP1 is additionally necessary for 
late liver stage development. Ablation of MSP1 in this stage results in aberrant 
merozoite formation, incomplete segmentation and an developmental arrest in 
the liver85. We intended to reproduce this phenotype by silencing MSP1 
expression using AgoshRNAs. 
As the initial vectors for integration of AgoshRNAs into PbAgo2 were 
inefficient (see Section 3.5.1), Vera Mitesser improved the vector design. The 
new strategy, depicted in Figure 43 A, avoided the unwanted integration of the 
selection marker only, while still permitting its removal by negative selection. 
This strategy improved the efficiency of full integration, and we obtained 
transgenic parasites for all AgoshRNAs. Limiting dilution yielded single clones 
for PbLISP2Ago2.scr, PbLISP2Ago2.GFP2c, PbLISP2Ago2.MSP1 1 and 
PbLISP2Ago2.MSP1 3 (Figure 43 B, C). No clones were obtained for 
PbLISP2Ago2.MSP1 2. As the diagnostic PCR of the parental population revealed 
that a subpopulation had integrated the AgoshRNA cassette (data not shown), it 
is safe to assume that limiting dilution in a larger cohort of mice would also 
yield a single clone of this line. It is interesting to note that for all lines, a 
proportion of the parasites already underwent the recombination event that 
leads to recycling of the resistance cassette (evidenced by the higher band 
visible in the diagnostic PCR amplifying the wild type locus). Sequencing of the 
locus confirmed correct AgoshRNA integration for all lines.  
3.8.4 KNOCKDOWN OF GFP IN PBLISP2AGO2.GFP2C 
To test if PbLISP2Ago2 is indeed capable of mediating RNAi exclusively in 
liver stages, I compared the GFP expression of PbLISP2Ago2.GFP2c to that to 
PbLISP2Ago2.scr. Even though the expression of Ago2 should be restricted to the 
late liver stage of PbLISP2Ago2, a leaky promoter might lead to Ago2 expression 
in other stages, which could induce RNAi-mediated GFP knockdown. Therefore, 
I analyzed the GFP fluorescence of PbLISP2Ago2.GFP2c and PbLISP2Ago2.scr not 
only in liver stages, but across the whole life cycle. The following data is 
obtained from a single biological replicate and should thus be treated as 
preliminary data from a pilot experiment.  
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FIGURE 44: GFP fluorescence of blood stages. Blood stage parasites of PbLISP2Ago2.scr or 
PbLISP2Ago2.GFP2c were imaged with a fluorescence microscope with equal settings. 
Images were processed alike. Shown are representative images of at least 10 per strain. 
The scale bars indicate 10 µm. 
In blood stages, Ago2 levels were below the detection limit of a Western 
blot (see Figure 41) but very low amounts might be sufficient to mediate target 
knockdown. However, in mixed blood stages, there was no difference in GFP 
expression between PbLISP2Ago2.scr and PbLISP2Ago2.GFP2c (Figure 45). Ring 
stages, early and late trophozoites and gametocytes showed comparable 
fluorescence intensity independent of the AgoshRNA expressed, indicating no 
RNAi activity. When transmitting both lines to mosquitoes and imaging oocysts 
13 days later, I found that also in this life cycle stage, the GFP expression is not 
affected by the expression of the GFP-AgoshR2c (Figure 45 A, B).  
Interestingly, when imaging salivary gland sporozoites at day 17 after 
infectious blood meal, I found a small, but significant reduction of GFP in 
PbLISP2Ago2.GFP2c (Figure 45 C, D). This is a unexpected finding, considering 
that the LISP2 promoter should not be active at that stage307,309. Compared to 
the fully RNAi-competent PbAgo2.GFP2c, the RNAi activity of PbLISP2Ago2 is, 
however, minor. While GFP was reduced to about 17 % in the fully RNAi-
competent PbAgo2.GFP2c (Figure 33 C, D), the knockdown in 
PbLISP2Ago2.GFP2c is much weaker, with a remaining 85 % of GFP 
fluorescence. In order to exclude the possibility that the detected difference in 
GFP fluorescence is due to technical variations, the experiment should be 
repeated with an independent set of sporozoites.  
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FIGURE 45: Knockdown of GFP in PbLISP2Ago2. Mosquitoes were fed on PbLISP2Ago2.scr- 
or PbLISP2Ago2.GFP2c-infected mice. (A) Midgut oocysts (day 13 post feeding) and (C) 
salivary gland sporozoites (day 17 post feeding) were imaged with a wide-field 
microscope. Shown are representative pictures of PbLISP2Ago2.scr and 
PbLISP2Ago2.GFP2c. The scale bar indicates 10 µm. The GFP fluorescence of (B) oocysts 
and (D) sporozoites was quantified using ImageJ and is here depicted as whiskers plot 
with 10-90 percentile. The numbers below the bars indicate the total number of 
individual parasites quantified. Statistics: Student’s T-test. ns: not significant; 
*** p<0.001. Note that these data are obtained from a single experiment only, and need 
to be validated in biological replicates.   
To assess a possible GFP knockdown in liver stages, HuH7 cells were 
infected with sporozoites of PbLISP2Ago2.scr or PbLISP2Ago2.GFP2c. The LISP2 
promoter is reported to be active in late liver stages from around 36 h to 65 h 
post-infection, with a peak at 48 h310. In order to evaluate whether a potential 
knockdown of GFP may differ during intrahepatic development, PbLISP2Ago2 
liver stages were thus fixed at 24 h, 48 h and 65 h post-infection. After 
immunofluorescence staining, the GFP signal of individual PbLISP2Ago2.GFP2c 
was quantified and normalized to that of PbLISP2Ago2.scr (Figure 46).   
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FIGURE 46: Knockdown of GFP in liver stages of PbLISPAgo2. Liver stages of 
PbLISP2Ago2.scr and PbLISP2Ago2.GFP2c were fixed at various time points post-invasion 
and stained with antibodies against HSP70 and GFP. The GFP signal of immunostained 
liver stages at (A) 24 h, (B) 48 h, and (C) 65 h post-infection was quantified using ImageJ, 
and normalized to the mean signal intensity of PbAgo2.scr liver stages to control for 
different staining efficiencies. The number below the bars indicate the total number of 
individual parasites quantified. Statistics: Student’s T-test. *** p<0.001; * p<0.05. Note 
that these data are obtained from a single experiment only, and need to be validated in 
biological replicates. (D) Representative images of a liver stage at 48 h post-infection. All 
pictures were taken with a wide-field microscope with same settings and processed 
alike. The scale bars indicate 10 µm.  
At an early time point, 24 h post-infection, the GFP fluorescence did not 
differ between the two transgenic lines, indicating no activity of Ago2 (Figure 
45 A). In contrast, at a later time point (48 h post-infection), the GFP signal of 
PbLISP2Ago2.GFP2c parasites dropped significantly compared to parasites 
expressing the scrambled AgoshRNA (Figure 45 B). The GFP fluorescence of 
PbLISP2Ago2.GFP2c is still reduced 65 h post-infection, albeit to a lesser extent 
(Figure 45 C). Importantly, the observed knockdown pattern coincided with the 
reported expression pattern of the LISP2 promoter, peaking at 48 h post-
infection310. In conclusion, the data of the pilot experiment supports that 
PbLISP2Ago2 is capable of eliciting a stage-specific knockdown in late liver 
stages. It will be interesting to see if such a knockdown also holds true for the 
endogenous gene MSP1.  
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 Discussion 
“When you study science, and especially these realms of the biology […], 
what's clear is that every time you find out something, that brings up ten new 
questions, and half of those are better questions than you started with.“311 
~ Robert Sapolsky (born 1957) 
4.1 PBAGO2 AS A TOOL TO STUDY GENE FUNCTION 
Despite years of research, Malaria continues to be a devastating infectious 
disease. Plasmodium parasites, belonging to the phylum Apicomplexa, are 
evolutionarily very distant from humans, and thus encode a great variety of 
genes that have no homologs in humans or other non-apicomplexan organisms. 
These “orphan” genes, about 60 % of all Plasmodium genes55, are promising 
drug targets, as specific inhibitors of their encoded proteins should not cause 
unintended side effects in humans. On the downside, the lack of homology to 
known genes renders the functional annotation of these orphan genes difficult, 
although such a characterization is of utmost importance to develop efficient 
drugs. To overcome this obstacle, a variety of different genetic tools have been 
developed to study gene function in Plasmodium. As summarized in Table 1, all 
of these technologies have different advantages and disadvantages.   
For genes that are not essential for blood-stage development, deletion by a 
classical gene knockout62 is still the most straightforward approach to assess 
the gene function. In P. falciparum, the efficiency has been greatly increased 
with the use of CRISPR/Cas9 technology73,72. Recombinases that are either 
inducible79,82 or stage-specifically expressed85 permit a temporarily controlled 
knockout. However, gene knockouts are limited to genes that are not essential 
for blood stages, and the complete ablation of gene expression prevents the 
investigation of intermediate phenotypes. To study blood-stage essential genes, 
several inducible systems have been established, among them the regulation of 
gene expression by the Tet-OFF system in P. berghei92, the inducible 
degradation of mRNA by the glmS-ribozyme103 or the degradation of proteins 
by fusion to a destabilization domain110,111,117. These systems all require the 
addition of a small molecule to regulate gene expression, which is prone to 
causing unwanted side effects. Also, success seems to be gene-dependent. In 
particular, degron-mediated protein degradation can only be used for proteins 
that tolerate C-terminal tagging. While varying the amounts of inducer allows, 
in principle, for tunability, the dynamic range is limited57. Most importantly, 
however, these technologies are mainly restricted to P. falciparum or P. berghei 
blood stages.  
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TABLE 1: Advantages and disadvantages of different genetic tools. 
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In this work, I successfully developed a new genetic tool by engineering 
RNAi into the rodent malaria parasite P. berghei. This novel technology for the 
first time permits a knockdown of genes throughout the whole life cycle of 
Plasmodium, as demonstrated by the efficient silencing of GFP in all stages of 
PbAgo2.GFP2c (see Section 3.5.3). In contrast to almost all technologies that 
are currently available, AgoshRNA-mediated gene silencing does not require 
the modification of the genetic locus of the GOI, a task that is often fairly 
laborious due to the high AT-content of the Plasmodium genome312. Instead, the 
transfection of AgoshRNA expression vectors, either for episomal expression or 
stable integration, is sufficient to target a GOI, greatly facilitating the 
application of the technology. The present work indicates a high efficiency of 
AgoshRNA-mediated knockdown, as 80 % of all tested AgoshRNAs yielded a 
significant reduction of target gene expression. As demonstrated in Section 
3.3.2 for GFP, the level of gene knockdown can be tuned using different 
AgoshRNAs. Additionally, the timing of gene silencing is flexible and can be 
readily modulated by controlling the expression of Ago2. As proof-of-principle, I 
developed in this work the parasite line PbLISP2Ago2, which permitted to restrict 
the silencing of GFP expression to late liver stages (see Section 3.8).  
The unique ability to modulate gene expression in a specific stage only, in 
combination with the facile application of the technology, distinguishes PbAgo2 
from all currently available genetic tools for Plasmodium. In addition, 
AgoshRNA-mediated knockdown can be easily adapted to a variety of different 
purposes as discussed below, rendering it a very versatile genetic tool.  
The most straightforward application of PbAgo2 is the knockdown of a 
single target gene by expressing an corresponding AgoshRNA (Figure 47 B). 
The efficiency of the AgoshRNA-mediated knockdown of a GOI depends on 
several factors. In the initial cell culture screen in this work, it became apparent 
that AgoshRNAs tend to be less efficient than shRNAs (2-fold knockdown 
versus around 10-fold knockdown in HEK293T cells, see Figure 10). Also others 
report that AgoshRNAs are less effective than matching shRNAs with the same 
sequence236. This observation may reflect a lack of knowledge regarding the 
optimal structural requirements for Dicer-independent AgoshRNA processing. 
Alternatively, Ago2-dependent processing of AgoshRNAs might be inherently 
less efficient than the canonical processing of miRNAs or shRNAs, which in turn 
limits the strength of the gene silencing. While the reduced activity of 
AgoshRNAs may seem disadvantageous for gene silencing, it is compensated by 
the observation that the potency of AgoshRNAs is increased in the absence of 
Dicer and endogenous miRNAs (see Figure 13)235. Indeed, AgoshRNAs were 
more efficient in Plasmodium than in vitro. While only one out of four GFP-
AgoshRNAs diminished GFP fluorescence in RNAi-competent cells, and only by 
about 50 %, all four AgoshRNAs significantly reduced GFP fluorescence in 
P.  berghei blood stages by 5- to 40-fold (see Figure 25).  
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The discrepancy of the knockdown efficiency in RNAi-competent cells 
versus Plasmodium could be explained by competition between AgoshRNAs and 
endogenous miRNAs for Ago2 processing. As a result, in the absence of miRNAs, 
AgoshRNA-mediated gene silencing is more efficient. It has also been suggested 
that in RNAi-competent cells, AgoshRNAs are alternatively loaded into Dicer 
and thereby sequestered from Ago2235. In addition, Ago2, as well as the 
AgoshRNAs, were expressed from different promoters in cell culture and in 
Plasmodium, yielding distinct expression levels of these factors which 
complicate a direct comparison of the two systems.  
The target gene itself also influences the efficiency of the knockdown. While 
I could achieve a potent knockdown of GFP and of PPLP2 (see Sections 3.3 and 
3.4), the expression of EXP1 could only be reduced by roughly 50 % (see 
Section 3.6). According to published and our own RNA-Seq data, the expression 
of EXP1 is about 10- to 100-fold higher than that of PPLP2 and the EF-1-
promoter driven GFP313. Thus, it seems that in PbAgo2, highly expressed targets 
are more difficult to silence. While it appears intuitive that RNAi efficiency 
decreases with higher target mRNA concentrations, several studies report the 
opposite. Experimental findings suggest that siRNA-mediated silencing of a GOI 
is more efficient in cells expressing a high amount of the target than in cells that 
express relatively low amounts of target mRNA314,315. This observation is 
further supported by a recent model suggesting that RNAi becomes more 
efficient with increasing target concentration due to more efficient loading of 
Ago2, and only very high target mRNA levels will reduce the strength of the 
gene silencing316. Yet, is important to note that these observations are based on 
siRNA-mediated silencing. In the case of AgoshRNA-mediated gene silencing, 
the rate-limiting step might not be the release of the cleaved target (as has been 
suggested for siRNA-mediated knockdown316), but the cleavage and processing 
of the AgoshRNA itself. It is tempting to speculate that in case of the EXP1 
silencing, the RNAi machinery of PbAgo2 might have already reached a point of 
saturation. Also other factors should be considered, such as target mRNA 
turnover, which negatively correlates with RNAi efficiency317. 
Depending on the targeted GOI, its expression strength and mRNA 
turnover, it will be necessary to screen several AgoshRNAs to find one that 
mediates efficient knockdown. In this respect, AgoshRNA-mediated RNAi in 
PbAgo2 is comparable to canonical RNAi in other cells. As the efficiency of a 
given shRNA cannot be predicted, also fully RNAi-competent cells require the 
screening of several shRNAs in order to identify one that is sufficiently 
potent318. The benefit of implementing well-established technology into 
Plasmodium is that the knowledge gathered in years of RNAi research can now 
be easily transferred to PbAgo2, to further improve the power and breadth of 
this tool. For conventional RNAi, a variety of software exists to design shRNAs 
and to predict off-targets in silico318. It would be of great assistance if such tools 
were developed for AgoshRNA-mediated knockdown as well and likewise in a 
freely accessible manner. Such a program would not only facilitate the targeting 
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of a GOI but also permit to in silico predict off-targets and test them 
experimentally.  
Despite the current absence of such a software tool, eight out of ten 
AgoshRNAs that I designed manually significantly reduced target expression in 
this study, albeit to varying extents. It is thus safe to conclude that AgoshRNA-
mediated gene knockdown can be  efficient in PbAgo2, and that the chances of 
identifying robust AgoshRNAs are high. Based on the experience gathered 
throughout this work, I recommend to directly test three to four different 
AgoshRNAs against a GOI in Plasmodium (since pre-screens in vitro might not 
be fully predictive, see above), and consider it likely that at least one of them 
silences the gene efficiently.  
For this purpose, the results of this work suggest that there are at least two 
possibilities. One is to express AgoshRNAs in PbAgo2 from episomal vectors, 
which provides a rapid way of screening several AgoshRNAs in parallel. 
Alternatively, for a more comprehensive phenotypic analysis, stable integration 
of the AgoshRNA expression cassette is recommended to avoid heterogeneous 
populations that arise from parasites carrying different plasmid copy numbers. 
Additionally, especially for targets whose silencing affects parasite growth, 
parasites that have spontaneously acquired pyrimethamine resistance are 
likely to outgrow the population that carries the episome. Last but not least, 
stable integration of AgoshRNAs allows to address the phenotype of the 
knockdown across all stages of the life cycle.  
The minimal RNAi machinery also allows, for the first time, a targeted gene 
silencing exclusively in a single life cycle stage by controlling the expression of 
Ago2 (Figure 47 A). In this work, we have already demonstrated with the line 
PbLISP2Ago2 that it is possible to restrict the expression of Ago2 to late liver 
stages. Consequently, expression of a GFP-specific AgoshRNA in this line 
silenced GFP expression in late liver stages only (see Figure 46). The only other 
technology that enables a stage-specific modulation of gene expression is a 
recombinase-mediated gene knockout in which FLP is expressed under a stage-
specific promoter. In contrast to PbLISP2Ago2, where all parasites express Ago2 
in the liver stage and thus gene expression is silenced to the same extent in the 
whole population, the liver-stage-specific FLP/frt system yields a somewhat 
heterogenous population, as around 10 % of the parasites do not excise the GOI 
as intended319. 
Intriguingly, the GFP knockdown induced by the GFP-AgoshR2c in 48 h 
liver stages of PbLISP2Ago2 was weaker than the one of PbAgo2 (50 % versus 
20 % remaining GFP fluorescence). These two lines differ only in the promoter 
driving Ago2. While  – to my knowledge – no publications exist that directly 
compare the LISP2 promoter to the HSP70 promoter, their relative strength can 
be indirectly inferred. The LISP2 promoter is reported to be about 3-fold more 
active in late liver stages than the EF-1 promoter307, while the HSP70 
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promoter is 10-fold stronger than the EF-1promoter. Taken together, this 
implies that the HSP70 promoter is approximately 3-fold stronger than the 
LISP2 promoter. Notably, this difference in promoter activity correlates 
reasonably well with the about 2.5-fold higher knockdown efficiency in PbAgo2 
versus PbLISP2Ago2. This suggests that in the liver stage, the level of Ago2 
protein is the limiting factor for gene knockdown in Plasmodium. This is highly 
reminiscent of mammalian cells where it has also been reported that Ago2 
expression limits RNAi efficiency, and that exogenous overexpression of Ago2 
improves RNAi-mediated knockdown in vitro and in vivo320.  
These results suggest that the liver-stage-restricted knockdown could be 
enhanced by using a stronger, but still liver-stage-specific promoter. An elegant 
strategy that would allow rapid, liver-stage-exclusive expression of Ago2 would 
be the use of the regulatory sequences of UIS4. UIS4 is transcribed in 
sporozoites, but remains translationally repressed by the Pumilio protein 
Puf2321. Upon initiation of the liver stage development, the repression is 
relieved and high levels of UIS4 protein are detected from early (5 h) to late 
(48 h) liver stages322. It has been suggested, albeit not experimentally validated, 
that a short, 8-nt-long motif in the open reading frame of UIS4 serves as Puf2-
binding signal321. If this holds true, the expression of Ago2 under the UIS4 
promoter along with the integration of this putative Puf2-binding site into the 
mRNA sequence should allow for a rapid expression of Ago2, and thus gene 
silencing, only in liver stages.   
A stage-specific knockdown is of course not only limited to late liver stages. 
Using different promoters, one could generate new lines that exhibit a specific 
pattern of Ago2 expression in one or several Plasmodium stages. For example, 
driving Ago2 by the promoter of the TRAP gene, which is active in mosquito 
stages, could be used to silence genes specifically in sporozoites and early liver 
stages. As the integration into SIL6 using the published vectors279 proved to be 
facile, such a tool box encompassing a variety of different PbAgo2 lines should 
be easy to generate.  
Gene knockdown is readily achieved in PbAgo2 and merely requires the 
expression of a short RNA molecule. Therefore, the parallel silencing of multiple 
genes should be achievable by co-expressing several AgoshRNAs (Figure 47 C). 
Such a multiplexed gene silencing could help to dissect complex pathways in 
which several proteins have redundant functions. It was shown, for example, 
that the gametocyte-specific proteins P25 and P28 are individually dispensable, 
but the double knockout has a severe developmental arrest at the 
ookinete/oocyst stage323. Moreover, for targets that are difficult to silence with 
a single AgoshRNA, the expression of multiple different AgoshRNAs could be an 
alternative to improve the knockdown.  
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FIGURE 47: PbAgo2 as a tool to study gene function. (A) If Ago2 is expressed from a 
ubiquitous promoter, the target gene can be silenced across the whole life cycle, as 
indicated here by a reduced green fluorescence. Stage-specific expression of Ago2 is 
predicted to yield a stage-specific gene silencing (here exemplified in the liver). (B) A 
single AgoshRNA can be expressed from an episome or a stably integrated cassette in 
PbAgo2 and induce target gene silencing. Different AgoshRNAs allow fine-tuning of gene 
expression. (C) Expression of multiple AgoshRNAs within one parasite should allow the 
silencing of multiple target genes in parallel. (D) A library of AgoshRNA expression 
vectors could be transfected into PbAgo2 to perform an RNAi screen. The pool of 
transfectants, each with a different gene silenced, can then be put under a selection 
pressure of interest. AgoshRNAs that are lost from the pool after selection likely silence 
a gene the parasite needs to survive the selection.  
Instead of having to perform sequential genetic modifications, e.g. gene 
knockouts on multiple genes, several expression cassettes encoding multiple 
AgoshRNAs could be introduced into PbAgo2 in a single step. As the repeated 
use of the PbU6 promoter sequence could lead to unwanted recombination 
events, it would be helpful to identify further Pol III promoters in Plasmodium 
to drive the expression of additional AgoshRNAs. Multiplexing also requires 
that Ago2 is not saturated by the expression of a single AgoshRNA and that the 
concurrent expression of multiple AgoshRNAs does not compromise their 
knockdown potency. If Ago2 is already saturated by a single AgoshRNA 
expressed from the PbU6 promoter (as it appears to be the case in PbLISP2Ago2 
liver stages, see above), a higher expression of Ago2 is required for efficient 
multiplexing. Still, multiplexed RNAi-mediated gene knockdown has been 
successfully employed before in mammalian cells, e. g. to simultaneously target 
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two subunits of a protein324. Considering that no other genetic tools for 
Plasmodium allow simultaneous targeting of several genes at once, AgoshRNA 
multiplexing in PbAgo2 is clearly an attractive option to explore in the future.  
Finally, the fact that gene targeting is determined solely by a short 
nucleotide sequence might ultimately enable another technology that has so far 
been inapplicable in Plasmodium: RNAi screens (Figure 47 D). This requires the 
generation of a library of AgoshRNAs which covers a gene family of interest or 
even the whole genome. This library would need to be transfected as a pool into 
PbAgo2. By comparing the AgoshRNAs present in the parasite population 
before and after applying a selection pressure (e.g. cycling through the 
mosquito), genes that are important for this selection can be identified, as 
AgoshRNAs targeting these genes should be lost in the process. Next generation 
sequencing (NGS) would be the easiest way to quantify the AgoshRNAs in the 
parasite population, as the sequence of the AgoshRNA itself could serve as a 
barcode. Akin to what has been done in the genome-wide knockout screen of 
the PlasmoGEM project65, NGS could also be used to directly determine relative 
growth rates of AgoshRNA-expressing parasites. Genome-wide RNAi screens 
have already provided a wealth of new information about gene function in a 
variety of in vitro or in vivo settings325. Of course, both the multiplexing of 
AgoshRNAs and RNAi screens could be combined with stage-specific expression 
of Ago2, rendering the current tool box even more flexible and powerful.  
4.2 ALTERNATIVE GENE SILENCING STRATEGIES IN 
PBAGO2 
One of the main advantages of PbAgo2 is that the knockdown of a target 
gene does not require the modification of the target locus. Yet, in rare cases it 
could happen that no efficient AgoshRNA against a GOI can be found. If the gene 
locus is amenable to genetic modification, in this situation the introduction of 
the targeting sequence of already established AgoshRNAs into the 3’UTR of the 
GOI could be an option. One could, for example, chose the targeting sequences 
of the GFP-AgoshRNAs that have been thoroughly characterized in this work 
and introduce them via homologous recombination into the 3’UTR of the GOI 
within the PbAgo2 line. An introduction of about 20 nt target sequence is not 
expected to affect the expression of the GOI, akin to loxP sites (34 bp long), 
whose introduction into UTRs also does not interfere with gene expression83. 
Using the established GFP-AgoshRNAs, the GOI should then be efficiently 
silenced to degrees comparable to what has been observed for the GFP 
silencing (5- to 40-fold in trophozoites, see Figure 25). If experiments show that 
the AgoshRNAs are less effective in the current PbGFPcon-based line as they 
can bind to two targets, GFP and the GOI, it might help to generate a GFP-free 
PbAgo2 line in a different background. Alternatively, artificial AgoshRNAs that 
have no other target in PbAgo2 could be established. Designing and testing 
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several sequences might yield a set of AgoshRNAs with known gene silencing 
efficiencies, which could additionally facilitate the fine-tuning of a GOI.  
It would also be interesting to explore alternative strategies besides the 
expression of AgoshRNAs to induce RNAi. Importantly, Ago2 uses not only 
DNA-encoded AgoshRNAs to mediate RNAi but also siRNAs, which could be 
introduced to target cells as RNA molecules. It was shown previously that 
Plasmodium takes up DNA from preloaded erythrocytes and was suggested that 
erythrocyte miR-451 translocates into the parasite326,327. It is thus conceivable 
that Plasmodium can take up AgoshRNAs or siRNAs from RBCs that were 
preloaded e g. by RNA transfection. Such a strategy would be more suitable for 
in vitro culture due to the easy accessibility of RBCs under these conditions, and 
thus might be particularly relevant if AgoshRNA-mediated knockdown is to be 
introduced to P. falciparum. Given the difficulties to transfect P. falciparum, 
using preloaded erythrocytes would be an interesting alternative for the 
introduction of the regulatory RNA to the parasite, albeit any resulting 
knockdown is likely to be transient due to the rapid replication of Plasmodium.  
Finally, the direct transfection of siRNAs into liver stages of PbAgo2 would 
facilitate the targeting of liver-stage genes. Currently, no technologies are 
available to directly transfect sporozoites or liver stages. Furthermore, own 
preliminary experiments indicate that preloading hepatocytes with AgoshRNAs 
prior to P. berghei infection is not sufficient to transfer the RNA to the parasite 
(data not shown). It could be helpful to study in detail the mechanisms how 
Plasmodium blood stages spontaneously take up nucleic acids from the 
erythrocyte326, as this would provide a strategy that could potentially be 
employed in the liver stage, too. Although it might be a difficult task to achieve, 
if successful, this would be greatly benefit future research on Plasmodium liver 
stages, as it would provide a rapid means to screen different siRNA target 
sequences without the need to generate an individual parasite line for each and 
to cycle it through the mosquito.  
4.3 IMPAIRMENT OF PBAGO2 IN THE MOSQUITO 
STAGE 
Curiously, the analysis of PbAgo2 revealed that the expression of Ago2 
impairs the parasite life cycle progression. In the blood, PbAgo2 grew 
moderately slower than PbGFPcon, and infected mice did not develop ECM. The 
development of ECM is in itself a quite variable outcome, and it is sensitive to 
small perturbations of parasite development and mouse environment. Within 
the same P. berghei species, only the strain ANKA causes ECM while the related 
strain NK65 does not induce cerebral symptoms328. Even within PbANKA, 
different clones vary in their ability to trigger ECM329. In fact, parasitemia 
progression and survival of PbAgo2-infected mice closely resemble that of 
PbNK65-infected mice. While PbAgo2 might thus not be the best tool to 
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investigate the specific disease model of ECM, the blood-stage growth behavior 
should not hamper the study of other Plasmodium-specific biology. Already 
using a different mouse strain, e. g. NMRI mice, can alleviate the differences 
between PbGFPcon and PbAgo2 blood stage growth (see Figure 19).  
A second and stronger phenotype that was initially unexpected is the 
reduced mosquito infectivity of PbAgo2. Due to an about 10-fold drop in 
sporozoite numbers, working with mosquito stages of PbAgo2 is fairly 
laborious, and the dynamic range to observe any further decrease of mosquito 
infectivity or sporozoite development caused by the knockdown of a GOI is 
diminished. We performed RNA-Seq comparing PbGFPcon to PbAgo2 and found 
that a group of genes that are known to be translationally repressed by the 
DOZI/CITH complex in gametocytes is downregulated in PbAgo2 (see Section 
3.7). The DOZI/CITH complex prevents translation of associated mRNAs and 
instead stores them in P-bodies108,305. Once gametocytes reach the mosquito 
environment, the repression is released, and the mRNAs are rapidly 
transcribed into protein, allowing for a quick transformation of the 
gametocytes into the subsequent life cycle stages. It has been described 
previously that a knockout of either DOZI or CITH results not in the premature 
translation of these mRNAs but in their degradation108,305. DOZI-deficient 
parasites are therefore not able to progress beyond the gametocyte stages, and 
do not infect mosquitoes108.  
The downregulation of this particular group of genes in PbAgo2 indicates 
that the ectopic Ago2 expression may interfere with DOZI-mediated mRNA 
storage. Indeed, it was reported that Ago2 interacts with the human homolog of 
DOZI, DDX6 (Dead-box helicase 6, also called Rck/p54)193. DOZI is a remarkably 
well-conserved protein and shares 67 % amino acid identity and 90 % 
similarity with its human homolog (www.uniprot.org/align) (Figure 48). It is 
thus tempting to speculate that the human Ago2 expressed in PbAgo2 binds to 
the Plasmodium DOZI protein, thereby inhibiting its function. This hypothesis 
provides an explanation why Ago2 expression in P. berghei adversely affects 
mosquito infectivity despite the formation of equal gametocyte numbers.  
While it has been shown that Ago2 interacts with DDX6193, it remains 
unclear if this interaction is direct or if mediator proteins are required. Indeed, 
a recent publication provides evidence that the interaction of DDX6 with Ago2 
is mediated by the scaffold protein Pat1b330. Notably, the same study reports 
that the DDX6 residues R346, K352, and K353, which form a positively charged 
patch on the surface of the protein, are required for Pat1b interaction. Mutation 
of these residues not only prevented the DDX6 interaction with Pat1b but also 
ablated Ago2 recruitment and delocalized DDX6 from P-bodies. Interestingly, 
this patch is conserved in Plasmodium DOZI (Figure 48), yet a BLAST search 
revealed no homolog of Pat1b in Plasmodium. It thus remains to be investigated 
if a distant homolog of Pat1b in Plasmodium or another scaffold protein is 
required to mediate the Ago2-DOZI interaction, or if it is in fact a direct binding.  
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FIGURE 48: Alignment of P. berghei DOZI with the human homolog DDX6. 
Uniprot/Clustal Omega alignment of the P. berghei ANKA DOZI protein sequence (upper 
line, UniProt ID Q4Z0M1_PLABA) to the human DDX6 protein (lower row, UniProt ID 
DDX6_HUMAN). Identical amino acids are indicated by a star and a dark gray shading; 
similar amino acids are specified by a colon (:) and a light gray shading (strong 
similarity) or by a dot (.) and light font (weak similarity). Black boxes indicate the 
conserved residues responsible for Pat1 binding of human DDX6. The alignment was 
performed using www.uniprot.org/align. 
So far, the interaction between hAgo2 and DOZI remains speculative and 
requires further validation by colocalization studies or immunoprecipitation 
experiments. If such experiments indeed implicate a DOZI-Ago2 interaction, it 
would open up possibilities to interfere with this interaction and thereby 
alleviate the growth defect. Interestingly, the interaction of Ago2 with DDX6 in 
human cells is required for miRNA-mediated, but not for shRNA-mediated gene 
silencing193. Thus, the slicing activity of Ago2 is independent of DDX6, and it is 
likely that the Ago2-DDX6/DOZI interaction can be disrupted without affecting 
AgoshRNA-mediated gene silencing. It would first be necessary to precisely 
identify the proteins involved in the Ago2-DOZI interaction and to map which 
Ago2 residues mediate the binding. Mutation of these residues should then 
hinder protein-protein interaction, preventing Ago2 from interfering with DOZI 
function and eventually alleviating the negative impact of Ago2 on mosquito 
infectivity.  
4.4 RECONSTITUTION OF RNAI IN OTHER 
PARASITES 
The effective engineering of the RNAi machinery in P. berghei in this work 
demonstrates that the concept of artificially introducing gene regulatory 
systems is a promising strategy to develop new genetic tools. A similar 
approach was successful in Saccharomyces cerevisiae (S. cerevisiae), where the 
expression of Dicer, TRBP, and Ago2 are sufficient to introduce the canonical 
RNAi pathway and to enable shRNA-mediated gene regulation331. Attempts to 
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likewise introduce the canonical RNAi machinery to P. falciparum remained 
unsuccessful so far, due to problems to express these large proteins and to 
introduce siRNAs into the parasite (personal communication with Oliver 
Billker, Sanger Institute, and Jake Baum, Imperial College, both from London, 
UK).  
Importantly, the strategy followed in this study is much simpler, requiring 
the expression of only a single protein instead of three. Therefore, it would be 
tempting to extend the strategy of AgoshRNA-mediated knockdown to other 
RNAi-negative organisms, first and foremost the deadliest of the human malaria 
parasites, P. falciparum. In collaboration with Dr. Jude Przyborski and Matthias 
Diehl at the Philips University in Marburg, Germany, I attempted to generate 
P. falciparum expressing Ago2 from a stably maintained episome. However, two 
independent transfectants failed to generate parasites that express Ago2 along 
with a control AgoshRNA (data not shown). Ago2 expression may thus be 
detrimental to P. falciparum, potentially because DOZI-mediated repression 
may also play a role in asexual P. falciparum blood stages332. Fusing Ago2 to a 
degron in order to be able to induce its expression could help to elucidate any 
negative effect of Ago2 expression on P. falciparum. Such a combination with 
other genetic tools would provide the added advantage that AgoshRNA-
mediated knockdown would become inducible, which would enhance the 
flexibility of the system. However, if Ago2 expression is truly incompatible with 
parasite development, further efforts have to be made to alleviate the growth 
defect, e. g. by disrupting the potential Ago2-DOZI interaction (in case this 
interaction can be confirmed as the reason for the growth impairment).  
It would also be interesting to introduce this minimal RNAi machinery into 
other RNAi-negative parasites such as L. major, L. donovani or T. cruzii. Such an 
approach would open up new possibilities to study gene function in these 
important pathogens, similar to what was discussed for Plasmodium parasites 
(Section 4). Also in the apicomplexan parasite T. gondii, AgoshRNA-mediated 
knockdown could be a promising approach to enable genomewide RNAi 
screens. In this particular parasite, the presence of an endogenous Ago 
(TgAgo1) protein might, however, interfere with this strategy. TgAgo1 is 
phylogenetically very distant from its human paralog260. Although it lacks the 
catalytical residues described to be required for RNA cleavage (Asp-Asp-His281), 
TgAgo1 was shown to have weak slicing activity when provided with a 
perfectly matched sequence, likely by using a non-canonical catalytical triad333. 
TgAgo1 associates with a variety of proteins known to be part of the RISC, and 
putative miRNAs have been identified in T. gondii260. These were suggested to 
mediate gene silencing by translational repression but direct experimental 
evidence is still missing. Curiously, a knockout of TgAgo1 did not yield a 
detectable phenotype compared to the wild type line333, and the importance of 
miRNA mediated gene silencing in T. gondii remains to be further elucidated. 
The known features of TgAgo1, in particular its poor homology to hAgo2 and 
the weak slicing activity, suggest that this enzyme will not process AgoshRNAs, 
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and that exogenous expression of hAgo2 is required for establishing the non-
canonical RNAi pathway in T. gondii. Additionally, it remains to be studied if the 
expression of the human Ago2 protein interferes with the putative miRNAs 
expressed by T. gondii260. In this parasite, exogenous expression of Ago2 might 
thus not only be a potential new tool but could provide novel insights into the 
role of Ago proteins and miRNAs in this parasite.  
Yet another option would be to exploit other mechanisms to regulate gene 
function, e. g. dCas9-mediated transcriptional inhibition. It has been shown that 
a catalytically inactive Cas9 protein (dead Cas9, dCas9) can still bind in a gRNA-
dependent manner to a target gene334–336. However, as the catalytic residues are 
mutated in the dCas9, the target DNA is not cleaved. Instead, dCas9 poses a 
steric hindrance for the RNA polymerase and thereby inhibits transcription334. 
This effect can be even enhanced by fusing Cas9 to inhibitory protein domains 
such as the Krüppel-associated box (KRAB) that silence gene expression335. 
Alternatively, dCas9 can be fused to activator domains in order to boost 
expression of an endogenous gene335,337,338, or, as another example, to 
fluorescent proteins as a means to label and track DNA339. Considering that 
CRISPR/Cas9 is functional in Plasmodium72,73, it is tempting to speculate that 
the dCas9 system would function as well. This strategy would require the 
constant expression of a dCas9 protein, which raises concerns about toxicity, 
such as has been observed for Cas9-expression in T. gondii75. Preliminary 
experiments indeed showed that the constitutive expression of Cas9 or dCas9 
in P. berghei completely abolished the mosquito passage of the parasite (data 
not shown). However, more detailed studies are required to pinpoint at which 
stage the block occurs and to unravel options to circumvent this defect.    
4.5 CONCLUSION 
Plasmodium parasites are the causative agents of one of the deadliest 
infectious diseases, malaria. As drug resistance is spreading and vaccination 
efforts are of limited success, basic research is of utmost importance to identify 
new targets for combatting the parasite. In this work, I reconstituted a non-
canonical RNAi pathway in the rodent model organism P. berghei, thereby 
developing a new tool that allows for the targeted manipulation of gene 
expression in order to study gene function. As a major advance over all existing 
comparable technologies, PbAgo2 enables the silencing of gene expression not 
only in blood stages but also in mosquito and liver stages. Due to the simplicity 
of the system, requiring only a single protein and a single RNA molecule, the 
tool is versatile and can be easily adapted to specific purposes, e. g. by 
restricting Ago2 expression, and thus gene silencing, to a single life cycle stage. 
I envision that this new technology will largely facilitate research on this 
important parasite and will thereby, eventually, contribute to ongoing world-
wide efforts to fight, and ideally to ultimately eradicate, malaria disease.   
 Materials and Methods 
5.1 MATERIALS  
“The human animal differs from the lesser primates in his passion for lists.”  
~ H. Allen Smith (1907 – 1976) 
5.1.1 LABORATORY EQUIPMENT 
All equipment used in this work is listed in Table 2.  
TABLE 2: Laboratory equipment 
Equipment Name Company 
Agarose gel 
electrophoresis 
Gel caster Bio-Rad (Hercules, CA, USA) 
Gel Doc XR Bio-Rad (Hercules, CA, USA) 
Microwave oven Sharp Electronics (Hamburg, 
Germany) 
Mini-SUB® cell GT/Sub-
Cell® GT DNA electro-
phoresis system 
Bio-Rad (Hercules, CA, USA) 
UV transilluminator UST-
30M-8E 
Biostep GmbH 
(Burkhardtsdorf, Germany) 
Balances 
 
KERN EG200-2NM Kern&Sohn GmbH (Bailingen, 
Germany) 
Analytical balance Pioneer Ohaus (Nanickon, Switzerland) 
Precision balance Mettler (Toledo, Switzerland) 
Centrifuges 
 
Allegra X-12R centrifuge Beckman Coulter (Brea, CA, 
USA) 
Avanti J-26 XP centrifuge Beckman Coulter (Brea, CA, 
USA) 
Megafuge 1.0R Heraeus Instruments (Hanau, 
Germany) 
Microcentrifuge 5415 D Eppendorf (Hamburg, 
Germany) 
Microcentrifuge 5415 R Eppendorf (Hamburg, 
Germany) 
5 
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Equipment Name Company 
Electroporation 
devices 
AMAXA Nucleofector II 
electroporator 
Lonza (Cologne, Germany) 
Gene Pulser XcellTM Bio-Rad (Hercules, CA, USA) 
Flow cytometer Cytomics FC500MPL 
analyzer 
Beckman Coulter (Brea, CA, 
USA) 
Heating blocks DB1010 Alpha Laboratories 
(Hampshire, UK) 
ThermoCell Mixing Block 
MB-102 
Bioer (Hangzhou, China) 
Thermomixer comfort Eppendorf (Hamburg, 
Germany) 
Incubators 
 
Bacterial incubator 
Heraeus Function Line 
Heraeus/Thermo Fisher 
Scientific (Waltham, MA, USA) 
Hera cell 150 incubator Heraeus/Thermo Fisher 
Scientific (Waltham, MA, USA) 
Hera cell incubator Heraeus/Thermo Fisher 
Scientific (Waltham, MA, USA) 
Shaking Incubator 
Multitron 
INFORS HT (Basel, 
Switzerland) 
Microscope 
 
Confocal microscope TCS 
SP5 
Leica (Wetzlar, Germany) 
Fluorescence microscope 
Axiovert 200M 
Carl Zeiss (Oberkochen, 
Germany) 
Inverted fluorescence 
microscope IX-81 
Olympus (Hamburg, Germany) 
Inverted microscope      
CKX-41 
Olympus (Hamburg, Germany) 
Light microscope      
Axiostar Plus 
Carl Zeiss (Oberkochen, 
Germany) 
Light microscope      
Axiovert 25 
Carl Zeiss (Oberkochen, 
Germany) 
Light microscope       
Axiskop 40 
Carl Zeiss (Oberkochen, 
Germany) 
Stereomicroscope         
Sterni 2000-C 
Carl Zeiss (Oberkochen, 
Germany) 
Pipets accu-jet® pro  BRAND (Wertheim, Germany)  
FisherbrandTM 
FinnpipetteTM  (5 - 50 µl, 10 
– 100 µl) 
Thermo Fisher Scientific 
(Waltham, MA, USA) 
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Equipment Name Company 
Pipets Pipetman (2-20 µl, 20-
100 µl, 100-1000 µl) 
Gilson, Inc. (Middleton, WI, 
USA) 
Pipetus® Hirschman Laborgeräte 
(Eberstadt, Germany) 
Research multichannel  (10 
– 100 µl) 
Eppendorf (Hamburg, 
Germany) 
Research plus multichannel 
(0.5 – 10 µl) 
Eppendorf (Hamburg, 
Germany) 
Research plus pipettes 
(0.1-2 µl, 0.5-10 µl, 2-20 µl, 
20-100 µl, 100-1000 µl) 
Eppendorf (Hamburg, 
Germany) 
Shaker and 
rotation 
devices 
Shaker DOS-10L neoLab (Heidelberg, Germany) 
Shaker DRS-12 neoLab (Heidelberg, Germany) 
Tube Rotator VWR (Radnor, PA, USA) 
Spectro-
photometer 
NanoDrop 2000 UV-Vis 
Spectrophotometer 
Thermo Fisher Scientific 
(Waltham, MA, USA) 
NanoVue 
Spectrophotometer 
GE Healthcare (Munich, 
Germany) 
Storage Freezer -20 °C Liebherr (Bulle, Switzerland) 
Fridge Liebherr (Bulle, Switzerland) 
Herafreeze Top -80 °C Heraeus/Thermo Fisher 
Scientific (Waltham, MA, USA) 
Liquid nitrogen tank 
Cryosystem 4000 series 
Panasonic (Kadoma, Japan) 
Liquid nitrogen tank MVE 
XC 34/18 
MTG (Bruckberg, Germany) 
Thermal 
cyclers 
ABI 7500 Real-Time PCR 
System 
Life Technologies (Paisley, UK) 
StepOnePlus Real-Time 
PCR System 
Applied Biosystems/Thermo 
Fisher Scientific (Waltham, MA, 
USA) 
FlexCycler analytikjena (Jena, Germany) 
Mastercycler® pro Eppendorf (Hamburg, 
Germany) 
Western blot 
equipment 
 
Film developing cassettes Dr. Goos-Suprema GmbH 
(Heidelberg, Germany) 
ChemoCam (ECL Imager) INTAS Science Imaging 
Instruments (Göttingen, 
Germany) 
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Equipment Name Company 
Western blot 
equipment 
Mini-PROTEAN® comb 15-
well 
Bio-Rad (Hercules, CA, USA) 
Mini-PROTEAN® short 
plates 
Bio-Rad (Hercules, CA, USA) 
Mini-PROTEAN® spacer 
plate (1 mm) 
Bio-Rad (Hercules, CA, USA) 
Mini-PROTEAN® tetra cell 
casting module 
Bio-Rad (Hercules, CA, USA) 
Mini-PROTEAN® tetra 
vertical electrophoresis cell 
Bio-Rad (Hercules, CA, USA) 
PowerPac Power Supply Bio-Rad (Hercules, CA, USA) 
Trans-Blot® SD Semi-Dry 
Electrophoretic Transfer 
Cell 
Bio-Rad (Hercules, CA, USA) 
X-OMAT 2000 processor KODAK (Rochester, NY, USA) 
Other 
 
CountessTM Automated 
Cell Counter 
Invitrogen/Life Technologies 
(Paisley, UK) 
Haemocytometer 
(Neubaur) 
Labotec Labor-Technik 
(Göttingen, Germany) 
Magnetic stirrer Heidolph 
MR3001 
NeoLab Migge (Heidelberg, 
Germany) 
Micropistill for 1.5 ml 
tubes, conical 
NeoLab Migge (Heidelberg, 
Germany) 
Mosquito cages BioQuip Products (Rancho 
Dominguez, CA, USA) 
MSH basic – magnetic 
stirrer with steel heating 
plate 
IKA Laboratory Equipment 
(Staufen, Germany) 
pH meter PB-11 Sartorius (Göttingen, Germany) 
Qubit® fluorometer Invitrogen/Live Technologies 
(Paisley, UK) 
Sterile workbench 
HeraSafe® 
Heraeus/Thermo Fisher 
Scientific (Waltham, MA, USA) 
Ultrasonic bath BANDELIN (Berlin, Germany) 
Vortex Genie 2 Scientific Industries Roth 
(Karlsruhe, Germany) 
Water bath 1003 GFL (Burgwedel, Germany) 
Water bath TW12 Julabo Labortechnik (Seelbach, 
Germany) 
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5.1.2 LABORATORY MATERIAL 
All consumables are listed in Table 3. 
TABLE 3: Consumables  
Name Description Company 
Cell culture flasks Cellstar® 75/175 cm2 Greiner Bio-One (Frickenhausen, 
Germany) 
Cell culture flasks Nunclon delta surface   
25 cm2 
Thermo Fisher Scientific 
(Waltham, MA, USA) 
Cell culture plates 6 / 12 / 24 / 96 well Greiner Bio-One (Frickenhausen, 
Germany)  
Nunc (Roskilde, Denmark) 
Cryogenic vials Cryo.STM, with screw cap, 
2 ml 
Greiner Bio-One (Frickenhausen, 
Germany) 
Electroporation 
Cuvettes  
25 x 1 mm gap Peqlab (Erlangen, Germany) 
Filter tips Biosphere® 
10/20/100/200/1000 µl  
Sarstedt (Nuembrecht, 
Germany) 
FT 10 E 1µl Greiner Bio-One (Frickenhausen, 
Germany) 
Inoculation loops 1 µl VWR (Darmstadt, Germany) 
Insulin syringe BD Micro-FineTM U-100, 
29G 
Becton Dickingson, (Franklin 
Lakes, NJ, USA) 
Lab-Tek chamber 
slides 
8 well, with cover, 
Permanox 
Thermo Fisher Scientific 
(Waltham, MA, USA) 
Microscopic 
cover glasses 
18 x 18 mm, 24 x 50 mm Marienfeld  (Lauda-Königshofen, 
Germany) 
Microscopic 
slides 
Frosted ends, 
76 x 25 x 1 mm 
Marienfeld (Lauda-Königshofen, 
Germany) 
Needles BD MicrolanceTM  3, 20G, 
23G, 27G 
Becton Dickingson, (Franklin 
Lakes, NJ, USA) 
Nitrocellulose 
membrane  
PROTAN® Whatman (Maidstone, UK) 
Parafilm M  Bernis, WI, USA 
Pasteur pipettes Plastic (Pastette) Alpha Laboratories Limited 
(Hampshire, UK) 
Glas, 150 mm, 230 mm Corning Incorporated, (Corning, 
NJ, USA) 
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Name Description Company 
PCR tubes 0.2 ml, 8-strip STARLAB (Hamburg, Germany) 
Petri dishes 10 cm Greiner Bio-One (Frickenhausen, 
Germany) 
Pipette tips 200/1000 µl Sarstedt (Nuembrecht, 
Germany) 
10 µl Kisker Biotech (Steinfurt, 
Germany) 
Precision wipes Kimtech Science 
precision wipes 
Kimberly-Clark (Ontario, 
Canada) 
qPCR seals Optical clear Peqlab biotechnology (Erlangen, 
Germany) 
qRT-PCR plate Thermofast 96 well PCR 
detection plate 
Thermo Fisher Scientific 
(Waltham, MA, USA) 
Reaction tubes 0.5/1/2 ml Sarstedt (Nuembrecht, 
Germany) 
Serological 
pipettes 
5/10/25 ml Greiner Bio-One (Frickenhausen, 
Germany) 
Syringes BD DiscarditTM 
2/5/10 ml  
Becton Dickingson, (Franklin 
Lakes, NJ, USA) 
BD PlastipakTM U-100, 
1 ml 
Becton Dickingson, (Franklin 
Lakes, NJ, USA) 
Tubes 15/50 ml Greiner Bio-One (Frickenhausen, 
Germany) 
Becton Dickingson, (Franklin 
Lakes, NJ, USA) 
Whatman paper 3 mm Whatman (Maidstone, UK) 
X-ray films Amersham HyperfilmTM 
ECL 
GE Healthcare (Munich, 
Germany) 
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5.1.3 PLASMODIUM, MICE, MOSQUITOES, BACTERIA AND CELLS  
All Plasmodium strains, mouse strains and mosquito strains used in this 
study can be found in Table 4, Table 5, and Table 6, respectively. E. coli strains 
and cell lines are listed in Table 7 and Table 8, respectively. 
TABLE 4: Plasmodium strains 
P. berghei line Description Source 
PbGFPcon P. berghei ANKA strain that constitutively 
expresses GFP under the Pbef1 5’ UTR
Franke-Fayard 
et al., (2004)274  
TABLE 5: Mouse strains 
Mouse strain Description Source 
C57BL/6J Inbred  Janvier Labs (France) 
Naval Medical Research 
Institute (NMRI) 
Outbred Janvier Labs (France) 
TABLE 6: Mosquito strains 
Mosquito line Source 
Anopheles stephensi  NIJ Nijmegen, Netherlands 
TABLE 7: Bacterial strains 
Bacterial strain Description Source 
E. coli MAX Efficiency 
DH5TM
Chemically competent Life Technologies 
(Paisley, UK) 
E. coli MegaX DH10BTM T1R Electro-competent Life Technologies 
(Paisley, UK) 
TABLE 8: Cell lines 
Cell line Description Source 
HEK293T Human embryonic kidney  DuBridge et al. (1987) 
HuH7 Human hepatocellular 
carcinoma 
Nakabayashi et al. (1982) 
MEF (1c1) Mouse embryonic 
fibroblasts 
Glasmacher et al. (2010)278 
Kind gift from Vigo 
Heissmeyer (Helmholtz-
Zentrum Munich, 
Germany)  
Dicer-/- MEF (2G4) Mouse embryonic 
fibroblasts, Dicer-deficient 
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5.1.4 REAGENTS 
Chemicals 
All chemicals and reagents were bought in the highest purity available and 
are listed in Table 9. 
TABLE 9: Chemicals and reagents 
Product Company 
Acetic acid Sigma-Aldrich (Munich, Germany) 
Agarose Biozym Scientific (Hessisch Oldendorf, 
Germany) 
Albumin fraction V (BSA) Carl Roth (Karlsruhe, Germany) 
Alsever’s solution Sigma-Aldrich (Munich, Germany) 
Ammonium persulfate (APS) Grüssing GmbH (Filsum, Germany) 
Ampicillin Carl Roth (Karlsruhe, Germany) 
40% Acryl/bisacrylamide Carl Roth (Karlsruhe, Germany) 
Aqua braun (ddH2O) B. Braun AG (Melsungen, Germany) 
BactoTM agar BD (Franklin Lakes, NJ, USA) 
BactoTM tryptone BD (Franklin Lakes, NJ, USA) 
BactoTM yeast extract BD (Franklin Lakes, NJ, USA) 
Bepanthen® eye and nose cream Bayer AG (Leverkusen, Germany) 
Bromophenol blue Waldeck GmbH (Münster, Germany) 
Calcium chloride (CaCl2) Carl Roth (Karlsruhe, Germany) 
Chloroform Sigma-Aldrich (Munich, Germany) 
CF-11 Cellulose powder Thermo Fisher Scientific (Waltham, 
MA, USA) 
Deoxynucleoside triphosphate (dNTP) NEB (Frankfurt am Main, Germany) 
Dimethyl sulfoxide (DMSO)  Grüssing GmbH (Filsum, Germany) 
Dimethyl sulfoxide (DMSO) for PCR Thermo Fisher Scientific (Waltham, 
MA, USA) 
Dodecylsulfate-Na-salt pellets (SDS) SERVA Electrophoresis GmbH 
(Heidelberg, Germany) 
Dithiothreitol (DTT) AppliChem (Darmstadt, Germany) 
Ethanol Sigma-Aldrich (Munich, Germany) 
Ethidium bromide Carl Roth (Karlsruhe, Germany) 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich (Munich, Germany) 
5-Fluorocytosine Sigma-Aldrich (Munich, Germany) 
Gentamycin Life Technologies (Paisley, UK) 
Giemsa stock solution Roth (Karlsruhe, Germany) 
Glass beads Sigma-Aldrich (Munich, Germany) 
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Product Company 
Glucose Merk (Darmstadt, Germany) 
Life Technologies (Paisley, UK) 
Glycerol  Carl Roth (Karlsruhe, Germany) 
Heparin Ratiopharm (Ulm, Germany) 
Hoechst 33342 Invitrogen (Eugene, OR, USA) 
Hydrochloric acid (HCl), 1 M Sigma-Aldrich (Munich, Germany) 
ImmersolTM 518F Carl Zeiss (Oberkochen, Germany) 
Immersion oil, refractory index 1.482 Waldeck (Münster, Germany) 
Isopropanol Sigma-Aldrich (Munich, Germany) 
Ketamine 10 % Bremer Pharma GmbH (Warburg, 
Germany) 
6x Loading dye NEB (Frankfurt am Main, Germany) 
Magnesium chloride (MgCl2) AppliChem (Darmstadt, Germany) 
Magnesium sulfate (MgSO4) Merck (Darmstadt, Germany) 
Methanol Sigma-Aldrich (Munich, Germany) 
Milk powder Carl Roth (Karlsruhe, Germany) 
MOPS (C7H15NO4S) Carl Roth (Karlsruhe, Germany) 
Nuclease-free water Qiagen (Hilden, Germany) 
Nycodenz powder Axis-Shield (Dundee, Scotland) 
Para-aminobenzoic acid Sigma-Aldrich (Munich, Germany) 
Ponceau S solution Sigma-Aldrich (Munich, Germany) 
Potassium acetate (KAc) AppliChem (Darmstadt, Germany) 
Potassium chloride (KCl) AppliChem (Darmstadt, Germany) 
Potassium dihydrogen phosphate 
(KH2PO4) 
AppliChem (Darmstadt, Germany) 
Protease inhibitor cocktail Roche (Basel, Switzerland) 
Pyrimethamine Sigma-Aldrich (Munich, Germany) 
RLT buffer Qiagen (Hilden, Germany) 
QIAzol lysis reagent Qiagen (Hilden, Germany) 
Sucrose AppliChem (Darmstadt, Germany) 
Saponin Sigma-Aldrich (Munich, Germany) 
Sodium acetate (NaAc) Grüssing (Filsum, Germany) 
Sodium bicarbonate (NaHCO3) Merck (Darmstadt, Germany) 
Sodium carbonate (Na2CO3) Merck (Darmstadt, Germany) 
Sodium chloride (NaCl) Sigma-Aldrich (Munich, Germany) 
Sodium fluoride (NaF) Sigma-Aldrich (Munich, Germany) 
Sodium hydroxide (NaOH) Sigma-Aldrich (Munich, Germany) 
TE buffer Life Technologies (Paisley, UK) 
TEMED (UltraPureTM) Life Technologies (Paisley, UK) 
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Product Company 
Tris/Glycine/SDS (TGS) buffer (10x) BioRad (Hercules, USA) 
Tris Roth (Karlsruhe, Germany) 
Tris-HCl Roth (Karlsruhe, Germany) 
Triton X-100 Merck (Darmstadt, Germany) 
TweenTM20 Roth (Karlsruhe, Germany) 
Xylazine (Xylariem®) Ecuphar GmbH (Greifswald, Germany) 
-mercaptoethanol Roth (Karlsruhe, Germany) 
Cell culture reagents  
Media and supplements used in cell culture are listed in Table 10; 
transfection reagents can be found in Table 11.  
TABLE 10: Media and supplements for cell culture 
Component Company 
Category 
Number 
Dulbecco’s Modified Eagle 
Medium (DMEM), high 
glucose, GlutaMAXTM 
Life Technologies (Paisley, UK) 61965-026 
Dulbecco’s phosphate-
buffered saline (1x PBS) 
Life Technologies (Paisley, UK) 14190-094 
Fetal bovine serum (FBS) Sigma-Aldrich (Munich, 
Germany) 
F7524 
Fetal calf serum, US Origin 
(FCS-US) 
Life Technologies (Paisley, UK) 16000-044 
Minimum Essential Medium 
Non-Essential Amino Acids 
(MEM-NEAA, 100x) 
Life Technologies (Paisley, UK) 11140-035 
Penicillin-Streptomycin  Life Technologies (Paisley, UK) 15140-122 
RPMI-1640  Life Technologies (Paisley, UK) 52400-025 
Trypsin-EDTA (0.25 %), 
phenol-red 
Life Technologies (Paisley, UK) 25200-056 
TABLE 11: Transfection reagents 
Component Company 
Category 
Number 
Lipofectamine 2000 Life Technologies (Paisley, UK) 11668-019 
Polyethylenimine (PEI) Polysciences (Warrington, PA, USA) 23966 
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Standard markers 
Standard markers listed in Table 12 were always loaded next to DNA or 
protein samples to allow size discrimination of the bands.  
TABLE 12: Standard markers 
Name Company 
1 kb plus ladder Life Technologies GmbH (Paisley, UK) 
100 bp ladder Life Technologies GmbH (Paisley, UK) 
PageRulerTM Plus Prestained Protein 
ladder 
Thermo Fisher Scientific (Waltham, 
MA, USA) 
Antibodies  
All primary and secondary antibodies used for Western blotting or 
immunofluorescence staining are listed in Table 13 and Table 14, respectively. 
Details of their application can be found in the respective methods section (see 
p. 118 for Western blots and p. 125 for immunofluorescence).   
TABLE 13: Primary antibodies 
Antibody Application Source 
Category 
Number 
Mouse-anti-FLAG IF Sigma-Aldrich (Munich, 
Germany) 
F1804-1MG 
Mouse-anti-GFP WB eBioscience Inc. (San 
Diego, CA, USA) 
14-6674-82 
Mouse-anti-HA WB Santa Cruz Biotechnology 
(Heidelberg, Germany) 
sc-7392 
Mouse-anti-HSP70 WB 
IF 
Tsuji et al., 1994 340 - 
Rabbit-anti-GFP IF Thermo Fisher Scientific 
(Waltham, MA, USA) 
PA146326 
A-11122 
rat-anti-Ago2 WB Sigma-Aldrich (Munich, 
Germany), Clone 11A9 
MABE253 
Rat-anti-EXP1 IF Sá E Cunha et al., 201719 - 
Mouse-anti-EXP1 WB Sá E Cunha et al., 201719 - 
 
 
 
 
 
 
WB: Western blot 
IF: Immuno-fluorescence 
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TABLE 14: Secondary antibodies 
Antibody Application Source 
Category 
Number 
Alexa Fluor ® 488 anti-
mouse IgG 
IF Life Technologies 
(Paisley, UK) 
A11029 
Alexa Fluor ® 488 anti-
rabbit IgG 
IF Life Technologies 
(Paisley, UK) 
A11034 
Alexa Fluor ® 546 anti-
mouse IgG 
IF Life Technologies 
(Paisley, UK) 
A11003 
Alexa Fluor ® 546 anti-rat 
IgG 
IF Life Technologies 
(Paisley, UK) 
A11081 
ECL™ Rat IgG, HRP-linked 
whole antibody (from 
goat) 
WB GE-Healthcare 
(Chalfont St. Giles, 
UK) 
NA935V 
Peroxidase-AffiniPure Goat 
Anti-Mouse IgG + IgM 
WB Jackson Immuno-
Research (West 
Grove, PA, USA) 
115-035-068 
Enzymes 
All enzymes that were used in this work are listed in Table 15. 
TABLE 15: Enzymes 
Enzyme Company 
Category 
Number 
Antarctic Phosphatase NEB (Frankfurt am Main, Germany) M0289S 
BpiI (BbsI) Thermo Fisher Scientific (Waltham, 
MA, USA) 
ER1011 
Gibson Assembly ® 
Master Mix 
NEB (Frankfurt am Main, Germany) E2611S 
OneTaq® 2x Master Mix 
with standard buffer 
NEB (Frankfurt am Main, Germany) M0486S 
Phusion Hot Start II DNA 
polymerase 
Thermo Fisher Scientific (Waltham, 
MA, USA)  
F-549L 
Power SYBR® Green PCR 
Master Mix 
Applied Biosystems (CA, USA) 4367659 
Restriction enzymes 
(except for BbsI) 
NEB (Frankfurt am Main, Germany) - 
RNaseA  Qiagen (Hilden, Germany) 19101 
T4 DNA ligase NEB (Frankfurt am Main, Germany) M0202L 
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Kits 
Unless mentioned otherwise, kits listed in Table 16 were always used 
according to the instructions of the manufacturer.  
TABLE 16:  Commercial Kits 
Kit Company 
Amaxa Human T cell Nucleofector Kit Lonza (Cologne, Germany) 
DNA Clean & Concentrator TM-5 Zymo Research (Irvine, CA, USA) 
DNeasy Blood & Tissue Kit QIAGEN (Hilden, Germany) 
miRNeasy Mini Kit QIAGEN (Hilden, Germany) 
NucleoBond® Xtra Maxi Macherey-Nagel GmbH (Duren, 
Germany) 
PureYieldTM Plasmid Midiprep Kit Promega (Madison, WI, USA) 
Qbit® protein assay kit Thermo Fisher Scientific (Waltham, 
MA, USA) 
QIAquick gel extraction kit QIAGEN (Hilden, Germany) 
Tetro cDNA Synthesis Kit Bioline (London, UK) 
Western lightning PLUS-ECL PerkinElmer (Waltham, MA, USA) 
5.1.5 BUFFERS AND SOLUTIONS 
The composition of all buffers and solutions used in this work is listed in 
Table 17.  
TABLE 17: Composition of buffers 
Buffer Composition  
Blocking buffer 
(Immunofluorescence) 
5 % (v/v) 
 
FBS  
in 1x PBS 
Blocking buffer (Western blot) 5 % (w/v) 
 
Milk powder 
in 1x TBS-T 
DMEM complete 10 % (v/v) 
1 % (v/v) 
 
FBS 
Penicillin-Streptomycin 
in DMEM GlutaMAXTM 
Giemsa staining solution 10 % 
 
Giemsa stock solution 
in dH2O 
Ketamine/Xylazine (K/X) 35.1 %  
5.3 % 
 
Ketamine 
Xylazine 
diluted in 1x PBS 
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Buffer Composition  
Lysogeny broth (LB) medium  1 % (w/v) 
0.5 % (w/v) 
1 % (w/v) 
 
Tryptone 
Yeast extract  
NaCl 
in ddH2O 
LB-Amp agar 1.5 % (w/v) 
100 µg/ml 
 
Agar 
Ampicillin 
in LB medium 
LB-Amp medium 50 µg/ml 
 
Ampicillin 
in LB medium 
Nycodenz stock solution 5 mM 
3 µM 
0.3 mM 
276 g/L 
 
 
 
Tris 
KCl 
EDTA 
Nycodenz 
in ddH2O, pH 7.5 
autoclaved and stored in 
the dark at 4 °C 
55 % Nycodenz/PBS 55 % (v/v) 
 
Nycodenz stock solution 
in 1x PBS 
P1 resuspension buffer 50 mM 
10 mM 
100 µg/ml 
 
Tris-HCl 
EDTA 
RNaseA 
in ddH2O, pH 8 
P2 lysis buffer 200 mM  
1 % (w/v) 
 
NaOH 
SDS 
in ddH2O 
P3 neutralization buffer 2.8 M 
 
KAc 
in ddH2O, pH 5.1 
Pyrimethamine drinking water 1x 
 
~5 % (v/v) 
 
Pyrimethamine stock 
solution 
HCl (1 M) to adjust pH 
in tap water, pH 3-5  
Pyrimethamine stock solution 
(100x) 
7 mg/ml 
 
Pyrimethamine 
in DMSO 
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Buffer Composition  
RIPA buffer 50 mM 
150 mM 
5 mM  
50 mM 
0.5% 
0.1 % 
1 % 
 
 
2 mM 
1x 
Tris  
NaCl 
EDTA 
NaF 
Sodium deoxycholate 
SDS 
Triton X-100 
in H2O, pH 7.5 
Add directly before use:  
DTT 
Protease inhibitor cocktail 
SDS sample buffer (2x) 2 mM 
100 mM 
4 % (w/v) 
20 % (v/v) 
10 % (v/v) 
0.02 % (w/v) 
 
EDTA 
Tris-HCl 
SDS 
Glycerol 
-mercaptoethanol 
Bromophenol blue 
in ddH2O, pH 7.5 
SDS sample buffer (6x) 6 mM 
300 mM 
12 % (w/v) 
60 % (v/v) 
30 % (v/v) 
0.06 % (w/v) 
 
EDTA 
Tris-HCl 
SDS 
Glycerol 
-mercaptoethanol 
Bromophenol blue 
in ddH2O, pH 7.5  
SDS-PAGE Running gel buffer 1.5 M 
0.4 % (w/v) 
 
Tris 
SDS 
in ddH2O, pH 8.8 
SDS-PAGE Stacking gel buffer 500 mM 
0.4 % (w/v) 
 
Tris 
SDS 
in ddH2O, pH 6.8 
SOB medium 2 % (w/v) 
0.5 % (w/v) 
0.05 % (w/v) 
2.5 mM 
10 mM 
10 mM 
 
Tryptone 
Yeast extract 
NaCl 
KCl 
MgCl2 (autoclaved) 
MgSO4 (autoclaved) 
in ddH2O 
SOC medium 20 mM 
 
Glucose (sterile-filtrated) 
in SOB medium 
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Buffer Composition  
TAE buffer (50x) 2 M 
50 mM  
5.71 % (v/v) 
 
Tris 
EDTA 
Acetic acid 
in ddH2O, pH 8.3 
TBS (10x) 250 mM 
1.25 M 
 
Tris 
NaCl 
in ddH2O, pH 7.5 
TBS-T (1x) 0.05 % (v/v) 
 
TweenTM20 
in 1x TBS 
TFBI 30.6 mM 
80 mM 
100 mM 
16 mM 
13.2 % (v/v) 
 
KAc 
MgCl2 
KCl 
CaCl2 
Glycerol 
in ddH2O, pH 5.8 
TFBII 4.8 mM 
76 mM 
10 mM 
13.2 % (v/v) 
 
MOPS 
CaCl2 
KCl 
Glycerol 
in ddH2O, pH 8.0 
Transfection medium 20 % (v/v) 
2 % (v/v) 
 
FCS-US 
Gentamycin 
in RPMI-1640 
Transfer buffer 20 % 
 
methanol 
in 1x TGS 
Washing buffer 
(Immunofluorescence) 
1 % (v/v) 
 
FBS 
in 1x PBS 
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5.1.6 DNA 
Oligonucleotides 
TABLE 18 shows the sequence of all oligonucleotides used in this work. 
Overhangs are depicted in small letters. Restriction sites used for cloning, 
overhangs created by oligo-annealing or homology arms for Gibson cloning are 
indicated in orange. If additional restriction sites were introduced to the 
oligonucleotide, they are labeled in bold. Sense strands of sh- or AgoshRNAs are 
marked in blue in the forward oligonucleotide. All oligonucleotides were 
ordered at Sigma-Aldrich (Munich, Germany) or Integrated DNA Technologies 
(Leuven, Belgium).  
Table 18: Oligonucleotides 
ID Name Sequence (5’  3’) 
P1 XhoI-GFP-mut3 F  gtcgcctcgagATGCGTAAAGGAGAAGAACTTTTC 
P2 NheI-GFP-mut3 R  gactagctagcTTATTTGTATAGTTCATCCATGCC 
P3 XbaI-Stuffer-BlpI F ctagaGAATTCAGATCTACTAGTGTTAACATGGGA
TCTGGATCTGGTGGTGGTGGAACCGGTgc 
P4 XbaI-Stuffer-BlpI R ttagcACCGGTTCCACCACCACCAGATCCAGATCCC
ATGTTAACACTAGTAGATCTGAATTCt 
P5 NdeI-PacI-AscI-
BamHI (MCS) F  
tatgATGTACGAGACGGGCGCGCCATGCATGCTT
AATTAACGTCTCAAGTGAg 
P6 NdeI-PacI-AscI-
BamHI (MCS) R 
gatccTCACTTGAGACGTTAATTAAGCATGCATG
GCGCGCCCGTCTCGTACATca 
P7 NdeI-FLAG-Ago2 F  gtcgccatatgATGGACTACAAGGACGACG 
P8 BamHI-Ago2 R  agactaggatccTCAGGCGAAGTACATGGTCC 
P9 5’LISP2 Gibson F gagaattcagatctactagtgttGCATTATCGTCAAAAGT
G 
P10 5’LISP2 Gibson R tcgtcgtccttgtagtccatcatatgtcccatatttaaatTTTTTA
TGTGTAAAAAAGTAAAATGATT 
P11 XmaI-BbsI-PbU6 F cactcgacccgggGCAATGGTCTTCAGTGAAGACT
CAATAATATTGTATAACTCGAAGTATGC 
P12 XhoI-PbU6-R cgatgctcgagCACACACCTATATATCGAGAAC 
P13 Gibson GFP to 
mCherry F 
tatcccaataaattacaattacaattatttaaatatggccatggg
acatATGGTGAGCAAGGGCG 
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ID Name Sequence (5’  3’) 
P14 Gibson GFP to 
mCherry R 
tccttaaacgggcttgcacaccttttagctagccgcggTTACT
TGTACAGCTCGTCCATG 
P15 NgoMVI-BamHI 
stuffer F 
ccggcAGACAACCATTACCTGTCCACACAATCTGC
CCg 
P16 NgoMVI-BamHI 
stuffer R 
gatccGGGCAGATTGTGTGGACAGGTAATGGTTG
TCTg 
P17 BclI-3'PbDHFS F atgcgatgatcaCTAGCTAAAAGGTGTGCAAGC 
P18 XhoI-3'PbDHFS R atgcgactcgagGGATATCATATTTGTAATGATGC 
P19 5’HSP70 seq CACTATTTTGCCATAAGCAC 
P20 3’PbDHFS-FPGS seq AATCCTTAAACGGGCTTGC 
P21 HA-Ago2-rev seq AATCGGGCACGTCATAAGG 
P22 SIL6R rev seq GTGCCTGAATTATAGTGCA 
P23 PbU6 to BbsI seq ACATAGCATGCCGAATGC 
P24 GFP AgoshR 1a F caccGTGTCTTGTAGTTCCCGTCAGAGACGGGAAC
TACAAGACAC 
P25 GFP AgoshR 1a R aaaaGTGTCTTGTAGTTCCCGTCTCTGACGGGAA
CTACAAGACAC 
P26 GFP AgoshR 2a F caccGTTAACTTTGATTCCATTCAGAGAATGGAAT
CAAAGTTAAC 
P27 GFP AgoshR 2a R aaaaGTTAACTTTGATTCCATTCTCTGAATGGAAT
CAAAGTTAAC 
P28 GFP AgoshR 3a F caccGTTGAACGCTTCCATCTTCAGAGAAGATGGA
AGCGTTCAAC 
P29 GFP AgoshR 3a R aaaaGTTGAACGCTTCCATCTTCTCTGAAGATGGA
AGCGTTCAAC 
P30 GFP AgoshR 4a F caccGTTGCATCACCTTCACCCTAGAAGGGTGAAG
GTGATGCAAC 
P31 GFP AgoshR 4a R aaaaGTTGCATCACCTTCACCCTTCTAGGGTGAAG
GTGATGCAAC 
P32 Ren shR 1 F caccGCAACGCAAACGCATGATCACTCAAGAGGTG
ATCATGCGTTTGCGTTGC    
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ID Name Sequence (5’  3’) 
P33 Ren shR 1 R aaaaGCAACGCAAACGCATGATCACCTCTTGAGT
GATCATGCGTTTGCGTTGC    
P34 GFP shR 1a F caccGGGTGAAGGTGATGCAACATATCAAGAGTA
TGTTGCATCACCTTCACCC 
P35 GFP shR 1a R aaaaGGGTGAAGGTGATGCAACATACTCTTGATA
TGTTGCATCACCTTCACCC 
P36 GFP shR 2a F caccGGCCAACACTTGTCACTACTTTCAAGAGAAG
TAGTGACAAGTGTTGGCC 
P37 GFP shR 2a R aaaaGGCCAACACTTGTCACTACTTCTCTTGAAAG
TAGTGACAAGTGTTGGCC 
P38 GFP shR 3a F caccGAAGATGGAAGCGTTCAACTATCAAGAGTAG
TTGAACGCTTCCATCTTC 
P39 GFP shR 3a R aaaaGAAGATGGAAGCGTTCAACTACTCTTGATA
GTTGAACGCTTCCATCTTC 
P40 GFP AgoshR 1b F caccGTTGCATCACCTTCACCCTCTCCAGGGGTGA
AGGTGATGCAAC 
P41 GFP AgoshR 1b R aaaaGTTGCATCACCTTCACCCCTGGAGAGGGTG
AAGGTGATGCAAC 
P42 GFP AgoshR 2b F caccGCTAGTTGAACGCTTCCATCTTCAGTGGAAG
CGTTCAACTAGC 
P43 GFP AgoshR 2b R aaaaGCTAGTTGAACGCTTCCACTGAAGATGGAA
GCGTTCAACTAGC 
P44 GFP AgoshR 3b F caccAACAAGAATTGGGACAACTCCAGTGGTTGTC
CCAATTCTTGTT 
P45 GFP AgoshR 3b R aaaaAACAAGAATTGGGACAACCACTGGAGTTGT
CCCAATTCTTGTT 
P46 GFP AgoshR 4b F caccAACTCAAGAAGGACCATGTGGTCTGCATGGT
CCTTCTTGAGTT   
P47 GFP AgoshR 4b R aaaaAACTCAAGAAGGACCATGCAGACCACATGG
TCCTTCTTGAGTT 
P48 GFP AgoshR 1c F caccATTGCATCACCTTCACCCTCTCCAGGGGTGA
AGGTGATGCAAC 
P49 GFP AgoshR 1c R aaaaGTTGCATCACCTTCACCCCTGGAGAGGGTG
AAGGTGATGCAAT 
P50 GFP AgoshR 2c F caccACTAGTTGAACGCTTCCATCTTCAGTGGAAG
CGTTCAACTAGC 
P51 GFP AgoshR 2c R aaaaGCTAGTTGAACGCTTCCACTGAAGATGGAA
GCGTTCAACTAGT 
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ID Name Sequence (5’  3’) 
P52 GFP AgoshR 3c F caccAACAAGAATTGGGACAACTCCAGTGGTTGTC
CCAATTCTTGTC 
P53 GFP AgoshR 3c R aaaaGACAAGAATTGGGACAACCACTGGAGTTGT
CCCAATTCTTGTT 
P54 GFP AgoshR 4c F caccAACTCAAGAAGGACCATGTGGTCTGCATGGT
CCTTCTTGAGTC   
P55 GFP AgoshR 4c R aaaaGACTCAAGAAGGACCATGCAGACCACATGG
TCCTTCTTGAGTT 
P56 AgoshR scr F caccAGACTCTCGTGTCCATAATCTTCAGTTATGG
ACACGAGAGTCC 
P57 AgoshR scr R aaaaGGACTCTCGTGTCCATAACTGAAGATTATG
GACACGAGAGTCT 
P58 PbU6 GFP AgoshR 
1c F 
tattATTGCATCACCTTCACCCTCTCCAGGGGTGAA
GGTGATGCAACTTTT 
P59 PbU6 GFP AgoshR 
1c R 
gcaaAAAAGTTGCATCACCTTCACCCCTGGAGAGG
GTGAAGGTGATGCAAT 
P60 PbU6 GFP AgoshR 
2c F 
tattACTAGTTGAACGCTTCCATCTTCAGTGGAAGC
GTTCAACTAGCTTTT 
P61 PbU6 GFP AgoshR 
2c R 
gcaaAAAAGCTAGTTGAACGCTTCCACTGAAGATG
GAAGCGTTCAACTAGT 
P62 PbU6 GFP AgoshR 
3c F 
tattAACAAGAATTGGGACAACTCCAGTGGTTGTC
CCAATTCTTGTCTTTT 
P63 PbU6 GFP AgoshR 
3c R 
gcaaAAAAGACAAGAATTGGGACAACCACTGGAG
TTGTCCCAATTCTTGTT 
P64 PbU6 GFP AgoshR 
4c F 
tattAACTCAAGAAGGACCATGTGGTCTGCATGGT
CCTTCTTGAGTCTTTT  
P65 PbU6 GFP AgoshR 
4c R 
gcaaAAAAGACTCAAGAAGGACCATGCAGACCACA
TGGTCCTTCTTGAGTT 
P66 PbU6 AgoshR scr F tattAGACTCTCGTGTCCATAATCTTCAGTTATGGA
CACGAGAGTCCTTTT 
P67 PbU6 AgoshR scr R gcaaAAAAGGACTCTCGTGTCCATAACTGAAGATT
ATGGACACGAGAGTCT 
P68 PbU6 PPLP2 
AgoshR 1 F 
tattATCTAGTAGCGCATTCCTTCTTCAGAGGAATG
CGCTACTAGACTTTT 
P69 PbU6 PPLP2 
AgoshR 1 R 
gcaaAAAAGTCTAGTAGCGCATTCCTCTGAAGAAG
GAATGCGCTACTAGAT 
P70 PbU6 PPLP2 
AgoshR 2 F 
tattATAGAAGGAGTACTTACCTCTTCAGGGTAAG
TACTCCTTCTACTTTT 
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P71 PbU6 PPLP2 
AgoshR 2 R 
gcaaAAAAGTAGAAGGAGTACTTACCCTGAAGAG
GTAAGTACTCCTTCTAT 
P72 PbU6 PPLP2 
AgoshR 3 F 
tattAATCTAGGTATCCATCATTCTTCAGATGATGG
ATACCTAGATCTTTT 
P73 PbU6 PPLP2 
AgoshR 3 R 
gcaaAAAAGATCTAGGTATCCATCATCTGAAGAAT
GATGGATACCTAGATT 
P74 PbU6 PPLP2 
AgoshR 4 F 
tattACTATTCCAAGGGAGTGTTCTTCAGACACTCC
CTTGGAATAGCTTTT 
P75 PbU6 PPLP2 
AgoshR 4 R 
gcaaAAAAGCTATTCCAAGGGAGTGTCTGAAGAA
CACTCCCTTGGAATAGT 
P76 PbU6 Exp1   
AgoshR 1 F 
tattAATTACTGGTTCTGCTGGTCTTCAGCCAGCA
GAACCAGTAATCTTTT 
P77 PbU6 Exp1   
AgoshR 1 R 
gcaaAAAAGATTACTGGTTCTGCTGGCTGAAGAC
CAGCAGAACCAGTAATT 
P78 PbU6 Exp1   
AgoshR 2 F 
tattATCTTTGAGCATAGCTTCTCTTCAGGAAGCTA
TGCTCAAAGACTTTT 
P79 PbU6 Exp1   
AgoshR 2 R 
gcaaAAAAGTCTTTGAGCATAGCTTCCTGAAGAGA
AGCTATGCTCAAAGAT 
P80 PbU6 Exp1   
AgoshR 3 F 
tattATTGTTGAAGATTTGGCATCTTCAGTGCCAAA
TCTTCAACAACTTTT 
P81 PbU6 Exp1   
AgoshR 3 R 
gcaaAAAAGTTGTTGAAGATTTGGCACTGAAGAT
GCCAAATCTTCAACAAT 
P82 PbU6 MSP1 
AgoshR 1 F 
tattATTTGTTGCAATAATGGCTCTTCAGGCCATTA
TTGCAACAAACTTTT 
P83 PbU6 MSP1 
AgoshR 1 R 
gcaaAAAAGTTTGTTGCAATAATGGCCTGAAGAG
CCATTATTGCAACAAAT  
P84 PbU6 MSP1 
AgoshR 2 F 
tattAGATTGTGATGAGGCTTGTCTTCAGCAAGCC
TCATCACAATCCTTTT 
P85 PbU6 MSP1 
AgoshR 2 R 
gcaaAAAAGGATTGTGATGAGGCTTGCTGAAGAC
AAGCCTCATCACAATCT 
P86 PbU6 MSP1 
AgoshR 3 F 
tattATATTCTTCTGATTGACCTCTTCAGGGTCAAT
CAGAAGAATACTTTT 
P87 PbU6 MSP1 
AgoshR 3 R 
gcaaAAAAGTATTCTTCTGATTGACCCTGAAGAGG
TCAATCAGAAGAATAT 
P88 SIL6 3' Integration F CCACCCCGTGTGAATATG 
P89 SIL6 3' WT R GCACATTTGTGTATTACATATCAC 
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ID Name Sequence (5’  3’) 
P90 SIL6 5' WT F AATACTGCAACAATTGTGTTTG 
P91 SIL6 5' Integration R ACAATTCCGCAATTTGTTGTAC 
P92 3'PbDHFS-FPGS for 
negative selection 
ATATACGTGAAAAAGCATCATTAC 
P93 GFPmut3 qRT-PCR F GGAGAGGGTGAAGGTGATGC 
P94 GFPmut3 qRT-PCR R TGACAAGTGTTGGCCATGGA 
P95 mCherry qRT-PCR F GCTCCAAGGCCTACGTGAAG 
P96 mCherry qRT-PCR R CCGTCCTCGAAGTTCATCAC 
P97 PPLP2 qRT-PCR F GCAAGTAGTAGAACAAAATGAAGC 
P98 PPLP2 qRT-PCR R TAGCAGATGATCTACCTGTTCC 
P99 GamHK qRT-PCR F GCCAGAATCATTATGTTTTACTATAATGG 
P100 GamHK qRT-PCR R CTTAATATATAATCCATAAATTGGTGC 
P101 BamHI-SacI stuffer F gatcAGTCGAAGCTTACGTGagct 
P102 BamHI-SacI stuffer R CACGTAAGCTTCGACT 
Plasmids 
All plasmids used in this work are listed in TABLE 19. The ID of each plasmid 
refers to its internal number in the plasmid library of the Grimm laboratory.  
Table 19: Plasmids used in this work  
ID Plasmid name Description  Source 
#1546 pBAT-SIL6 Vector to integrate 
expression cassettes into 
P. berghei 
Kooij et al., 
2015279 
#1547 pBAT-SIL6-MCS A modified vector of #1546, 
lacking the mCherry-tag and 
with a multiple cloning site 
instead of the GFP 
This work 
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ID Plasmid name Description  Source 
#1548 pBAT-SIL6-Ago2 Vector to integrate the 
5’HSP70-Ago2-expression 
cassette into P. berghei 
This work 
#1873 pBAT-SIL6-5’LISP2-
Ago2 
Vector to integrate the 
5’LISP2-Ago2-expression 
cassette into P. berghei 
This work 
#1870 pBAT-SIL6-mCherry-
PbU6 
Vector to episomally express 
AgoshRNAs in P. berghei 
along with an mCherry as 
fluorescence marker 
This work 
#1871 pBAT-SIL6-PbU6int 
(V1) 
First version to integrate a 
PbU6-AgoshRNA cassette into 
PbAgo2 
This work 
#1872 pBAT-SIL6-
PbU6int(V2) 
Optimized vector to integrate 
a PbU6-AgoshRNA into 
PbAgo2.  
This work 
#1552 pBS-sds-mCherry-U6-
empty 
Vector to express an sh- or 
AgoshRNA in vitro along with 
an mCherry fluorescence 
marker 
Dominik 
Niopek 
#1339 pBS-sds-CMV-mCherry Control vector expressing 
only mCherry 
Silke Uhrig 
#66 pBS-sds-CMV-GFP CMV-GFP expression vector 
in an AAV context 
Nina 
Schuermann 
#1551 pBS-sds-CMV-
GFPmut3 
Vector to express the GFP 
encoded by PbGFPcon in vitro 
This work 
#1424 #1552-Ren-shRNA1 Based on #1552, encoding for 
a non-targeting shRNA 
This work 
#1873 #1552-U6-GFP-
shRNA1a 
Based on #1552, encoding for 
the GFP-shRNA 1a
This work 
#1875 #1552-U6-GFP-
shRNA2a 
Based on #1552, encoding for 
the GFP-shRNA 2a 
This work 
#1876 #1552-U6-GFP-
shRNA3a 
Based on #1552, encoding for 
the GFP-shRNA 3a 
This work 
#1877 #1552-U6-GFP-
shRNAscr 
Based on #1552, encoding for 
the GFP-shRNAscr 
This work 
#1878 #1552-U6-GFP-
AgoshR1a 
Based on #1552, encoding for 
the GFP-AgoshRNA 1a  
This work 
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#1879 #1552-U6-GFP-
AgoshR2a 
Based on #1552, encoding for 
the GFP-AgoshRNA 2a 
This work 
#1880 #1552-U6-GFP-
AgoshR3a 
Based on #1552, encoding for 
the GFP-AgoshRNA 3a 
This work 
#1881 #1552-U6-GFP-
AgoshR4a 
Based on #1552, encoding for 
the GFP-AgoshRNA 4a 
This work 
#1882 #1552-U6-GFP-
AgoshR1b 
Based on #1552, encoding for 
the GFP-AgoshRNA 1b 
This work 
#1883 #1552-U6-GFP-
AgoshR2b 
Based on #1552, encoding for 
the GFP-AgoshRNA 2b 
This work 
#1884 #1552-U6-GFP-
AgoshR3b 
Based on #1552, encoding for 
the GFP-AgoshRNA 3b 
This work 
#1885 #1552-U6-GFP-
AgoshR4b 
Based on #1552, encoding for 
the GFP-AgoshRNA 4b 
This work 
#1886 #1552-U6-GFP-
AgoshR1c 
Based on #1552, encoding for 
the GFP-AgoshRNA 1c 
This work 
#1887 #1552-U6-GFP-
AgoshR2c 
Based on #1552, encoding for 
the GFP-AgoshRNA 2c 
This work 
#1888 #1552-U6-GFP-
AgoshR3c 
Based on #1552, encoding for 
the GFP-AgoshRNA 3c 
This work 
#1889 #1552-U6-GFP-
AgoshR4c 
Based on #1552, encoding for 
the GFP-AgoshRNA 4c 
This work 
#1890 #1552-U6-GFP-
AgoshRscr 
Based on #1552, encoding for 
the AgoshRNAscr 
This work 
#1891 pBAT-SIL6-mCherry- 
PbU6-GFP-AgoshR1c 
Based on #1870, encoding for 
the GFP-AgoshRNA 1c 
This work 
#1892 pBAT-SIL6-mCherry- 
PbU6-GFP-AgoshR2c 
Based on #1870, encoding for 
the GFP-AgoshRNA 2c 
This work 
#1893 pBAT-SIL6-mCherry- 
PbU6-GFP-AgoshR3c 
Based on #1870, encoding for 
the GFP-AgoshRNA 3c 
This work 
#1894 pBAT-SIL6-mCherry- 
PbU6-GFP-AgoshR4c 
Based on #1870, encoding for 
the GFP-AgoshRNA 4c 
This work 
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#1895 pBAT-SIL6-mCherry-
PbU6-AgoshRscr 
Based on #1870, encoding for 
the AgoshRNAscr 
This work 
#1896 pBAT-SIL6- 
PbU6int(V1)-
AgoshRscr 
Based on #1871, encoding for 
the AgoshRNAscr 
This work 
#1897 pBAT-SIL6- 
PbU6int(V1)-GFP-
AgoshR2c 
Based on #1871, encoding for 
the GFP-AgoshRNA 2c 
This work 
#1898 pBAT-SIL6-mCherry- 
PbU6-PPLP2-
AgoshR1 
Based on #1870, encoding for 
the PPLP2-AgoshRNA 1 
This work 
#1899 pBAT-SIL6-mCherry- 
PbU6- PPLP2-
AgoshR2 
Based on #1870, encoding for 
the  PPLP2-AgoshRNA 2 
This work 
#1900 pBAT-SIL6-mCherry- 
PbU6- PPLP2-
AgoshR3 
Based on #1870, encoding for 
the  PPLP2-AgoshRNA 3 
This work 
#1901 pBAT-SIL6-mCherry- 
PbU6- PPLP2-
AgoshR4 
Based on #1870, encoding for 
the  PPLP2-AgoshRNA 4 
This work 
#1902 pBAT-SIL6-mCherry- 
PbU6-Exp1-AgoshR1 
Based on #1870, encoding for 
the Exp1-AgoshRNA 1 
This work 
#1903 pBAT-SIL6-mCherry- 
PbU6-Exp1-AgoshR2 
Based on #1870, encoding for 
the Exp1-AgoshRNA 2 
This work 
#1904 pBAT-SIL6-mCherry- 
PbU6-Exp1-AgoshR3 
Based on #1870, encoding for 
the Exp1-AgoshRNA 3 
This work 
#1905 pBAT-SIL6- 
PbU6int(V2)-
AgoshRscr 
Based on #1872, encoding for 
the AgoshRNAscr 
This work 
#1906 pBAT-SIL6- 
PbU6int(V2)-MSP1-
AgoshR1 
Based on #1872, encoding for 
the MSP1-AgoshRNA 1 
This work 
#1907 pBAT-SIL6- 
PbU6int(V2)-MSP1-
AgoshR2 
Based on #1872, encoding for 
the MSP1-AgoshRNA 2 
This work 
#1908 pBAT-SIL6- 
PbU6int(V2)-MSP1-
AgoshR3 
Based on #1872, encoding for 
the MSP1-AgoshRNA 3 
This work 
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5.1.7 SOFTWARE 
Software that is either associated with laboratory equipment used in this 
work or has been used to further process data is listed in Table 20. 
TABLE 20: Software 
Name Description Source/Reference 
Flowing Software 2.5 To analyze flow 
cytometric data 
http://www.uskonaskel.fi/ 
flowingsoftware/  
AxioVision 4.8.2 SP3 For taking images at the 
fluorescence microscope 
Carl Zeiss (Oberkochen, 
Germany) 
Serial Cloner 2.6.1 For in silico cloning and 
primer design 
http://serialbasics.free.fr/ 
Serial_Cloner.html 
GraphPad Prism 5 For statistical analysis of 
data and graph design 
GraphPad Software Inc.,  
StepOneTM Software 
v2.3 
For evaluating qRT-PCR 
data 
Applied Biosystems/ 
Thermo Fisher Scientific 
(Waltham, CA, USA) 
Fiji For image analysis  https://fiji.sc/ 
Schindelin et al., 2012341 
Quantity One 1-D 
Analysis 4.6.9 
Gel Doc XR-associated 
software  
Bio-Rad (Hercules, CA, 
USA) 
MXP Cytomics FC500MPL 
analyzer-associated 
software 
Beckman Coulter (Brea, 
MA, USA) 
ChemoStar Imager Software associated with 
the Western blot imaging 
system 
INTAS Science Imaging 
Instruments (Göttingen, 
Germany) 
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5.2  METHODS 
“An experiment is a question which science poses to nature, and a 
measurement is the recording of nature’s answer.”342  
~ Max Planck (1858 – 1947) 
5.2.1 CLONING PROCEDURES 
The following part details the cloning strategy used for each plasmid (listed 
in TABLE 19) and which oligonucleotides were used (listed in TABLE 18). The ID 
number of each plasmid is indicated in brackets behind the name.  
To express GFP in HEK293T or MEF cells, the GFPmut3 encoded by the 
strain PbGFPcon343 was amplified using primers P1 and P2 and cloned in the 
XhoI/NheI-digested vector pBS-sds-CMV-GFP (#66), yielding pBS-sds-CMV-
GFPmut3 (#1551).  
A 
 
 
B 
 
FIGURE 49: Plasmid maps of (A) pBAT-SIL6 and (B) pBAT-SIL6-MCS. Indicated are all 
restriction sites that are used in subsequent cloning steps as well as the PvuI site, which 
is used to linearize the plasmid before transfection into P. berghei. The selection marker, 
comprising the 5’PbDHFR-TS, the hDHFR, the ScFcy1/ScFur1 and the 3’PbDHFR-TS 
regions (depicted in (A)), is in (B) as well as in all subsequent plasmid maps depicted as 
a single feature.  
All vectors designed to express genes in Plasmodium are based on a 
modified version of the previously published vector pBAT-SIL6279 (#1546) 
(Figure 49 A). To reduce vector size and facilitate cloning, I removed the 
mCherry open reading frame by XbaI/BlpI digest and ligation to the annealed 
oligonucleotides P3 und P4. Digestion with BamHI/NdeI removed the GFP open 
reading frame from this vector, allowing the insertion of the annealed 
oligonucleotides P5/P6 downstream of the HSP70 promoter, which introduced 
a cloning site consisting of PacI and AscI. The resulting vector, pBAT-SIL6-MCS 
(#1547), is a versatile vector that can be used to easily express extra copies of 
genes in P. berghei (Figure 49 B).   
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To integrate an Ago2-expression cassette under the control of the HSP70 
promoter (5’HSP70) into P. berghei, I cloned the vector pBAT-SIL6-Ago2 
(#1548) (Figure 50 A). For this, I PCR-amplified a previously published, codon-
optimized version of the human Ago2344 using primers P7/P8, and inserted the 
fragment via standard restriction digest with NdeI/BamHI into pBAT-SIL6-MCS. 
Correct cloning was confirmed by sequencing Ago2 using the primers P19/P20. 
To drive Ago2-expression not by the 5’HSP70, but by the LISP2 promoter 
(5’LISP), Vera Mitesser excised the HSP70 promoter from pBAT-SIL6-Ago2 by 
SpeI/SwaI digestion and inserted a previously published ~1 kB long region 
upstream of the LISP2 gene307 (PbANKA_10_v3:190,309..191,296; amplified 
from genomic DNA with the primers P9/P10) via Gibson Assembly. This 
resulting vector, which sequence was confirmed by sequencing the promoter 
using primer P21, was called pBAT-SIL6-5’LISP2-Ago2 (#1873) (Figure 50 B).  
A 
 
B 
 
FIGURE 50: Plasmid maps of (A) pBAT-SIL6-Ago2 and (B) pBAT-SIL6-5’LISP2-Ago2. 
Indicated is the PvuI site, which is used to linearize the plasmid before transfection into 
P. berghei. 
For expression of AgoshRNAs in Plasmodium, I amplified a ~500 bp long 
region upstream of the PbU6 promoter using the primers P11/P12 and ligated 
it into the XhoI/XmaI-digested vector pBAT-SIL6-MCS. The correct sequence of 
the 5’PbU6 was confirmed by sequencing with primer P22. I then cloned the 
vector pBAT-SIL6-mCherry-PbU6 (#1870) by integrating an mCherry gene 
(amplified with the primers P13/P14) via Gibson assembly into the 
SwaI/BamHI-digested pBAT-SIL6-MCS vector (Figure 51 A). Sequencing with 
P19/P20 verified the correct integration of mCherry.  
The initial vector to integrate AgoshRNAs, pBAT-SIL6-PbU6int(V1) (#1871) 
was cloned by removing the left homology arm of SIL6 and the HSP70 promoter 
from pBAT-SIL6-MCS-PbU6 with NgoMVI/BamHI and inserting the annealed 
oligonucleotides P15/P16 (Figure 51 B). Since this construct design was 
inefficient to integrate AgoshRNAs due to an internal homologous region, I 
further improved the construct by replacing the PbDHFR-TS duplicate with a 
duplicate of the 3’PbDHFS-FPGS region. To this end, I PCR-amplified the 
3’PbDHFS-FPGS with primers P17/18, digested the PCR product with XhoI/BclI 
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and ligated it into the equally digested backbone. Subsequently, I removed the 
first 3’PbDHFS-FPGS via BamHI/SacI digest and ligation of the backbone to the 
annealed oligonucleotides P101/102, resulting in pBAT-SIL6-PbU6int V2 
(#1872) (Figure 51 C).  
A 
 
 
 
B 
 
C 
 
FIGURE 51: Plasmid maps of AgoshRNA expression plasmids. Indicated are all 
restriction sites that are used in subsequent cloning steps as well as the PvuI site, which 
is used to linearize the plasmid before transfection into P. berghei (not applicable for (A), 
which is transfected circular). 
AgoshRNAs were inserted into pBAT-SIL6-mCherry-PbU6 or pBAT-SIL6-
PbU6int V1 and V2 by BbsI-digest and ligation to annealed oligonucleotides, as 
further described in the next Section. The sequence of the AgoshRNA was 
verified in each plasmid by sequencing with P23. 
Design of AgoshRNAs 
“AgoshRNA target sequences were identified using the siRNA wizard 
(http://www.invivogen.com/sirnawizard/design.php), searching for 19 nt 
target sequences that start with an A and end with a T. The antiparallel 
sequence (antisense) of this sequence then precedes a 5 bp long loop sequence 
that can consist either of the target sequence or of CTTCA, followed by the 
110 MATERIALS AND METHODS  
 
sense sequence. To create an initial A-C and terminal G-U mismatch, the first 
and the last nucleotide of the sense sequence was substituted for a G and a C, 
respectively. The reverse oligonucleotide is formed of the reverse complement 
sequence. Initial and terminal overhangs were created to match the respective 
overhangs of the BbsI-digested target vector. For cloning behind the PbU6 
promoter, additional four Ts were added to the AgoshRNA to serve as a 
termination signal.” (Hentzschel et al., 2017, manuscript in preparation).  
 
FIGURE 52: “Design and structure of AgoshRNAs. Depicted is the design of forward and 
reverse oligonucleotide for cloning of AgoshRNAs into a target vector. The sense strand 
equal to the mRNA target sequence is depicted in dark blue, the complementary 
antisense strand in light blue. The first and last nucleotide of the sense strand is 
swapped for a G and a C, respectively, to facilitate recognition and processing by Ago2. 
(A) Overhangs for cloning behind the PbU6 promoter in pBAT-SIL6-PbU6 or pBAT-SIL6-
mCherry-PbU6. (B) Overhangs for cloning behind the MmU6 promoter of pBS-sds-CMV-
mCherry-U6. (C) The secondary structure of the transcribed AgoshRNA.” (Hentzschel 
et al., 2017, manuscript in preparation)  
The design of the AgoshRNA is depicted in Figure 52. Sequences of all 
AgoshRNA-target sequences are listed in Table 21, which also includes the ID of 
the oligonucleotides that were designed for that particular RNA. The sequence 
of the oligonucleotides can be found in TABLE 18. “For in vitro screens, 
AgoshRNAs were cloned as annealed oligonucleotides into the BbsI-digested 
pBS-sds-CMV-mCherry-U6 kindly provided by Kathleen Boerner (University 
Hospital Heidelberg, Centre for Infectious Diseases, Virology). For expression in 
Plasmodium, AgoshRNAs were cloned in the BbsI-digested pBAT-SIL6-mCherry-
PbU6 or pBAT-SIL6-PbU6int vector.” (Hentzschel et al., 2017, manuscript in 
preparation).  
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TABLE 21: Sequence of all AgoshRNAs 
AgoshRNA Sequence (5’  3’) 
Oligo-
nucleotides 
Plasmid 
AgoshRscr GTTATGGACACGAGAGTCC P56/P57 
P66/P67 
#1889 
#1894 
#1895 
#1905 
GFP-AgoshR1a GACGGGAACTACAAGACAC P24/P25 #1878 
GFP-AgoshR2a GAATGGAATCAAAGTTAAC P26/P27 #1879 
GFP-AgoshR3a GAAGATGGAAGCGTTCAAC P28/P29 #1880 
GFP-AgoshR4a AGGGTGAAGGTGATGCAAC P30/P31 #1881 
GFP-AgoshR1b AGGGTGAAGGTGATGCAAC P40/P41 #1882 
GFP-AgoshR2b ATGGAAGCGTTCAACTAGC P42/P43 #1883 
GFP-AgoshR3b AGTTGTCCCAATTCTTGTT P44/P45 #1884 
GFP-AgoshR4b ACATGGTCCTTCTTGAGTT P46/P47 #1885 
GFP-AgoshR1c AGGGTGAAGGTGATGCAAC P48/P49 
P58/P59 
#1886 
#1891 
GFP-AgoshR2c ATGGAAGCGTTCAACTAGC P50/P51 
P60/P61 
#1887 
#1892 
#1897 
GFP-AgoshR3c AGTTGTCCCAATTCTTGTT P52/P53 
P62/P63 
#1888 
#1893 
GFP-AgoshR4c ACATGGTCCTTCTTGAGTT P54/P55 
P64/P65 
#1889 
#1894 
PPLP2-AgoshR1 AAGGAATGCGCTACTAGAT P68/P69 #1898 
PPLP2-AgoshR2 AGGTAAGTACTCCTTCTAT P70/P71 #1899 
PPLP2-AgoshR3 AATGATGGATACCTAGATT P72/P73 #1900 
PPLP2-AgoshR4 AACACTCCCTTGGAATAGT P74/P75 #1901 
Exp1-AgoshR1 ACCAGCAGAACCAGTAATT P76/P77 #1902 
Exp1-AgoshR2 AGAAGCTATGCTCAAAGAT P78/P79 #1903 
Exp1-AgoshR3 ATGCCAAATCTTCAACAAT P80/P81 #1904 
MSP1-AgoshR1 AGCCATTATTGCAACAAAT P88/P89 #1909 
MSP1-AgoshR2 ACAAGCCTCATCACAATCT P90/P91 #1910 
MSP1-AgoshR3 GGGTCAATCAGAAGAATAT P92/P93 #1911 
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5.2.2 MICROBIOLOGY 
Production and transformation of chemo-competent E. coli 
One milliliter of an overnight culture of DH5 E. coli was used to inoculate 
200 ml SOB medium and bacteria were grown at 37 °C, 180 rpm. When they 
reached an optical density of 0.5 at 600 nm, bacteria were cooled down on ice 
to 4 °C and pelleted for 15 min at 1800x g, 4 °C. Subsequent steps were all 
performed at 4 °C. The pellet was resuspended in 40 ml TFB I and incubated for 
10 min on ice before a second centrifugation for 12 min at 1800x g and 4 °C. 
The pelleted cells were then resuspended in another 10 ml TFB II buffer and 
again incubated for 10 min on ice. Cells were then aliquoted à 50 µl, shock-
frozen in liquid N2 and stored at -80 °C.  
For transformation, 50 µl freshly thawed chemo-competent E. coli were 
mixed with 5-10 µl ligation reaction and incubated for 30 min on ice before 
exposing them to a heat shock for 45 s at 42 °C. After another 2 min on ice, cells 
were plated on LB-amp plates and incubated overnight at 37 °C.  
Production and transformation of electrocompetent E. coli 
For the preparation of electrocompetent E. coli, 30 ml LB medium were 
inoculated with Mega X DH10B bacteria and cultured overnight at 37 °C. Four 
cultures of 400 ml LB media were inoculated with 5 ml pre-culture and 
incubated at 37 °C until the culture reached an optical density of 0.5-0.55 at 
600 nm. Bacteria were then incubated on ice for 15 to 20 min before 
centrifugation for 15 min at 4 °C, 4424x g. The pellet was resuspended in a total 
volume of 60 ml ice-cold ddH2O, and bacteria were transferred to four pre-
cooked dialysis tubings (Typ 20/32 inch, wall thickness 0.02 mm) and dialyzed 
overnight against 8 l H2O at 4 °C. Subsequently, bacteria were pelleted again for 
15 min at 4 °C, 4424x g, and resuspended in sufficient 10 % glycerin to reach a 
final optical density of 1 at 600 nm.  Cells were aliquoted, shock frozen in liquid 
N2 and stored at -80 °C until electroporation.  
For transformation, 2 µl of ligation mix were added to 30 µl electro-
competent bacteria that were freshly thawed on ice. The mix was transferred to 
a 1 mm cuvette and electroporated in a Gene Pulser Xcell® electroporation 
system machine using the following settings: 1800 V, 25 µF and 200 W. After 
electroporation, bacteria were resuspended in 1 ml SOC medium and recovered 
for 1 h at 37 °C, shaking. Cells were pelleted by 2.5 min centrifugation at 
2300x g; the pellet was resuspended in 100 µl SOC and then plated on LB-amp 
plates.  
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5.2.3 MOLECULAR BIOLOGY  
Plasmid DNA preparations 
Depending on the amount of plasmid needed, DNA was prepared in small, 
medium or large scale. For small-scale DNA preparation, 3 ml of ampicillin-
containing LB-medium (50 µg/ml final concentration) were inoculated with 
E. coli carrying the desired plasmid and incubated at 37 °C for 8 h at 220 rpm or 
overnight at 180 rpm. Part of the culture (2 ml) was pelleted for 2.5 min at full 
speed, and the pellet was resuspended in 300 µl P1 resuspension buffer. Cells 
were lysed by addition of 300 µl P2 lysis buffer and incubation for 3 min at 
room temperature. Lysis was stopped by addition of 300 µl P3 neutralization 
buffer prior to centrifugation for 10 min at full speed. The supernatant (800 µl) 
was added to 600 µl isopropanol and then spun for 15 min at full speed. The 
DNA pellet was washed once with 70 % ethanol (5 min at full speed) and then 
air-dried before resuspension in 30 – 50 µl DNA.  
For medium or large scale plasmid preparations, 40 – 80 ml or 200 ml LB-
Amp medium, respectively, were inoculated with a single colony or 50 – 200 µl 
liquid culture of E. coli and incubated overnight at 37 °C and 180 rpm. Medium 
plasmid preparations were performed using the PureYieldTM Plasmid Midiprep 
Kit (Promega) according to manufacturer’s instruction. DNA was eluted in 
500 – 800 µl ddH2O. Large-scale plasmid preparations were performed using 
the NucleoBond® Xtra Maxi kit (Machery-Nagel) according to manufacturer’s 
instruction, and the DNA pellet was resuspended in 1 – 2 ml ddH2O. DNA 
concentrations were determined spectro-photometrically. 
Polymerase chain reaction (PCR) 
DNA fragments for cloning or diagnostic purposes were amplified via PCR. 
For all cloning reactions, PCRs were performed in 50 µl reactions using the 
Phusion Hot Start (HS) II polymerase (Thermo Fisher Scientific) according to 
manufacturer’s instructions using approximately 10-100 ng template DNA. 
Final concentrations for each reaction were 1x HF buffer, 200 µM dNTPs, 1 µM 
forward and reverse primer, 3 % DMSO and 1 U Phusion polymerase. If no 
specific amplification was observed, the HF buffer was substituted by the GC 
buffer. Diagnostic PCRs were performed in 10 µl reactions with 0.5 to 2 µl gDNA 
as a template, using either the Phusion HS II polymerase as described above, 
but with GC buffer instead of HF buffer, or the OneTaq® 2x master mix (NEB). 
For the latter, the gDNA template was added to 1x master mix supplemented 
with 10 µM forward and reverse primer. A list of primer combinations used for 
diagnostic PCR and the polymerase used for each reaction can be found in Table 
22. Subsequently, DNA was amplified using the cycling conditions listed in 
Table 23. 
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TABLE 22: Primers and polymerases for diagnostic PCR   
Diagnostic PCR Primer combination Polymerase 
Wild type locus P95/P96 Taq 
5’ Integration P96/P97 or P21* Taq 
3’ Integration P94/P95 Phusion HS II 
Negative Selection P98/P95 Phusion HS II 
TABLE 23: Cycling conditions of PCRs   
Polymerase Phusion HS II Taq 
Application Non-Plasmodium Plasmodium Diagnostic PCR 
 T  time T  time T  time 
Initial denaturation 98 °C 10 min 98 °C 10 min 95 °C 2 min 
 Denaturation    98 °C 10 s 98 °C 10 s 95 °C 15 s 
35 x Annealing 60 °C 10 s 55 °C 10 s 55 °C 15 s 
 Extension 72 °C 15 s/kb 68 °C 30 s/kb 60 °C 45 s/kb 
Final extension 72 °C 10 min 68 °C 10 min 60 °C 10 min 
Enzymatic digests of DNA 
Restriction enzymes and corresponding buffers, except BbsI (Fermentas), 
were purchased from NEB. For preparative digests, 3-10 µg plasmid DNA or 
30 µl of purified PCR product and for analytical digests, 0.5-1 µg plasmid DNA 
were digested with 2-10 U restriction enzymes in buffers recommended by the 
manufacturer. Reactions were usually incubated for 2-4 h or overnight at 37 °C 
unless the enzyme required a different reaction temperature.  
DNA agarose gel electrophoresis 
DNA fragments were separated on agarose gels consisting of 1 % agarose 
(w/v) in TAE buffer and approximately 1 µl/ml ethidium bromide. DNA was 
mixed with 6x loading dye and loaded next to a standard marker for size 
determination. Electrophoresis was performed in TAE buffer at 80 – 150 V for 
approximately 20 to 30 min, depending on the separation required. DNA 
fragments in the gel were visualized by UV illumination. If necessary, DNA 
fragments were excised and purified using the QIAquick gel extraction kit 
(QIAGEN) according to manufacturer’s instruction and eluted in 30 to 50 µl 
ddH2O.  
DNA clean-up 
If the purification of DNA did not require a separation of differently sized 
fragments, e. g. in the case of linearized plasmids, or if DNA needed to be 
further concentrated in a smaller volume, the DNA sample was purified and 
concentrated over a column. For this, the DNA Clean& Concentrator-5 kit 
(Zymo Research) was used according to manufacturer’s instructions.  
For the integration of 
AgoshRNAs, the “negative 
selection” PCR served as 
diagnostic PCR for the 
parental locus 
PbAgo2 was genotyped 
with P97, PbLISP2Ago2 was 
genotyped with P21 
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Oligonucleotide annealing 
For cloning inserts shorter than 100 nt in length, such as sh- or AgoshRNAs, 
complementary forward and reverse oligonucleotides were designed in such a 
way that the overhangs of the annealed dsDNA match the overhangs of the 
digested backbone. An annealing reaction consisted of forward and reverse 
oligonucleotide (5 µM final concentration) and 1x NEB buffer 2 in 50 µl ddH2O. 
The reaction was heated to 95 °C for 5 min and then slowly cooled down to 
room temperature over the course of 2-3 h. Annealed oligonucleotides were 
diluted 1:200 in ddH2O before ligation (see below).  
Gibson Assembly  
Large vectors were preferably assembled by Gibson assembly345. Inserts for 
the vectors were PCR-amplified (see p. 113) using primers that create a 
homology arm of about 20 to 40 nucleotides to the neighboring gene. The PCR 
products were gel-purified (see p. 114), followed by a digest with 1 µl DpnI to 
remove remaining plasmid (30-60 min at 37 °C). The backbone was digested as 
required for the cloning strategy and also gel-purified. To improve purity and 
concentration, PCR fragments and backbone were additionally column-purified 
(see p. 114) and eluted in 10-15 µl H2O before assembly. Vector and insert were 
mixed in a 1:3 molar ratio, in a total volume of 5 µl, before addition of 5 µl 
Gibson Assembly Master Mix (NEB). The reaction was incubated for 1-2 h at 
40 °C. Subsequently, 1 µl of a 1:3 dilution was electroporated into E. coli as 
described on p. 112. 
Ligation of DNA fragments 
DNA fragments were ligated using the T4 DNA ligase. A reaction consisted 
typically of 100 – 300 ng total DNA in a molar ratio of 1:3 to 1:5 (backbone to 
insert), or of 100 ng digested plasmid and 1 µl of annealed oligonucleotides. 
Ligations were performed in 10 µl total volume containing 1 µl ligase and 1x 
supplied ligase buffer and incubated for either 0.5 to 2 h at room temperature 
or overnight at 16 °C. Subsequently, 1 µl (electroporation) or 5 – 10 µl (heat 
shock transformation) were used to transform E. coli (see also pp. 112, 112). 
Ethanol precipitation 
To increase the quality of DNA preparations or for transfections, DNA was 
purified by ethanol precipitation. To this end, NaAc (pH 5.3) was added to the 
DNA to a final concentration of 300 mM, and then DNA was precipitated by 
addition of 2.5 volumes 100 % ethanol. The DNA was incubated for 1 h at -80 °C 
or overnight at -20 °C and then pelleted by centrifugation for 15 min at 4 °C, full 
speed. The DNA pellet was washed with 500 µl 70 % ethanol (5 min at 4 °C, full 
speed). The DNA was then resuspended in varying amounts of ddH2O, 
depending on the further application.  
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Preparation of genomic DNA  
For diagnostic PCR, genomic DNA was isolated from mixed blood stage 
parasites using the Qiagen DNA Blood & Tissue kit according to manufacturer’s 
instructions. DNA was eluted in 75 µl AE buffer supplied with the kit.  
RNA extraction 
HEK293T cells (seeded in 24-well format) or parasite samples were 
resuspended in 700 µl Qiazol. After addition of 140 µl chloroform, phases were 
separated by 15 min centrifugation at 4 °C, full speed. The upper, clear phase 
was transferred to a new tube, and 1.5 volumes ethanol were added. RNA was 
purified using the miRNeasy kit (QIAGEN) according to manufacturer’s 
instructions. The protocol included an on-column DNase digest to remove 
remnants of DNA. RNA was eluted in 30 – 100 µl of nuclease-free ddH2O.  
cDNA synthesis 
cDNA was synthesized from RNA using the Tetro cDNA synthesis kit 
(Bioline) as described in the supplied protocol but in a final volume of 10 µl. 
One reaction consisted of 6 µl RNA, 2 µl buffer, 0.5 µl random primer, 0.5 µl 
dNTPs, 0.5 µl RNase inhibitor and 0.5 µl reverse transcriptase. Within one 
experiment, equal RNA amounts of all samples were used, ranging from 100 ng 
to 2.4 µg RNA per reaction depending on the concentration of RNA available. If 
possible, cDNAs were prepared in parallel. A single –RT sample was prepared 
per experiment without RNase inhibitor and reverse transcriptase as a negative 
control, comprising equal amounts of all RNA samples. Reactions were 
incubated for 5 min at 25 °C, followed by 45 min at 42 °C and 5 min at 85 °C. 
cDNA was diluted 1:5 to 1:100 before quantitative reverse-transcription PCR 
(qRT-PCR), depending on the target assessed.  
Quantitative reverse-transcription PCR (qRT-PCR) 
Quantitative RT-PCR was performed on a StepOnePlus Real-Time PCR 
System (Applied Biosystems) using the Power SYBR® Green PCR Master Mix 
(Applied Biosystems). A single reaction consisted of 1.25 µl cDNA, 6.25 µl RT-
Mix, 1.25 µl primer (10 µM of each forward and reverse primer) and 3.75 µl 
H2O. All primer sequences for qRT-PCR are listed in TABLE 18 (P93 – P100). The 
PCR cycles for mammalian and for Plasmodium cycles are listed in Table 24. All 
reactions were followed by a standard melting curve to assess the formation of 
any by-products or primer dimers. The CT values were determined by using the 
auto threshold feature of the software StepOneTM Software v2.3.  
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TABLE 24: qRT-PCR cycling conditions 
Target Non-Plasmodium Plasmodium 
 T  time T  time 
Initial denaturation 95 °C 10 min 95 °C 10 min 
 Denaturation    95 °C 15 s 95 °C 15 s 
40 x Annealing 60 °C 15 s 55 °C 15 s 
 Extension 72 °C 15 s 72 °C 15 s 
The relative mRNA expression was calculated using the Pfaffl method, 
which adjusts for the different primer efficiencies346. The efficiency of the 
primer pairs was determined using a serial dilution of cDNA and plotting the CT 
value against the log(DNA dilution). From the slope m of the linear regression 
of this plot, the efficiency E is calculated as follows:  
𝐸 = 10−
1
𝑚 
The mRNA expression of a GOI in a sample was calculated relative to its 
expression in an untreated control. First, the expression of both GOI and 
reference gene (ref) in the sample were normalized to their respective 
expression in an untreated control by calculating the CT. 
∆𝐶𝑇(𝐺𝑂𝐼) = 𝐶𝑇(𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝐶𝑇(𝑠𝑎𝑚𝑝𝑙𝑒) 
 
Then, the expression of the GOI was normalized to the expression of the 
reference gene (ref), thereby adjusting for RNA input.  
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑚𝑅𝑁𝐴 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =
(𝐸𝐺𝑂𝐼)
∆𝐶𝑇(𝐺𝑂𝐼)
(𝐸𝑟𝑒𝑓)∆𝐶𝑇(𝑟𝑒𝑓)
 
 
5.2.4 PROTEIN BIOCHEMISTRY 
Preparation and quantification of protein samples 
Schizont-enriched parasite protein samples (see p. 122) were incubated for 
1 h on ice and vortexed every ten minutes. Parasite debris was removed by 
2 min centrifugation at 4 °C and full speed. The protein concentration in the 
supernatant was measured using the Qbit® protein assay kit (Thermo Fisher 
Scientific) as described in the supplied protocol.  
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting 
Protein samples were denatured by adding required amounts of 2x or 6x 
SDS sample buffer and 5 min incubation at 95 °C.  For the analysis of small 
proteins, e. g. GFP, 10 % SDS-gels, for the analysis of larger proteins, such as 
Ago2, 6 % SDS-gels were used for SDS-PAGE. The composition of these gels is 
found in Table 25. If the protein concentration of the sample was quantified 
before, 100 µg protein, else 15 µl sample were loaded on each lane. As a 
marker, 3 µl PageRulerTM Plus prestained protein ladder were loaded next to 
the samples. Gels were run in 1x TGS at 90 – 120 V for approximately 2 h until 
the loading dye ran out.  
TABLE 25: Composition of SDS-PAGE gels 
Components Stacking gel 
Resolving gel 
6% 
Resolving gel 
10% 
H20 1.46 ml 2.9 ml 2.4 ml 
40% acryl-bisacrylamide 0.25 ml 0.75 ml 1.25 ml 
0.5M Tris (pH 6.8) 0.25 ml - - 
1.5M Tris (pH 8.8) - 1.25 ml 1.25 ml 
10% SDS 20 µl 50 µl 50 µl 
10% APS 20 µl 50 µl 50 µl 
TEMED 2 µl 4 µl 2 µl 
For semi-dry blotting, a stack consisting of four filter papers, a 
nitrocellulose membrane, the gel and another four filter papers was soaked in 
transfer buffer and placed in the electrophoretic transfer cell. The proteins 
were transferred onto the membrane by applying 150 mA for 1 h at 4 °C. 
Successful blotting was assessed by staining the membrane for 3 min in 
Ponceau S solution.  
TABLE 26: Dilutions and incubation settings for WB antibodies 
Antibody Dilution Incubation time 
mouse-anti-GFP 1:300  2 h at RT 
rat-anti-Ago2  1:300 Overnight at 4 °C 
mouse-anti-HSP70 1:300 2 h at RT or overnight at 4 °C 
mouse-anti-EXP1 1:1000 Overnight at 4 °C 
HRP-anti-mouse 
HRP-anti-rat 
1:10,000 1 h at RT 
The membrane was washed with 1xTBS-T until the staining disappeared 
and blocked in 5 % milk/TBS-T (w/v) (blocking buffer) for 1 – 3 h at room 
temperature, shaking. Blots were then incubated with primary antibody diluted 
in blocking buffer, washed three times for 5 min in 1xTBS-T and incubated with 
secondary, HRP-conjugated antibody also diluted in blocking buffer. Dilutions 
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and incubation conditions of the individual antibodies can be found in Table 26. 
After another three times washing in 1x TBS-T, bands were revealed with ECL 
solutions by adding about 1 ml of a 1:1 mixture of the reagents on the blot and 
incubation for 3 min at room temperature. Blots were developed either at the 
ECL imager with the camera (ChemoCam, INTAS) or using a film developing 
machine (X-OMAT 2000 processor, KODAK).   
5.2.5 CELL BIOLOGY  
Standard maintenance of cell lines 
Cell lines (HEK293T, Huh7, wt MEF, and Dicer-/- MEF) were cultured under 
standard conditions at 37 °C, 5 % CO2, in DMEM complete. Huh7 cells were 
additionally supplemented with 1 % MEM-non-essential amino acids. Cells 
were split two- to three times a week, depending on growth and viability. For 
this, cells were washed once with PBS, detached by incubating for 3 min at 
37 °C with 0.025 % trypsin (1 ml for a T175 flask) and resuspended in 10 ml 
pre-warmed DMEM complete. Between 1/5 and 1/20 of the final volume was 
used to inoculate a new flask. In order to seed a defined amount, cells were 
quantified by mixing 10 µl of cell suspension with 10 µl of trypan blue and 
counting in an automated cell counter. TABLE 27 lists the amount of cells seeded 
per well for different cell types and different formats.  
Table 27: Seeding density of different cell types 
Format 
Volume of 
medium 
Cells per well 
         
HEK293T 
WT or    
Dicer-/- MEF 
                
Huh7 
96-well 100 µl 3.3*104 1*104 - 
24-well  0.5 ml 1.4*105 - - 
6-well 2 ml 5*105 - - 
8-well LabTek  0.25 ml - - 4*104 
Transfection with lipofectamine 2000 
For flow cytometric analysis, HEK293T cells were seeded in 96-well format 
one day before lipofectamine 2000-mediated transfection. For this, 200 ng total 
DNA (equal parts of co-transfected plasmids) were mixed with 25 µl DMEM 
without supplements. In parallel, a Lipofectamine mix consisting of 0.5 µl 
Lipofectamine in 25 µl DMEM was prepared and incubated for 5 min at room 
temperature. The DNA- and Lipofectamine mix were combined and incubated 
for 30 min at RT before adding the total 50 µl to the cells. For qRT-PCR, 
transfections were performed in a 24-well format, using the same protocol, but 
500 ng DNA and 1 µl Lipofectamine. Cells were usually analyzed two days post 
transfection.  
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Flow cytometry 
In preparation for flow cytometry analysis, cells seeded in a 96-well format 
were washed once with PBS, then detached with 30 µl 0.025 % Trypsin/EDTA 
per well and 7 min incubation at 37°C. Cells were resuspended thoroughly after 
addition of 170 µl 1 % BSA/PBS per well. Flow-cytometric analysis was 
performed on a Cytomics FC500MPL analyzer (Beckman Coulter), gating for 
living cells (Forward scatter (FSC)high/Side scatter (SSC)high population) and 
using non-transduced or non-transfected cells as a negative control to set up 
the flow cytometer. The mCherry- and the GFP-signal were compensated using 
single-transfected/transduced cells. The mCherry-positive events were gated, 
and median GFP fluorescence of this population was calculated using the 
software Flowing Software. 
5.2.6 VIROLOGY  
Crude lysate production of AAV vectors 
To produce crude lysates of AAVs, HEK293T cells were seeded in a 6-well 
format (5*105 cells per well) and transfected one day later using 
polyethyleneimine (PEI)-based transfection. Per well, 2.6 µg DNA consisting of 
equal parts of Adeno-helper plasmid347, a plasmid encoding the capsid AAV-
DJ277 and the AAV-genome were mixed with 49 µl H2O and 49 µl NaCl 
(300 mM). A separate mix consisted of 22 µl PEI solution, 49 µl NaCl (300 mM), 
and 27 µl H2O. The DNA- and the PEI-mix were mixed, vortexed and incubated 
for 10 min at room temperature, before adding the mixture dropwise to the 
cells. Cells were incubated for three days at 37 °C and 5% CO2.  
Crude lysates were harvested by removing media from the cells and 
washing the wells once with 500 µl PBS. Cells were resuspended in 1 ml PBS 
and pelleted by 10 min centrifugation at 1500x g. The pellet was resuspended 
in 500 µl PBS and cells were lysed through five freeze-thaw cycles (alternating 
2 min in liquid N2 and 5 min in a 37 °C-water bath). Cells were sonicated for 
1 min, and cell debris was removed by pelleting for 10 min at full speed. The 
supernatant containing the AAV was then transferred to a fresh tube and stored 
at -80 °C until transduction.  
Transduction of cells 
Wild type (wt) MEF cells and Dicer-/- MEF cells were seeded in a 96-well 
format (1*105 cells/well) one day prior to transduction. Cells were transduced 
by adding 5 µl crude lysate supernatant (see above) of each AAV. Cells were 
analyzed four days after transduction by flow cytometry.  
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5.2.7 PARASITOLOGY 
Maintenance of mice 
“All animal experiments were performed according to European 
regulations concerning FELASA category B and GV-SOLAS standard guidelines. 
Animal experiments were approved by German authorities 
(Regierungspräsidium Karlsruhe, Germany), § 8 Abs. 1 Tierschutzgesetz 
(TierSchG) under the license G-260/12 and were performed according to 
National and European regulations.” (Hentzschel et al., 2017, manuscript in 
preparation) Female inbred C57BL/6J or outbred NMRI mice were purchased 
from Janvier at the age of 6 to 8 weeks. Mice were kept under specified 
pathogen-free (SPF) conditions at a constant room temperature of 22 °C, 50 -
 60 % humidity, and a 12/12 h light/dark cycle within the animal facility of the 
Heidelberg University (Interfakultäre Biodedizinische Forschungseinrichtung). 
Animals were fed with standard dry pellet food.   
Maintenance of P. berghei blood stages 
Mice were inoculated with P. berghei by either i.p. injection of 
cryopreserved parasites (see below) or i.v. or i.p. administration of parasite-
infected blood, depending on the parasitemia of the donor blood and the 
parasite growth required. Parasitemia of the infected mice was monitored as 
described below. Blood containing parasites was collected either from the tail 
vein or by bleeding anesthetized mice through puncture of the inferior vena 
cava, depending on the amount of blood needed, using heparinized syringes.   
Determination of parasitemia 
Parasites in the blood of infected mice were detected by smearing a drop of 
tail blood onto a glass slide, fixing it for approximately 5 s in methanol and 
staining the dried slide in 10 % Giemsa/H2O.  Slides were microscopically 
examined, using the 100x objective with immersion oil. For a rough estimation 
of the parasitemia, the number of infected erythrocytes (#iRBCs) was counted 
in 10 to 20 fields of view (FOV). For a precise determination of parasitemia, e. g. 
for assessment of parasite growth or limited dilutions, sufficient FOV were 
examined to observe at least 30 parasites (at most 50 FOV). In all cases, the 
number of erythrocytes (#RBCs) was determined in every tenth FOV. The 
parasitemia is thus calculated as follows:  
𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑚𝑖𝑎 (𝑖𝑛 %) =
#𝑖𝑅𝐵𝐶𝑠
#𝑅𝐵𝐶𝑠 ∗ 10
∗ 100% 
Cryopreservation of P. berghei 
For long-term storage of parasites, 100 µl of freshly isolated blood with at 
least 1 % parasitemia was mixed with 200 µl freezing solution and immediately 
stored in liquid N2.  
122 MATERIALS AND METHODS  
 
Purification of blood-stage parasites 
If purified blood-stage parasites were needed, e. g. for genotyping, 
leucocytes were removed from freshly isolated parasite-infected blood by size-
exclusion over self-made cellulose columns. To prepare the columns, the 
plunger was removed from a 5 ml syringe, and the syringe was filled with a 
small amount of cotton (~ 3 mm), about 4 cm of CF-11 cellulose powder and on 
top ~ 0.5 cm glass beads. Columns were equibrilated with 5 ml PBS before 
loading the blood. Leucocyte-depleted blood was eluted in 15 ml PBS, pelleted 
by 8 min centrifugation at 400x g and erythrocytes were lysed in 0.2 % 
Saponin/PBS (w/v). Parasites were pelleted by a second centrifugation (8 min, 
1400x g) and washed once more with 1 ml PBS. Parasites were resuspended in 
200 µl PBS for gDNA isolation or in 30 – 50 µl RIPA buffer for Western blotting.  
Preparation of gametocyte-enriched parasites 
In order to increase gametocytaemia in infected mice, NMRI mice were 
pretreated with phenylhydrazine (2 µg in 200 µl PBS, i.p.) to stimulate 
reticulocytosis294. Two days later, mice were i.v. infected with 2*106 iRBC. 
Exflagellation assays as well as collecting blood for RNA extraction was 
performed four days later. Gametocyte-enriched parasites were purified from 
whole blood as described above and resuspended in 700 µl Qiazol for 
subsequent RNA extraction.  
Preparation of schizont-enriched parasites 
Schizont-enriched parasite samples were prepared as described 
previously303. In brief, Plasmodium-infected mice were bled via the inferior 
vena cava using a heparinized needle. Blood cells were washed once with 10 ml 
pre-warmed transfection medium by centrifugation for 8 min, 400x g. The 
pellet was resuspended in 15 ml pre-warmed transfection medium, transferred 
to a 25 cm2 cell-culture flask and parasites were cultured for 16 to 18 h at 37 °C 
and 5 % CO2, 5% O2. The next day, the culture was examined for the presence of 
schizonts via Giemsa-stained smear. If positive, parasites were transferred to a 
tube, underlaid with 12 ml of 55 % Nycodenz/PBS (v/v), and separated from 
uninfected red blood cells via centrifugation for 25 min at 180x g, without 
brake. Infected RBCs were collected from the intermediate phase forming at the 
top of the Nycodenz layer using a Pasteur pipette and washed in a total volume 
of 35 ml transfection medium (8 min, 400x g). The pellet containing schizont-
enriched parasites and leukocytes was then resuspended depending on the 
purpose: In 30-60 µl RIPA buffer for protein extraction or in 1 ml transfection 
medium for transfection (for the latter, the schizont pellet was divided up 
according to the number of transfections required).  
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Transfection of P. berghei 
P. berghei parasites were transfected following a previously published 
protocol303. Per transfection, 10 µg linearized or circular DNA (for stable 
integration or episomal expression, respectively) was ethanol-precipitated as 
described on p. 115 and resuspended in 10 µl PBS. The DNA was then mixed 
with 100 µl Nucleofector solution and stored on ice until transfection. Schizont-
enriched samples (prepared as described above) were resuspended in 1 ml 
transfection medium per transfection, split to individual tubes (1 tube per 
transfection) and pelleted for 20 sec at full speed. The schizont pellet was 
resuspended in the DNA-Nucleofector Mix and transferred to an 
electroporation cuvette. The sample was electroporated on an Amaxa gene 
pulser, with the program U033. After addition of 50 µl transfection medium, the 
transfected schizonts were i.v. injected into one NMRI mouse. One day after 
transfection, the drinking water of mice was supplemented with 7 mg/L 
pyrimethamine, pH 3-5. Giemsa-stained blood smears of the mice were 
monitored every second day starting day 7 post-transfection for the 
appearance of parasites. When parasitemia reached over 1-2 %, mice were 
bled, and parasites were genotyped.  
Generation of clonal transgenic P. berghei lines by limiting dilution 
If genotyping revealed the correct integration of a construct in a 
subpopulation of the transfected parasites, single clones of these transgenic 
parasites were obtained by limiting dilution. For this, the blood of a donor 
mouse (with a parasitemia between 0.1 and 1 %) was diluted in RPMI medium 
in a serial dilution comprising six 1:10 dilutions (resulting in a final 1:106 
dilution). Assuming an RBC density in the undiluted blood of 7 *106 RBCs/µl, 
the concentration of iRBCs in the final 1:106 dilution can be calculated from the 
parasitemia P%. The volume that statistically contains a single iRBC is then 
determined as follows:  
𝑉(1 𝑖𝑅𝐵𝐶) =
1
7 ∗ 106
𝑅𝐵𝐶
µ𝑙 ∗ 10
−6 ∗
𝑃%
100
=
1 µ𝑙
7 ∗
𝑃%
100
  
Four to twenty mice were i.v. injected with statistically one iRBC in a final 
volume of 100 µl. Approximately half of the mice became parasite-positive 
around 7 days post-injection, and parasites were genotyped.  
Recycling of the selection marker in transgenic parasites 
If required, the resistance marker was subsequently recycled from a single 
clone by administering 5-FC (1 µg/ml) to the drinking water of mice infected 
with a parasitemia of 1 %348.  Parasitemia then dropped below the detection 
limit and resurged about 5 to 7 days later. Upon reaching a parasitemia over 
1 %, mice were bled, and parasites were genotyped. A single parasite clone that 
recycled the resistance marker was obtained by another limiting dilution. 
 
 
 
 
 
 
 
The number of mice 
injected for the limiting 
dilution depended on the 
abundance of the 
transgenic parasites in as 
estimated from the 
genotyping.  
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Visualization and quantification of exflagellation 
“To increase gametocytaemia, mice were pretreated with phenylhydrazine 
(2 µg per mouse in 200 µl PBS, intraperitoneally (i.p.) injected)294. Two days 
later, mice were infected i.p. with AgoshRNA-transfected PbAgo2. Four to five 
days after Plasmodium infection, a drop of blood was collected from tail veins, 
mixed with 2 µl of xanthurenic acid (50 µM), covered with a coverslip and 
incubated for 12 min at room temperature. Exflagellations were observed 
under a 40x microscope and scored for 2.5 min according to the presence of 
free flagella (normal) or one or two thick superflagella (abnormal). This 
procedure was repeated until at least 100 exflagellations per PbAgo2 + 
AgoshRNA line could be observed. To quantify exflagellation rates, PHZ-
pretreated mice were infected intravenously with 2x106 iRBC, and at least three 
exflagellation assays per mouse were performed 4 days post infection. Fields of 
view were counted additionally to determine exflagellation per field of view. 
Exflagellation rates were always normalized to the exflagellation rate of 
PbAgo2 + AgoshRscr determined in parallel.” (Hentzschel et al., 2017, 
manuscript in preparation).  
Breeding of Anopheles stephensi mosquitoes 
Anopheles stephensi mosquitoes were reared at 28°C and 80% humidity 
under a 14 h/10 h light/dark cycle and fed on 10% sucrose/PABA solution. 
Adult mosquitoes were fed on parasite-infected mice as described below and 
maintained at 21°C and 80% humidity 
Transmission of P. berghei to mosquitoes and back  
Prior to the characterization of a new P. berghei line, parasites were first 
passaged once through the mosquito to avoid that long blood-stage passage 
selects for parasites that are unable to transmit. To infect mosquitoes with 
P. berghei, two NRMI mice were intravenously injected with 1*106 iRBC. Four 
days later, mice were anesthetized by i.p, injection of 80 – 120 µl 
Ketamine/Xylazine (K/X) and mosquitoes were allowed to feed on the mice for 
15 to 20 min. The feeding was repeated on the next day. From day 17 post-
feeding, P. berghei sporozoites are found in salivary glands of mosquitoes, and 
the parasites can be transmitted back to the mammalian host. To infect mice via 
the natural route (“bite-back infection”), C57BL/6J mice were anesthetized by 
i.p. injection of 80 µl K/X per mouse, and placed on top of a P. berghei-infected 
mosquito cage. The mosquitoes were allowed to feed on the mice for about 
10 to 15 min. Mice were monitored for the appearance of parasites by Giemsa-
stained blood smears and usually bled 5 to 6 days post-infection to collect 
parasites and prepare cryostabilates.  
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Isolation of midgut oocysts  
The infectivity of a mosquito cage was estimated by isolating the midguts of 
10 – 20 mosquitoes on day 10 to 14 post-infection. Dissection was done in 3 % 
RPMI/BSA (w/v) under a stereomicroscope using needles. The number of 
green-fluorescent oocysts per midgut was estimated by examining the midguts 
under a fluorescent microscope.  Midguts were classified with the following 
categories: 0; 1-10; 11-30; 31-100 and >100 oocysts/midgut.  
Isolation and purification of salivary gland sporozoites 
To isolate sporozoites, salivary glands of female mosquitoes were dissected 
18 days after the blood meal. Salivary glands were collected in 3 % BSA/RPMI 
(w/v) and smashed using a pestle. Debris was removed by a first centrifugation 
for 3 min at 100x g, 4 °C, and the supernatant was carefully collected. After 
addition of about 30-100 µl 3 % BSA/RPMI (w/v) to the pellet, it was smashed 
a second time, and the centrifugation was repeated. The supernatant of the first 
and the second centrifugation were pooled, and an aliquot was diluted 1:10 to 
count the sporozoite numbers in a Neubaur counting chamber. Sporozoites 
were then used for in vitro or in vivo experiments as described below or 
pelleted by 10 min centrifugation at full speed, 4 °C and resuspended in 30 µl 
RIPA buffer for Western blotting.  
For determining the sporozoite-induced blood stage growth, 
104 sporozoites were diluted to a total volume of 100 µl in RPMI medium and 
intravenously administered to C57BL/6J mice. Mice were monitored from day 3 
to day 14 post-infection via Giemsa-stained blood smears   
In vitro culture of liver stages and immunofluorescence 
For monitoring liver stage development in vitro, Huh7 cells were seeded in 
an 8-well labtek slide as described on p. 119. The next day, the medium was 
removed and 104 freshly isolated sporozoites in 100 µl RPMI were added to 
each well. Sporozoites were allowed to invade for 1.5 h at 37 °C and then 
removed by washing the cells once with 500 µl PBS per well. After addition of 
250 µl medium per well, cells were incubated for 48 h at 37 °C, 5% CO2.  
TABLE 28: Dilutions and incubation settings for IF antibodies 
Antibody Dilution 
rabbit-anti-GFP 1:125  
Mouse-anti-HSP70 1:100 
Mouse-anti-FLAG 1:125 
Rat-anti-EXP1 1:33 
Alexa-488-anti-mouse 
Alexa-546-anti-rat 
1:300 
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Liver stages were fixed by replacing the medium with 400 µl/well ice-cold 
methanol and 10 min incubation at RT. After washing twice with 400 µl/well 
1 % FCS/PBS (v/v), unspecific binding partners were blocked with 400 µl/well 
10 % FCS/PBS (v/v) (30 min at 37 °C or overnight at 4 °C). The blocking 
solution was then replaced by 100 µl/well primary antibody, which was 
incubated for at least 45 min at 37 °C.  Cells were again washed twice with 
400 µl/well 1 % FCS/PBS (v/v) and then incubated with 100 µl secondary 
antibody for at least 45 min at 37 °C. The dilutions of the primary and 
secondary antibodies used are listed in Table 28. Five minutes prior the end of 
the incubation time, Hoechst was added to a final dilution of 1:10,000. Cells 
were washed a final time three times with 400 µl/well 1 % FCS/PBS (v/v), then 
mounted with 10 % glycerol/PBS (v/v) and sealed with nail polish.  
5.2.8 MICROSCOPY AND IMAGE PROCESSING 
All microscopy to quantify GFP fluorescence or to image liver stages for 
size measurements has been done on the Axiovert 200M widefield fluorescence 
microscope (Zeiss). Within one experiment, settings were kept constant to 
allow comparison between samples (Table 29). All images, except for HEK293T 
cells (10x objective),  were taken with the 63x objective and a 1.0 optovar. 
Some representative images of liver stages were taken with a 1.6 optovar.  
TABLE 29: Exposure times (ms) and gain settings  
 Green Red Blue DIC Gain 
HEK293T 80 500 - - 1 
Blood stages 200 100 1000 20 3 
Oocysts 200 - - 20 1 
Sporozoites 200 - - 20 3 
Liver stages* 10-200 100 1000 20 1 
*Settings adjusted depending on the quality of the staining 
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To quantify the GFP fluorescence of individual parasites, images were 
opened in FIJI and a single parasite was selected. Then, the following macro 
was run:  
run("Duplicate...", "title=[12] duplicate"); 
setMinAndMax(0, 65536);  
run("16-bit"); 
run("Duplicate...", "title=[background mask] duplicate"); 
run("Median...", "radius=5"); 
run("Auto Threshold", "method=Huang white"); 
run("Divide...", "value=255.000"); 
run("Duplicate...", "title=[sample mask] duplicate"); 
selectWindow("background mask"); 
run("Multiply...", "value=255.000"); 
run("Invert"); 
run("Divide...", "value=255.000"); 
imageCalculator("Multiply create", "12","sample mask"); 
run("Duplicate...", "title=[sample] duplicate"); 
imageCalculator("Multiply create", "12","background mask"); 
run("Duplicate...", "title=[background] duplicate"); 
selectWindow("sample"); 
run("Measure"); 
run("Subtract...", "value=1"); 
run("Measure"); 
selectWindow("background"); 
run("Measure"); 
run("Subtract...", "value=1"); 
run("Measure"); 
selectWindow("Result of 12"); 
close(); 
selectWindow("Result of 12"); 
close(); 
selectWindow("background mask"); 
close(); 
selectWindow("background"); 
close(); 
selectWindow("sample mask"); 
close(); 
selectWindow("12"); 
close(); 
wait(1000) 
selectWindow("sample"); 
close(); 
The macro separates the parasite from the background by thresholding and 
then determines the integrated fluorescence for each. It then subtracts 1 from 
the value of every pixel of both background and parasite and repeats the 
intensity measurement. Subtraction of the second from the first value thus 
yields the size of both the parasite and the background in pixels. Dividing the 
total intensity by the size in pixel then yields the average fluorescence per pixel 
for both background and parasite. The background intensity per pixel is 
subtracted from the parasite intensity per pixel to remove the background 
signal. Multiplying the background-corrected parasite intensity per pixel again 
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with the size of the parasite in pixel finally yields the integrated fluorescence 
intensity of the parasite.  
For determining the liver stage size, a macro was used that first converts 
the first channel (green, usually Hsp70 signal) of the .zvi output file and saves it 
as a .tiff file. In a second step, it then thresholds the .tiff image and determines 
the size of individual particles (corresponding to an individual liver stage) by 
using the ImageJ command “Analyze Particles…”. The macro is depicted below.  
directory = getDirectory("Choose input files"); 
fileList = getFileList(directory); 
outputDirectory = getDirectory("Choose output directory"); 
 
run("Bio-Formats Macro Extensions"); 
setBatchMode(true); 
 
for (i=0; i<fileList.length; i++) { 
  file = directory + fileList[i]; 
  
    Ext.setId(file); 
    Ext.getImageCount(imageCount); 
    for (image=0; image<1; image++) { 
      Ext.openImage("", image); 
      Ext.getPixelsPhysicalSizeX(sizeX); 
      outFile = outputDirectory + fileList[i] + "-" + image + ".tiff"; 
      saveFile(outFile); 
      run("Set Scale...", "distance=1 known=sizeX unit=µm"); 
      save(outFile); 
      close(); 
    } 
    Ext.close(); 
} 
 
fileList = getFileList(outputDirectory); 
 
for (i=0; i<fileList.length; i++) { 
  tifffile = outputDirectory + fileList[i]; 
  open(tifffile); 
 run("Auto Threshold", "method=Huang white"); 
 run("Invert"); 
 run( 
"Analyze Particles...",  
"size=10-Infinity show=Overlay display exclude summarize" 
); 
 close(); 
} 
 
showStatus("Finished."); 
setBatchMode(false); 
 
function saveFile(outFile) { 
   run("Bio-Formats Exporter", "save=[" + outFile + "] compression=Uncompressed"); 
} 
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5.2.9 RNA-SEQ 
Sample preparation 
To prepare samples for RNA-Seq, mice were bled at a parasitemia of 
around 1-2 % and leucocytes were removed from the blood by column 
filtration as described on p. 122. Over-night cultures were prepared as on p. 
122. To ensure highest-possible synchrony of the cultures, the incubation was 
always started at 1.30 pm and samples were harvested 18 h later (7.30 am). 
Blood from the culture was pelleted for 8 min at 1500 rpm, and the blood was 
resuspended in 3 ml RLT buffer supplemented with 1% -Mercaptoethanol. 
RNA-Seq library preparation 
 “Total RNA was extracted using the RNeasy Mini Kit (Qiagen, #74106; 
including on-column DNase treatment and RNA clean-up) and PolyA-selected 
using the Oligotex mRNA Mini Kit (Qiagen, #70022) according to 
manufacturer’s instructions. PolyA-selected RNA was checked for genomic DNA 
contamination via qPCR and additionally treated twice with TURBO DNase 
(Ambion, #AM2238) to eliminate remaining genomic DNA. 2 µg of PolyA-
selected total RNA equivalent were fragmented by alkaline hydrolysis (5x 
fragmentation buffer: 200 mM Tris acetate pH 8.2, 500 mM potassium acetate, 
150 mM magnesium acetate) for 2 min at 85 °C in 250 µl volume as described 
[previously]349, precipitated and further processed for strand-specific RNA-seq 
as described [previously]350. In short, first strand cDNA synthesis was 
performed using AT-corrected Random N9 primers and in presence of 0.2 µg 
Actinomycin D to prevent unwanted DNA-dependent second strand cDNA 
synthesis, and during second strand synthesis dTTPs were replaced with 
dUTPs. For each sequencing library, 5 ng of double stranded cDNA were end 
repaired, extended with 3’ A-overhangs, ligated to barcoded NextFlex adapters 
(Bio Scientific, #514122) and treated with USER enzyme (NEB, #M5505L) to 
induce dUTP-dependent second strand-specific degradation. Subsequently, 
libraries were amplified using KAPA HiFi HotStart ready mix (KAPA 
Biosystems, #KM2602), NEXTflex primer mix (Bio Scientific, #514122) and the 
following PCR program: 98 °C for 2 min; 4 cycles of 98 °C for 20 sec, 62 °C for 
3 min; 62 °C for 5 min. Amplified libraries were gel size-selected for 300 – 
400 bp using 2% E-Gel Size Select agarose gels (Invitrogen, #G6610-02) and 
amplified for additional 8 cycles as described above. Adapter dimer depletion 
and DNA clean-up were performed using Agencourt AMPure XP beads 
(Beckman Coulter, #A63880) in a 1:1 library beads ratio.” (Hentzschel et al., 
2017, manuscript in preparation)  
 
 
 
The preparation of the 
RNA library and RNA-Seq 
has been done by Sabine 
Fraschka, Radboud 
University, Nijmwegen, 
The Netherlands. The 
analysis of the data was 
done by Sabine Fraschka 
and Richard Bartfái, 
Radboud University, 
Nijmwegen, The 
Netherlands. 
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High throughput sequencing and data analysis  
“Strand-specific RNA-seq libraries were sequenced on the Illumina NextSeq 
500 system to obtain 75bp single-end reads (TruSeq SR Cluster Kit v2). 75bp 
reads were mapped against the annotated P. berghei ANKA transcriptome from 
PlasmoDB version 26 and the GFP coding sequence encoded by the PbGFPcon 
parasite line using BWA samse (version 0.7.12-r1039). Single-end RNA reads 
were filtered to mapping quality ≥15 (samtools version 1.2) and only uniquely 
mapped reads (between 5.3 and 8.1 million reads) were used for further 
analysis. To assess RNA abundance of each gene, only reads aligned to the sense 
strand (FLAG16) were taken into account. Tags were counted for all transcripts 
(excluding mitchochondrial RNA, apicoplast RNA and RNAs without PolyA tail 
such as rRNAs and tRNAs) and offset by +1 to avoid division by zero while 
calculating fold change in expression. Transcript counts were normalized to the 
amount of reads per kb per million mapped reads (RPKM). Correlations 
between datasets were calculated and plotted with R studio (R version 3.2.2, 
standard packages).” (Hentzschel et al., 2017, manuscript in preparation)  
5.2.10 STATISTICAL ANALYSIS 
“Statistics are no substitute for judgment” 
~ Henry Clay (1777 – 1852) 
All statistical analysis was done using the software GraphPad Prism 5.0. 
Experiments were usually performed in biological duplicates or triplicates on 
separate occasions, with three technical replicates each. Where appropriate, 
data was compared to a control using a standard t-test (if the experiment 
included only two groups) or a one-way ANOVA (if the experiments included 
three or more groups). The statistical analysis used for each data analysis is 
indicated in the respective figure legend.  
 
 Bibliography  
“ If I have seen further, it is by standing on the shoulders of giants.”351 
~ Isaak Newton (1642-1726) 
 
1. Laveran, A. Paludism. (New Sydenham Society, 1893). 
doi:10.5962/bhl.title.106948 
2. Reiter, P. From Shakespeare to Defoe: Malaria in England in the Little Ice Age. 
Emerging Infectious Diseases 6, 1–11 (2000). 
3. World Health Organization. WHO | World Malaria Report 2015. WHO (2016). 
4. World Health Organization. Guidelines for the treatment of malaria. (2015). 
5. RTS, S. C. T. P. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without 
a booster dose in infants and children in Africa: final results of a phase 3, 
individually randomised, controlled trial. Lancet 386, 31–45 (2015). 
6. Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. 
N. Engl. J. Med. 361, 455–67 (2009). 
7. Ashley, E. A. et al. Spread of Artemisinin Resistance in Plasmodium falciparum 
Malaria. N. Engl. J. Med. 371, 411–423 (2014). 
8. Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium 
falciparum malaria. Nature 505, 50–55 (2013). 
9. Olotu, A. et al. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young 
African Children. N. Engl. J. Med. 374, 2519–2529 (2016). 
10. Etymologia: Anopheles. Emerg. Infect. Dis. 18, 1511–1511 (2012). 
11. Craig, A. G. et al. The role of animal models for research on severe malaria. PLoS 
Pathog. 8, e1002401 (2012). 
12. Wykes, M. N. & Good, M. F. What have we learnt from mouse models for the 
study of malaria? Eur. J. Immunol. 39, 2004–2007 (2009). 
13. Amino, R. et al. Quantitative imaging of Plasmodium transmission from 
mosquito to mammal. Nat. Med. 12, 220–224 (2006). 
14. Coppi, A. et al. Heparan Sulfate Proteoglycans Provide a Signal to Plasmodium 
Sporozoites to Stop Migrating and Productively Invade Host Cells. Cell Host 
Microbe 2, 316–327 (2007). 
15. Tavares, J. et al. Role of host cell traversal by the malaria sporozoite during liver 
infection. J. Exp. Med. 210, 905–15 (2013). 
16. Baer, K. et al. Kupffer cells are obligatory for Plasmodium yoelii sporozoite 
infection of the liver. Cell. Microbiol. 9, 397–412 (2007). 
 
6 
132 BIBLIOGRAPHY  
 
17. Frevert, U. et al. Intravital Observation of Plasmodium berghei Sporozoite 
Infection of the Liver. PLoS Biol. 3, e192 (2005). 
18. Mota, M. M. et al. Migration of Plasmodium sporozoites through cells before 
infection. Science (80-. ). 291, 141–4 (2001). 
19. Sá e Cunha, C. et al. Plasmodium berghei EXP-1 interacts with host 
Apolipoprotein H during Plasmodium liver-stage development. Proc. Natl. Acad. 
Sci. 201606419 (2017). doi:10.1073/pnas.1606419114 
20. Itoe, M. A. et al. Host cell phosphatidylcholine is a key mediator of malaria 
parasite survival during liver stage infection. Cell Host Microbe 16, 778–786 
(2014). 
21. Graewe, S., Stanway, R. R., Rennenberg, A. & Heussler, V. T. Chronicle of a death 
foretold: Plasmodium liver stage parasites decide on the fate of the host cell. 
FEMS Microbiol. Rev. 36, 111–130 (2012). 
22. Kaushansky, A. & Kappe, S. H. Selection and refinement: the malaria parasite’s 
infection and exploitation of host hepatocytes. Curr. Opin. Microbiol. 26, 71–78 
(2015). 
23. Lang, K. S. et al. Immunoprivileged status of the liver is controlled by Toll-like 
receptor 3 signaling. J. Clin. Invest. 116, 2456–2463 (2006). 
24. Liehl, P. et al. Host-cell sensors for Plasmodium activate innate immunity 
against liver-stage infection. Nat. Med. 20, 47–53 (2014). 
25. Nussenzweig, R. S., Vanderberg, J., Most, H. & Orton, C. Protective immunity 
produced by the injection of x-irradiated sporozoites of plasmodium berghei. 
Nature 216, 160–162 (1967). 
26. Seder, R. A. et al. Protection against malaria by intravenous immunization with a 
nonreplicating sporozoite vaccine. Science 341, 1359–65 (2013). 
27. Mueller, A.-K., Labaied, M., Kappe, S. H. I. & Matuschewski, K. Genetically 
modified Plasmodium parasites as a protective experimental malaria vaccine. 
Nature 433, 164–7 (2005). 
28. Mordmüller, B. et al. Sterile protection against human malaria by 
chemoattenuated PfSPZ vaccine. Nature 58, 7250–7 (2014). 
29. Bijker, E. M. et al. Novel approaches to whole sporozoite vaccination against 
malaria. Vaccine 33, 7462–7468 (2015). 
30. Sturm, A. et al. Manipulation of host hepatocytes by the malaria parasite for 
delivery into liver sinusoids. Science 313, 1287–90 (2006). 
31. Graewe, S. et al. Hostile takeover by plasmodium: Reorganization of parasite 
and host cell membranes during liver stage egress. PLoS Pathog. 7, e1002224 
(2011). 
32. Tarun, A. S. et al. Quantitative isolation and in vivo imaging of malaria parasite 
liver stages. Int. J. Parasitol. 36, 1283–1293 (2006). 
33. Baer, K., Klotz, C., Kappe, S. H. I., Schnieder, T. & Frevert, U. Release of hepatic 
Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS 
Pathog. 3, 1651–1668 (2007). 
34. Koch, M. & Baum, J. The mechanics of malaria parasite invasion of the human 
erythrocyte - towards a reassessment of the host cell contribution. Cell. 
Microbiol. 18, 303–450 (2016). 
 133 
 
35. Gilson, P. R., Chisholm, S. A., Crabb, B. S. & de Koning-Ward, T. F. Host cell 
remodelling in malaria parasites: a new pool of potential drug targets. Int. J. 
Parasitol. 47, 119–127 (2017). 
36. de Koning-Ward, T. F. et al. A newly discovered protein export machine in 
malaria parasites. Nature 459, 945–9 (2009). 
37. Leech, J. H., Barnwell, J. W., Miller, L. H. & Howard, R. J. Identification of a strain-
specific malarial antigen exposed on the surface of Plasmodium falciparum-
infected erythrocytes. J. Exp. Med. 159, 1567–75 (1984). 
38. Baruch, D. I. et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial 
variant antigen and adherence receptor on the surface of parasitized human 
erythrocytes. Cell 82, 77–87 (1995). 
39. Pasternak, N. D. & Dzikowski, R. PfEMP1: an antigen that plays a key role in the 
pathogenicity and immune evasion of the malaria parasite Plasmodium 
falciparum. Int. J. Biochem. Cell Biol. 41, 1463–6 (2009). 
40. Smith, J. D., Rowe, J. A., Higgins, M. K. & Lavstsen, T. Malaria’s deadly grip: 
Cytoadhesion of Plasmodium falciparum-infected erythrocytes. Cell. Microbiol. 
15, 1976–1983 (2013). 
41. Smith, J. D. et al. Switches in expression of plasmodium falciparum var genes 
correlate with changes in antigenic and cytoadherent phenotypes of infected 
erythrocytes. Cell 82, 101–110 (1995). 
42. Scherf, A., Lopez-Rubio, J. J. & Riviere, L. Antigenic variation in Plasmodium 
falciparum. Annu. Rev. Microbiol. 62, 445–70 (2008). 
43. Guizetti, J. & Scherf, A. Silence, activate, poise and switch! Mechanisms of 
antigenic variation in Plasmodium falciparum. Cell. Microbiol. 15, 718–726 
(2013). 
44. Wah, S. T. et al. Molecular basis of human cerebral malaria development. Trop. 
Med. Health 44, 1–7 (2016). 
45. Yoeli, M. & Hargreaves, B. J. Brain capillary blockage produced by a virulent 
strain of rodent malaria. Science 184, 572–573 (1974). 
46. Mantel, P.-Y. et al. Malaria-Infected Erythrocyte-Derived Microvesicles Mediate 
Cellular Communication within the Parasite Population and with the Host 
Immune System. Cell Host Microbe 13, 521–534 (2013). 
47. Regev-Rudzki, N. et al. Cell-Cell Communication between Malaria-Infected Red 
Blood Cells via Exosome-like Vesicles. Cell 153, 1120–1133 (2013). 
48. Joice, R. et al. Plasmodium falciparum transmission stages accumulate in the 
human bone marrow. Sci. Transl. Med. 6, 244re5 (2014). 
49. Aguilar, R. et al. Molecular evidence for the localization of plasmodium 
falciparum immature gametocytes in bone marrow. Blood 123, 959–966 (2014). 
50. Billker, O. et al. Identification of xanthurenic acid as the putative inducer of 
malaria development in the mosquito. Nature 392, 289–292 (1998). 
51. Bennink, S., Kiesow, M. J. & Pradel, G. The development of malaria parasites in 
the mosquito midgut. Cellular Microbiology 18, 905–918 (2016). 
52. Aly, A. S. I., Vaughan, A. M. & Kappe, S. H. I. Malaria Parasite Development in the 
Mosquito and Infection of the Mammalian Host. Annu. Rev. Microbiol. 63, 195–
221 (2009). 
134 BIBLIOGRAPHY  
 
53. Klug, D. & Frischknecht, F. Motility precedes egress of malaria parasites from 
oocysts. Elife 6, 71–73 (2017). 
54. Douglas, R. G., Amino, R., Sinnis, P. & Frischknecht, F. Active migration and 
passive transport of malaria parasites. Trends in Parasitology 31, 357–362 
(2015). 
55. Gardner, M. J. et al. Genome sequence of the human malaria parasite 
Plasmodium falciparum. Nature 419, 498–511 (2002). 
56. de Koning-Ward, T. F., Gilson, P. R. & Crabb, B. S. Advances in molecular genetic 
systems in malaria. Nat. Rev. Microbiol. 13, 373–387 (2015). 
57. Shaw, P. J. & Aroonsri, A. Tools for attenuation of gene expression in malaria 
parasites. Int. J. Parasitol. (2017). doi:10.1016/j.ijpara.2016.11.006 
58. Wu, Y., Sifri, C. D., Lei, H. H., Su, X. Z. & Wellems, T. E. Transfection of 
Plasmodium falciparum within human red blood cells. Proc. Natl. Acad. Sci. U. S. 
A. 92, 973–7 (1995). 
59. Wu, Y., Kirkman, L. A. & Wellems, T. E. Transformation of Plasmodium 
falciparum malaria parasites by homologous integration of plasmids that confer 
resistance to pyrimethamine. Proc. Natl. Acad. Sci. U. S. A. 93, 1130–4 (1996). 
60. van Dijk, M. R., Waters,  a P. & Janse, C. J. Stable transfection of malaria parasite 
blood stages. Science 268, 1358–1362 (1995). 
61. Crabb, B. S. & Cowman, A. F. Characterization of promoters and stable 
transfection by homologous and nonhomologous recombination in Plasmodium 
falciparum. Proc. Natl. Acad. Sci. U. S. A. 93, 7289–7294 (1996). 
62. Ménard, R. & Janse, C. Gene targeting in malaria parasites. Methods 13, 148–57 
(1997). 
63. Ménard, R. et al. Circumsporozoite protein is required for development of 
malaria sporozoites in mosquitoes. Nature 385, 336–340 (1997). 
64. Crabb, B. S. et al. Targeted Gene Disruption Shows That Knobs Enable Malaria-
Infected Red Cells to Cytoadhere under Physiological Shear Stress. Cell 89, 287–
296 (1997). 
65. Gomes, A. R. et al. A genome-scale vector resource enables high-throughput 
reverse genetic screening in a malaria parasite. Cell Host Microbe 17, 404–413 
(2015). 
66. Schwach, F. et al. PlasmoGEM, a database supporting a community resource for 
large-scale experimental genetics in malaria parasites. Nucleic Acids Res. 43, 
D1176–D1182 (2015). 
67. Miller, J. C. et al. An improved zinc-finger nuclease architecture for highly 
specific genome editing. Nat. Biotechnol. 25, 778–85 (2007). 
68. Straimer, J. et al. Site-specific genome editing in Plasmodium falciparum using 
engineered zinc-finger nucleases. Nat. Methods 9, 993–8 (2012). 
69. Lee, A. H., Symington, L. S. & Fidock, D. A. DNA Repair Mechanisms and Their 
Biological Roles in the Malaria Parasite Plasmodium falciparum. Microbiol. Mol. 
Biol. Rev. 78, 469–486 (2014). 
70. Moraes Barros, R. R. et al. Editing the Plasmodium vivax Genome, Using Zinc-
Finger Nucleases. J. Infect. Dis. 211, 125–129 (2015). 
 
 135 
 
71. Singer, M. et al. Zinc finger nuclease-based double-strand breaks attenuate 
malaria parasites and reveal rare microhomology-mediated end joining. Genome 
Biol 16, 249 (2015). 
72. Ghorbal, M. et al. Genome editing in the human malaria parasite Plasmodium 
falciparum using the CRISPR-Cas9 system. Nat. Biotechnol. (2014). 
doi:10.1038/nbt.2925 
73. Wagner, J. C., Platt, R. J., Goldfless, S. J., Zhang, F. & Niles, J. C. Efficient CRISPR-
Cas9–mediated genome editing in Plasmodium falciparum. Nat. Methods 11, 
915–918 (2014). 
74. Wang, H., La Russa, M. & Qi, L. S. CRISPR/Cas9 in Genome Editing and Beyond. 
Annu. Rev. Biochem. 85, 227–264 (2016). 
75. Sidik, S. M. et al. A Genome-wide CRISPR Screen in Toxoplasma Identifies 
Essential Apicomplexan Genes. Cell 166, 1423–1435.e12 (2016). 
76. Zhang, C. et al. Efficient Editing of Malaria Parasite Genome Using the 
CRISPR/Cas9 System. MBio 5, (2014). 
77. McLeod, M., Craft, S. & Broach, J. R. Identification of the crossover site during 
FLP-mediated recombination in the Saccharomyces cerevisiae plasmid 2 
microns circle. Mol. Cell. Biol. 6, 3357–67 (1986). 
78. Hoess, R. H., Ziese, M. & Sternberg, N. P1 site-specific recombination: nucleotide 
sequence of the recombining sites. Proc. Natl. Acad. Sci. U. S. A. 79, 3398–3402 
(1982). 
79. O’Neill, M. T., Phuong, T., Healer, J., Richard, D. & Cowman, A. F. Gene deletion 
from Plasmodium falciparum using FLP and Cre recombinases: Implications for 
applied site-specific recombination. Int. J. Parasitol. 41, 117–123 (2011). 
80. Jullien, N. Regulation of Cre recombinase by ligand-induced complementation of 
inactive fragments. Nucleic Acids Res. 31, 131e–131 (2003). 
81. Andenmatten, N. et al. Conditional genome engineering in Toxoplasma gondii 
uncovers alternative invasion mechanisms. Nat. Methods 10, 125–7 (2013). 
82. Yap, A. et al. Conditional expression of apical membrane antigen 1 in 
Plasmodium falciparum shows it is required for erythrocyte invasion by 
merozoites. Cell. Microbiol. 16, 642–656 (2014). 
83. Jones, M. L. et al. A versatile strategy for rapid conditional genome engineering 
using loxP sites in a small synthetic intron in Plasmodium falciparum. Sci. Rep. 6, 
21800 (2016). 
84. Gordon, E. B. et al. Inhibiting the mammalian target of rapamycin blocks the 
development of experimental cerebral malaria. MBio 6, e00725 (2015). 
85. Combe, A. et al. Clonal Conditional Mutagenesis in Malaria Parasites. Cell Host 
Microbe 5, 386–396 (2009). 
86. Bargieri, D. Y. et al. Apical membrane antigen 1 mediates apicomplexan parasite 
attachment but is dispensable for host cell invasion. Nat. Commun. 4, (2013). 
87. Lacroix, C. et al. FLP/FRT-mediated conditional mutagenesis in pre-erythrocytic 
stages of Plasmodium berghei. Nat. Protoc. 6, 1412–1428 (2011). 
88. Laurentino, E. C. et al. Experimentally controlled downregulation of the histone 
chaperone FACT in Plasmodium berghei reveals that it is critical to male gamete 
fertility. Cell. Microbiol. 13, 1956–1974 (2011). 
136 BIBLIOGRAPHY  
 
89. Le Roch, K. G. Discovery of Gene Function by Expression Profiling of the Malaria 
Parasite Life Cycle. Science (80-. ). 301, 1503–1508 (2003). 
90. Kooij, T. W., Janse, C. J. & Waters, A. P. Plasmodium post-genomics: better the 
bug you know? Nat Rev Microbiol 4, 344–357 (2006). 
91. Meissner, M. et al. Tetracycline analogue-regulated transgene expression in 
Plasmodium falciparum blood stages using Toxoplasma gondii transactivators. 
Proc. Natl. Acad. Sci. U. S. A. 102, 2980–5 (2005). 
92. Pino, P. et al. A Tetracycline-Repressible Transactivator System to Study 
Essential Genes in Malaria Parasites. Cell Host Microbe 12, 824–834 (2012). 
93. Balaji, S., Madan Babu, M., Iyer, L. M. & Aravind, L. Discovery of the principal 
specific transcription factors of Apicomplexa and their implication for the 
evolution of the AP2-integrase DNA binding domains. Nucleic Acids Res. 33, 
3994–4006 (2005). 
94. Ghosh, S. et al. The Plasmodium rhoptry associated protein complex is 
important for parasitophorous vacuole membrane structure and 
intraerythrocytic parasite growth. Cell. Microbiol. (2017). 
doi:10.1111/cmi.12733 
95. Baum, J. et al. Molecular genetics and comparative genomics reveal RNAi is not 
functional in malaria parasites. Nucleic Acids Res. 37, 3788–98 (2009). 
96. Wang, G. & Xu, X. S. Peptide nucleic acid (PNA) binding-mediated gene 
regulation. Cell Res. 14, 111–116 (2004). 
97. Dahan-Pasternak, N. et al. PfSec13 is an unusual chromatin-associated 
nucleoporin of Plasmodium falciparum that is essential for parasite 
proliferation in human erythrocytes. J. Cell Sci. 126, 3055–69 (2013). 
98. Kolevzon, N., Nasereddin, A., Naik, S., Yavin, E. & Dzikowski, R. Use of peptide 
nucleic acids to manipulate gene expression in the malaria parasite Plasmodium 
falciparum. PLoS One 9, e86802 (2014). 
99. Garg, A. et al. Targeting protein translation, RNA splicing, and degradation by 
morpholino-based conjugates in Plasmodium falciparum. Proc. Natl. Acad. Sci. 
112, 201515864 (2015). 
100. Piccinelli, P., Rosenblad, M. A. & Samuelsson, T. Identification and analysis of 
ribonuclease P and MRP RNA in a broad range of eukaryotes. Nucleic Acids Res. 
33, 4485–4495 (2005). 
101. Augagneur, Y., Wesolowski, D., Tae, H. S., Altman, S. & Ben Mamoun, C. Gene 
selective mRNA cleavage inhibits the development of Plasmodium falciparum. 
Proc. Natl. Acad. Sci. 109, 6235–6240 (2012). 
102. Winkler, W. C., Nahvi, A., Roth, A., Collins, J. A. & Breaker, R. R. Control of gene 
expression by a natural metabolite-responsive ribozyme. Nature 428, 281–286 
(2004). 
103. Prommana, P. et al. Inducible Knockdown of Plasmodium Gene Expression 
Using the glmS Ribozyme. PLoS One 8, e73783 (2013). 
104. Aroonsri, A. et al. Identifying antimalarial compounds targeting dihydrofolate 
reductase-thymidylate synthase (DHFR-TS) by chemogenomic profiling. Int. J. 
Parasitol. 46, 527–535 (2016). 
105. Belmont, B. J. & Niles, J. C. Engineering a direct and inducible protein-RNA 
interaction to regulate RNA biology. ACS Chem. Biol. 5, 851–861 (2010). 
 137 
 
106. Goldfless, S. J., Wagner, J. C. & Niles, J. C. Versatile control of Plasmodium 
falciparum gene expression with an inducible protein-RNA interaction. Nat. 
Commun. 5, 5329 (2014). 
107. Ganesan, S. M., Falla, A., Goldfless, S. J., Nasamu, A. S. & Niles, J. C. Synthetic RNA-
protein modules integrated with native translation mechanisms to control gene 
expression in malaria parasites. Nat Commun 7, 1–10 (2016). 
108. Mair, G. R. et al. Regulation of sexual development of Plasmodium by 
translational repression. Science 313, 667–9 (2006). 
109. Banaszynski, L. A., Chen, L. chun, Maynard-Smith, L. A., Ooi, A. G. L. & Wandless, 
T. J. A Rapid, Reversible, and Tunable Method to Regulate Protein Function in 
Living Cells Using Synthetic Small Molecules. Cell 126, 995–1004 (2006). 
110. Armstrong, C. M. & Goldberg, D. E. An FKBP destabilization domain modulates 
protein levels in Plasmodium falciparum. Nat. Methods 4, 1007–1009 (2007). 
111. Muralidharan, V., Oksman, A., Iwamoto, M., Wandless, T. J. & Goldberg, D. E. 
Asparagine repeat function in a Plasmodium falciparum protein assessed via a 
regulatable fluorescent affinity tag. Proc. Natl. Acad. Sci. U. S. A. 108, 4411–6 
(2011). 
112. Jain, S. et al. The prokaryotic ClpQ protease plays a key role in growth and 
development of mitochondria in Plasmodium falciparum. Cell. Microbiol. 15, 
1660–1673 (2013). 
113. Azevedo, M. F. et al. Inhibition of Plasmodium falciparum CDPK1 by conditional 
expression of its J-domain demonstrates a key role in schizont development. 
Biochem. J. 452, 433–41 (2013). 
114. de Azevedo, M. F. et al. Systematic analysis of FKBP inducible degradation 
domain tagging strategies for the human malaria parasite Plasmodium 
falciparum. PLoS One 7, e40981 (2012). 
115. Pei, Y. et al. Plasmodium yoelii inhibitor of cysteine proteases is exported to 
exomembrane structures and interacts with yoelipain-2 during asexual blood-
stage development. Cell. Microbiol. 15, 1508–1526 (2013). 
116. Kreidenweiss, A., Hopkins, A. V & Mordmüller, B. 2A and the auxin-based degron 
system facilitate control of protein levels in Plasmodium falciparum. PLoS One 8, 
e78661 (2013). 
117. Philip, N. & Waters, A. P. Conditional Degradation of Plasmodium Calcineurin 
Reveals Functions in Parasite Colonization of both Host and Vector. Cell Host 
Microbe 18, 122–131 (2015). 
118. Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An 
auxin-based degron system for the rapid depletion of proteins in nonplant cells. 
Nat. Methods 53, 1689–1699 (2009). 
119. Saridaki, T., Sanchez, C. P., Pfahler, J. & Lanzer, M. A conditional export system 
provides new insights into protein export in Plasmodium falciparum-infected 
erythrocytes. Cell. Microbiol. 10, 2483–2495 (2008). 
120. Birnbaum, J. et al. A genetic system to study Plasmodium falciparum protein 
function. Nat. Methods (2017). doi:10.1038/nmeth.4223 
121. Hughes, K. R. & Waters, A. P. Rapid inducible protein displacement in 
Plasmodium in vivo and in vitro using knocksideways technology. Wellcome 
Open Res. 2, 18 (2017). 
 
138 BIBLIOGRAPHY  
 
122. Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843–854 
(1993). 
123. Friedman, R. C., Farh, K. K.-H., Burge, C. B. & Bartel, D. P. Most mammalian 
mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105 (2009). 
124. Rodriguez, A., Griffiths-Jones, S., Ashurst, J. L. & Bradley, A. Identification of 
mammalian microRNA host genes and transcription units. Genome Res. 14, 
1902–1910 (2004). 
125. Kim, Y.-K. & Kim, V. N. Processing of intronic microRNAs. EMBO J. 26, 775–83 
(2007). 
126. Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 
15, 509–524 (2014). 
127. Cai, X., Hagedorn, C. H. & Cullen, B. R. Human microRNAs are processed from 
capped, polyadenylated transcripts that can also function as mRNAs. RNA 10, 
1957–66 (2004). 
128. Saini, H. K., Griffiths-Jones, S. & Enright, A. J. Genomic analysis of human 
microRNA transcripts. Proc. Natl. Acad. Sci. U. S. A. 104, 17719–24 (2007). 
129. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 
425, 415–419 (2003). 
130. Lee, Y., Jeon, K., Lee, J. T., Kim, S. & Kim, V. N. MicroRNA maturation: Stepwise 
processing and subcellular localization. EMBO J. 21, 4663–4670 (2002). 
131. Ballarino, M. et al. Coupled RNA processing and transcription of intergenic 
primary microRNAs. Mol. Cell. Biol. 29, 5632–8 (2009). 
132. Morlando, M. et al. Primary microRNA transcripts are processed co-
transcriptionally. Nat. Struct. Mol. Biol. 15, 902–9 (2008). 
133. Han, J. et al. The Drosha-DGCR8 complex in primary microRNA processing. 
Genes Dev. 18, 3016–3027 (2004). 
134. Gregory, R. I. et al. The Microprocessor complex mediates the genesis of 
microRNAs. Nature 432, 235–240 (2004). 
135. Denli, A. M., Tops, B. B. J., Plasterk, R. H. a, Ketting, R. F. & Hannon, G. J. 
Processing of primary microRNAs by the Microprocessor complex. Nature 432, 
231–5 (2004). 
136. Landthaler, M., Yalcin, A. & Tuschl, T. The human DiGeorge syndrome critical 
region gene 8 and its D. melanogaster homolog are required for miRNA 
biogenesis. Curr. Biol. 14, 2162–2167 (2004). 
137. Bohnsack, M. T., Czaplinski, K. & Gorlich, D. Exportin 5 is a RanGTP-dependent 
dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 
185–91 (2004). 
138. Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E. & Kutay, U. Nuclear export of 
microRNA precursors. Science (80-. ). 303, 95–98 (2004). 
139. Yi, R., Qin, Y., Macara, I. G. & Cullen, B. R. Exportin-5 mediates the nuclear export 
of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011–6 (2003). 
140. Patel, R. C. & Sen, G. C. PACT, a protein activator of the interferon-induced 
protein kinase, PKR. EMBO J. 17, 4379–90 (1998). 
 139 
 
141. Ketting, R. F. et al. Dicer functions in RNA interference and in synthesis of small 
RNA involved in developmental timing in C. elegans. Genes Dev. 15, 2654–2659 
(2001). 
142. Grishok, A. et al. Genes and mechanisms related to RNA interference regulate 
expression of the small temporal RNAs that control C. elegans developmental 
timing. Cell 106, 23–34 (2001). 
143. Hutvagner, G. et al. A Cellular Function for the RNA-Interference Temporal RNA 
Small let-7 Enzyme Dicer in the Maturation of the . Science (80-. ). 293, 1–6 
(2010). 
144. Knight, S. W. & Bass, B. L. A role for the RNase III enzyme DCR-1 in RNA 
interference and germ line development in Caenorhabditis elegans. Science (80-. 
). 293, 2269–2271 (2001). 
145. Chendrimada, T. P. et al. TRBP recruits the Dicer complex to Ago2 for microRNA 
processing and gene silencing. Nature 436, 740–4 (2005). 
146. Haase, A. D. et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, 
interacts with Dicer and functions in RNA silencing. EMBO Rep. 6, 961–7 (2005). 
147. Lee, Y. et al. The role of PACT in the RNA silencing pathway. EMBO J. 25, 522–32 
(2006). 
148. Lee, H. Y., Zhou, K., Smith, A. M., Noland, C. L. & Doudna, J. A. Differential roles of 
human Dicer-binding proteins TRBP and PACT in small RNA processing. Nucleic 
Acids Res. 41, 6568–6576 (2013). 
149. Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R. & Hannon, G. J. 
Argonaute2, a Link Between Genetic and Biochemical Analyses of RNAi. Science 
(80-. ). 293, 1146–1150 (2001). 
150. Mourelatos, Z. et al. miRNPs: A novel class of ribonucleoproteins containing 
numerous microRNAs. Genes Dev. 16, 720–728 (2002). 
151. Tabara, H. et al. The rde-1 gene, RNA interference, and transposon silencing in C. 
elegans. Cell 99, 123–32 (1999). 
152. Azuma-Mukai, A. et al. Characterization of endogenous human Argonautes and 
their miRNA partners in RNA silencing. Proc. Natl. Acad. Sci. U. S. A. 105, 7964–9 
(2008). 
153. Meister, G. et al. Human Argonaute2 mediates RNA cleavage targeted by 
miRNAs and siRNAs. Mol. Cell 15, 185–197 (2004). 
154. Dueck, A., Ziegler, C., Eichner, A., Berezikov, E. & Meister, G. MicroRNAs 
associated with the different human Argonaute proteins. Nucleic Acids Res. 40, 
9850–9862 (2012). 
155. Khvorova, A., Reynolds, A. & Jayasena, S. D. Functional siRNAs and miRNAs 
exhibit strand bias. Cell 115, 209–216 (2003). 
156. Schwarz, D. S. et al. Asymmetry in the assembly of the RNAi enzyme complex. 
Cell 115, 199–208 (2003). 
157. Matranga, C., Tomari, Y., Shin, C., Bartel, D. P. & Zamore, P. D. Passenger-strand 
cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme 
complexes. Cell 123, 607–620 (2005). 
158. Shin, C. Cleavage of the star strand facilitates assembly of some microRNAs into 
Ago2-containing silencing complexes in mammals. Mol. Cells 26, 308–313 
(2008). 
140 BIBLIOGRAPHY  
 
159. Diederichs, S. & Haber, D. A. Dual Role for Argonautes in MicroRNA Processing 
and Posttranscriptional Regulation of MicroRNA Expression. Cell 131, 1097–
1108 (2007). 
160. Leuschner, P. J. F., Ameres, S. L., Kueng, S. & Martinez, J. Cleavage of the siRNA 
passenger strand during RISC assembly in human cells. EMBO Rep 7, 314–320 
(2006). 
161. Rand, T. A., Petersen, S., Du, F. & Wang, X. Argonaute2 cleaves the anti-guide 
strand of siRNA during RISC activation. Cell 123, 621–629 (2005). 
162. Tomari, Y. et al. RISC assembly defects in the Drosophila RNAi mutant armitage. 
Cell 116, 831–841 (2004). 
163. Meister, G. et al. Identification of novel argonaute-associated proteins. Curr. Biol. 
15, 2149–2155 (2005). 
164. Nykänen, A., Haley, B. & Zamore, P. D. ATP requirements and small interfering 
RNA structure in the RNA interference pathway. Cell 107, 309–321 (2001). 
165. Robb, G. B. & Rana, T. M. RNA Helicase A Interacts with RISC in Human Cells and 
Functions in RISC Loading. Mol. Cell 26, 523–537 (2007). 
166. Liu, X., Jin, D. Y., McManus, M. T. & Mourelatos, Z. Precursor MicroRNA-
Programmed Silencing Complex Assembly Pathways in Mammals. Mol. Cell 46, 
507–517 (2012). 
167. Kawamata, T., Seitz, H. & Tomari, Y. Structural determinants of miRNAs for RISC 
loading and slicer-independent unwinding. Nat. Struct. Mol. Biol. 16, 953–960 
(2009). 
168. Yoda, M. et al. ATP-dependent human RISC assembly pathways. Nat. Struct. Mol. 
Biol. 17, 17–23 (2010). 
169. Yang, J.-S. et al. Widespread regulatory activity of vertebrate microRNA* species. 
RNA 17, 312–326 (2011). 
170. Leung, A. K. L. & Sharp, P. A. Quantifying argonaute proteins in and out of GW/P-
bodies: Implications in microRNA activities. Adv. Exp. Med. Biol. 768, 165–182 
(2013). 
171. Lai, E. C., Tam, B. & Rubin, G. M. Pervasive regulation of Drosophila Notch target 
genes by GY-box-, Brd-box-, and K-box-class microRNAs. Genes Dev. 19, 1067–
1080 (2005). 
172. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. 
Prediction of Mammalian MicroRNA Targets. Cell 115, 787–798 (2003). 
173. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by 
RNAi. Nat. Biotechnol. 21, 635–637 (2003). 
174. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 
215–33 (2009). 
175. Pasquinelli, A. E. MicroRNAs and their targets: recognition, regulation and an 
emerging reciprocal relationship. Nat. Rev. Genet. 13, 271–82 (2012). 
176. Wilczynska, A. & Bushell, M. The complexity of miRNA-mediated repression. Cell 
Death Differ. 22, 22–33 (2014). 
177. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 
1437–41 (2004). 
 141 
 
178. Doench, J. G., Petersen, C. P. & Sharp, P. A. siRNAs can function as miRNAs. Genes 
Dev. 17, 438–42 (2003). 
179. Pillai, R. S. et al. Inhibition of translational initiation by Let-7 MicroRNA in human 
cells. Science 309, 1573–1576 (2005). 
180. Thermann, R. & Hentze, M. W. Drosophila miR2 induces pseudo-polysomes and 
inhibits translation initiation. Nature 447, 875–8 (2007). 
181. Bhattacharyya, S. N., Habermacher, R., Martine, U., Closs, E. I. & Filipowicz, W. 
Relief of microRNA-Mediated Translational Repression in Human Cells 
Subjected to Stress. Cell 125, 1111–1124 (2006). 
182. Iwasaki, S., Kawamata, T. & Tomari, Y. Drosophila Argonaute1 and Argonaute2 
Employ Distinct Mechanisms for Translational Repression. Mol. Cell 34, 58–67 
(2009). 
183. Humphreys, D. T., Westman, B. J., Martin, D. I. K. & Preiss, T. MicroRNAs control 
translation initiation by inhibiting eukaryotic initiation factor 4E/cap and 
poly(A) tail function. Proc. Natl. Acad. Sci. U. S. A. 102, 16961–6 (2005). 
184. Wakiyama, M., Takimoto, K., Ohara, O. & Yokoyama, S. Let-7 microRNA-
mediated mRNA deadenylation and translational repression in a mammalian 
cell-free system. Genes Dev. 21, 1857–1862 (2007). 
185. Kong, Y. W. et al. The mechanism of micro-RNA-mediated translation repression 
is determined by the promoter of the target gene. Proc. Natl. Acad. Sci. U. S. A. 
105, 8866–8871 (2008). 
186. Mathonnet, G. et al. MicroRNA inhibition of translation initiation in vitro by 
targeting the cap-binding complex eIF4F. Science 317, 1764–1767 (2007). 
187. Eulalio, A., Huntzinger, E. & Izaurralde, E. GW182 interaction with Argonaute is 
essential for miRNA-mediated translational repression and mRNA decay. Nat. 
Struct. Mol. Biol. 15, 346–353 (2008). 
188. Eulalio, A., Helms, S., Fritzsch, C., Fauser, M. & Izaurralde, E. A C-terminal 
silencing domain in GW182 is essential for miRNA function. RNA 15, 1067–77 
(2009). 
189. Till, S. et al. A conserved motif in Argonaute-interacting proteins mediates 
functional interactions through the Argonaute PIWI domain. Nat. Struct. Mol. 
Biol. 14, 897–903 (2007). 
190. Fabian, M. R. et al. miRNA-mediated deadenylation is orchestrated by GW182 
through two conserved motifs that interact with CCR4–NOT. Nat. Struct. Mol. 
Biol. 19, 1211–1217 (2012). 
191. Braun, J. E., Huntzinger, E., Fauser, M. & Izaurralde, E. GW182 proteins directly 
recruit cytoplasmic deadenylase complexes to miRNA targets. Mol. Cell 44, 120–
133 (2011). 
192. Chekulaeva, M. et al. miRNA repression involves GW182-mediated recruitment 
of CCR4–NOT through conserved W-containing motifs. Nat. Struct. Mol. Biol. 18, 
1218–1226 (2011). 
193. Chu, C. Y. & Rana, T. M. Translation repression in human cells by MicroRNA-
induced gene silencing requires RCK/p54. PLoS Biol. 4, 1122–1136 (2006). 
194. Mathys, H. et al. Structural and Biochemical Insights to the Role of the CCR4-
NOT Complex and DDX6 ATPase in MicroRNA Repression. Mol. Cell 54, 751–765 
(2014). 
142 BIBLIOGRAPHY  
 
195. Chen, Y. et al. A DDX6-CNOT1 Complex and W-Binding Pockets in CNOT9 Reveal 
Direct Links between miRNA Target Recognition and Silencing. Mol. Cell 54, 
737–750 (2014). 
196. Rouya, C. et al. Human DDX6 effects miRNA-mediated gene silencing via direct 
binding to CNOT1. RNA 20, 1398–409 (2014). 
197. Eulalio, A., Behm-Ansmant, I., Schweizer, D. & Izaurralde, E. P-Body Formation Is 
a Consequence, Not the Cause, of RNA-Mediated Gene Silencing ᰔ. Mol. Cell. Biol. 
27, 3970–3981 (2007). 
198. Behm-Ansmant, I. et al. mRNA degradation by miRNAs and GW182 requires 
both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev. 
20, 1885–1898 (2006). 
199. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference 
in cultured mammalian cells. Nature 411, 494–8 (2001). 
200. Paddison, P. J., Caudy, A. A., Bernstein, E., Hannon, G. J. & Conklin, D. S. Short 
hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. 
Genes Dev. 16, 948–58 (2002). 
201. Alsford, S. et al. High-throughput phenotyping using parallel sequencing of RNA 
interference targets in the African trypanosome. Genome Res. 21, 915–924 
(2011). 
202. Kamath, R. S. et al. Systematic functional analysis of the Caenorhabditis elegans 
genome using RNAi. Nature 421, 231–237 (2003). 
203. Boutros, M. et al. Genome-wide RNAi analysis of growth and viability in 
Drosophila cells. Science (80-. ). 303, 832–835 (2004). 
204. Daugaard, I. & Hansen, T. B. Biogenesis and Function of Ago-Associated RNAs. 
Trends Genet. 33, 208–219 (2017). 
205. Miyoshi, K., Miyoshi, T. & Siomi, H. Many ways to generate microRNA-like small 
RNAs: Non-canonical pathways for microRNA production. Molecular Genetics 
and Genomics 284, 95–103 (2010). 
206. Burroughs, A. M. et al. Deep-sequencing of human Argonaute-associated small 
RNAs provides insight into miRNA sorting and reveals Argonaute association 
with RNA fragments of diverse origin. RNA Biol. 8, 158–77 (2011). 
207. Cole, C. et al. Filtering of deep sequencing data reveals the existence of abundant 
Dicer-dependent small RNAs derived from tRNAs. Rna 15, 2147–2160 (2009). 
208. Haussecker, D. et al. Human tRNA-derived small RNAs in the global regulation of 
RNA silencing. RNA (New York, NY) 16, 673–695 (2010). 
209. Hasler, D. & Meister, G. From tRNA to miRNA: RNA-folding contributes to 
correct entry into noncoding RNA pathways. FEBS Letters 2354–2363 (2016). 
doi:10.1002/1873-3468.12294 
210. Ender, C. et al. A Human snoRNA with MicroRNA-Like Functions. Mol. Cell 32, 
519–528 (2008). 
211. Taft, R. J. et al. Small RNAs derived from snoRNAs. RNA 15, 1233–40 (2009). 
212. Brameier, M., Herwig, A., Reinhardt, R., Walter, L. & Gruber, J. Human box C/D 
snoRNAs with miRNA like functions: Expanding the range of regulatory RNAs. 
Nucleic Acids Res. 39, 675–686 (2011). 
 
 143 
 
213. Watanabe, T. et al. Endogenous siRNAs from naturally formed dsRNAs regulate 
transcripts in mouse oocytes. Nature 453, 539–543 (2008). 
214. Okamura, K. & Lai, E. C. Endogenous small interfering RNAs in animals. Nat. Rev. 
Mol. Cell Biol. 9, 673–8 (2008). 
215. Tam, O. H. et al. Pseudogene-derived small interfering RNAs regulate gene 
expression in mouse oocytes. Nature 453, 534–538 (2008). 
216. Xie, M. et al. Mammalian 5???-capped microRNA precursors that generate a 
single microRNA. Cell 155, 1568–1580 (2013). 
217. Berezikov, E., Chung, W. J., Willis, J., Cuppen, E. & Lai, E. C. Mammalian Mirtron 
Genes. Mol. Cell 28, 328–336 (2007). 
218. Okamura, K., Hagen, J. W., Duan, H., Tyler, D. M. & Lai, E. C. The Mirtron Pathway 
Generates microRNA-Class Regulatory RNAs in Drosophila. Cell 130, 89–100 
(2007). 
219. Ruby, J. G., Jan, C. H. & Bartel, D. P. Intronic microRNA precursors that bypass 
Drosha processing. Nature 448, 83–6 (2007). 
220. Westholm, J. O. & Lai, E. C. Mirtrons: MicroRNA biogenesis via splicing. Biochimie 
93, 1897–1904 (2011). 
221. Hansen, T. B. et al. Argonaute-associated short introns are a novel class of gene 
regulators. Nat Commun 7, 1–10 (2016). 
222. Nelson, P. T. et al. A novel monoclonal antibody against human Argonaute 
proteins reveals unexpected characteristics of miRNAs in human blood cells. 
RNA 13, 1787–92 (2007). 
223. Rasmussen, K. D. et al. The miR-144/451 locus is required for erythroid 
homeostasis. J. Exp. Med. 207, 1351–8 (2010). 
224. Pase, L. et al. miR-451 regulates zebrafish erythroid maturation in vivo via its 
target gata2. Blood 113, 1794–1804 (2009). 
225. Patrick, D. M. et al. Defective erythroid differentiation in miR-451 mutant mice 
mediated by 14-3-3?? Genes Dev. 24, 1614–1619 (2010). 
226. Yu, D. et al. miR-451 protects against erythroid oxidant stress by repressing 14-
3-3?? Genes Dev. 24, 1620–1633 (2010). 
227. Dore, L. C. et al. A GATA-1-regulated microRNA locus essential for 
erythropoiesis. Proc. Natl. Acad. Sci. U. S. A. 105, 3333–8 (2008). 
228. Cheloufi, S., Dos Santos, C. O., Chong, M. M. & Hannon, G. J. A dicer-independent 
miRNA biogenesis pathway that requires Ago catalysis. Nature 465, 584–589 
(2010). 
229. Cifuentes, D. et al. A novel miRNA processing pathway independent of Dicer 
requires Argonaute2 catalytic activity. Science 328, 1694–8 (2010). 
230. Yang, J. S. & Lai, E. C. Dicer-independent, Ago2-mediated microRNA biogenesis 
in vertebrates. Cell Cycle 9, 4455–4460 (2010). 
231. Yoda, M. et al. Poly(A)-specific ribonuclease mediates 3’-end trimming of 
argonaute2-cleaved precursor micrornas. Cell Rep. 5, 715–726 (2013). 
232. Liu, Y. P., Schopman, N. C. T. & Berkhout, B. Dicer-independent processing of 
short hairpin RNAs. Nucleic Acids Res. 41, 3723–33 (2013). 
144 BIBLIOGRAPHY  
 
233. Ma, H., Zhang, J. & Wu, H. Designing Ago2-specific siRNA/shRNA to Avoid 
Competition with Endogenous miRNAs. Mol. Ther. Nucleic Acids 3, e176 (2014). 
234. Herrera-Carrillo, E., Harwig, A., Liu, Y. P. & Berkhout, B. Probing the shRNA 
characteristics that hinder Dicer recognition and consequently allow Ago-
mediated processing and AgoshRNA activity. RNA 20, 1410–1408 (2014). 
235. Liu, Y. P. et al. Mechanistic insights on the Dicer-independent AGO2-mediated 
processing of AgoshRNAs. RNA Biol. 12, 92–100 (2015). 
236. Liu, Y. P., Karg, M., Herrera-Carrillo, E. & Berkhout, B. Towards Antiviral shRNAs 
Based on the AgoshRNA Design. PLoS One 10, e0128618 (2015). 
237. Herrera-Carrillo, E., Gao, Z., Harwig, A., Heemskerk, M. T. & Berkhout, B. The 
influence of the 5′-terminal nucleotide on AgoshRNA activity and biogenesis: 
importance of the polymerase III transcription initiation site. Nucleic Acids Res. 
gkw1203 (2016). doi:10.1093/nar/gkw1203 
238. Harwig, A., Herrera-Carrillo, E., Jongejan, A., van Kampen, A. H. & Berkhout, B. 
Deep Sequence Analysis of AgoshRNA Processing Reveals 3’ A Addition and 
Trimming. Mol. Ther. - Nucleic Acids 4, e247 (2015). 
239. Grimm, D. et al. Fatality in mice due to oversaturation of cellular 
microRNA/short hairpin RNA pathways. Nature 441, 537–41 (2006). 
240. Coley, W. et al. Absence of DICER in monocytes and its regulation by HIV-1. J. 
Biol. Chem. 285, 31930–31943 (2010). 
241. Rathjen, T., Nicol, C., McConkey, G. & Dalmay, T. Analysis of short RNAs in the 
malaria parasite and its red blood cell host. FEBS Lett. 580, 5185–5188 (2006). 
242. Xue, X., Zhang, Q., Huang, Y., Feng, L. & Pan, W. No miRNA were found in 
Plasmodium and the ones identified in erythrocytes could not be correlated 
with infection. Malar. J. 7, 47 (2008). 
243. Mantel, P.-Y. et al. Infected erythrocyte-derived extracellular vesicles alter 
vascular function via regulatory Ago2-miRNA complexes in malaria. Nat. 
Commun. 7, 12727 (2016). 
244. Chen, S. Y., Wang, Y., Telen, M. J. & Chi, J. T. The genomic analysis of erythrocyte 
microRNA expression in sickle cell diseases. PLoS One 3, (2008). 
245. LaMonte, G. et al. Translocation of sickle cell erythrocyte MicroRNAs into 
Plasmodium falciparum inhibits parasite translation and contributes to malaria 
resistance. Cell Host Microbe 12, 187–199 (2012). 
246. Friedman, M. J. Erythrocytic mechanism of sickle cell resistance to malaria. Proc. 
Natl. Acad. Sci. U. S. A. 75, 1994–7 (1978). 
247. Delić, D., Dkhil, M., Al-Quraishy, S. & Wunderlich, F. Hepatic miRNA expression 
reprogrammed by Plasmodium chabaudi malaria. Parasitol. Res. 108, 1111–
1121 (2011). 
248. Hentzschel, F. et al. AAV8-mediated in vivo overexpression of miR-155 enhances 
the protective capacity of genetically-attenuated malarial parasites. Mol. Ther. 
22, 2130–2141 (2014). 
249. El-Assaad, F. et al. Differential microRNA expression in experimental cerebral 
and noncerebral malaria. Infect. Immun. 79, 2379–84 (2011). 
250. Barker, K. R. et al. miR-155 Modifies Inflammation, Endothelial Activation and 
Blood-Brain Barrier Dysfunction in Cerebral Malaria. Mol. Med. 23, 24–33 
(2017). 
 145 
 
251. Ngô, H., Tschudi, C., Gull, K. & Ullu, E. Double-stranded RNA induces mRNA 
degradation in Trypanosoma brucei. Proc. Natl. Acad. Sci. U. S. A. 95, 14687–
14692 (1998). 
252. Patrick, K. L. et al. Distinct and overlapping roles for two Dicer-like proteins in 
the RNA interference pathways of the ancient eukaryote Trypanosoma brucei. 
Proc. Natl. Acad. Sci. U. S. A. 106, 17933–8 (2009). 
253. Shi, H., Tschudi, C. & Ullu, E. An unusual Dicer-like1 protein fuels the RNA 
interference pathway in Trypanosoma brucei. Rna 12, 2063–2072 (2006). 
254. Durand-Dubief, M. & Bastin, P. TbAGOI, an Argonaute protein required for RNA 
interference, is involved in mitosis and chromosome segragation in 
Trypanosoma brucei. BMC Biol. 1, (2003). 
255. Shi, H., Djikeng, A., Tschudi, C. & Ullu, E. Argonaute protein in the early divergent 
eukaryote Trypanosoma brucei: control of small interfering RNA accumulation 
and retroposon transcript abundance. Mol. Cell. Biol. 24, 420–7 (2004). 
256. Mony, B. M. et al. Genome-wide dissection of the quorum sensing signalling 
pathway in Trypanosoma brucei. Nature 505, 681–685 (2014). 
257. Lye, L.-F. et al. Retention and Loss of RNA Interference Pathways in 
Trypanosomatid Protozoans. PLoS Pathog. 6, e1001161 (2010). 
258. Darocha, W. D., Otsu, K., Teixeira, S. M. R. & Donelson, J. E. Tests of cytoplasmic 
RNA interference (RNAi) and construction of a tetracycline-inducible T7 
promoter system in Trypanosoma cruzi. Mol. Biochem. Parasitol. 133, 175–186 
(2004). 
259. Robinson, K. A. & Beverley, S. M. Improvements in transfection efficiency and 
tests of RNA interference (RNAi) approaches in the protozoan parasite 
Leishmania. Mol. Biochem. Parasitol. 128, 217–228 (2003). 
260. Braun, L. et al. A Complex Small RNA Repertoire Is Generated by a Plant/Fungal-
Like Machinery and Effected by a Metazoan-Like Argonaute in the Single-Cell 
Human Parasite Toxoplasma gondii. PLoS Pathog. 6, e1000920 (2010). 
261. Riyahi, A. Al, Al-Anouti, F., Al-Rayes, M. & Ananvoranich, S. Single argonaute 
protein from Toxoplasma gondii is involved in the double-stranded RNA 
induced gene silencing. Int. J. Parasitol. 36, 1003–1014 (2006). 
262. Crater, A. K., Manni, E. & Ananvoranich, S. Utilization of inherent miRNAs in 
functional analyses of Toxoplasma gondii genes. J. Microbiol. Methods 108, 92–
102 (2015). 
263. Al-Anouti, F. & Ananvoranich, S. Comparative analysis of antisense RNA, double-
stranded RNA, and delta ribozyme-mediated gene regulation in Toxoplasma 
gondii. Antisense Nucleic Acid Drug Dev. 12, 275–81 (2002). 
264. Yu, L. et al. Toxoplasma gondii: siRNA can mediate the suppression of adenosine 
kinase expression. Exp. Parasitol. 118, 96–102 (2008). 
265. Kolev, N. G., Tschudi, C. & Ullu, E. RNA interference in protozoan parasites: 
achievements and challenges. Eukaryot. Cell 10, 1156–63 (2011). 
266. McRobert, L. & McConkey, G. A. RNA interference (RNAi) inhibits growth of 
Plasmodium falciparum. Mol. Biochem. Parasitol. 119, 273–278 (2002). 
267. Malhotra, P. et al. Double-stranded RNA-mediated gene silencing of cysteine 
proteases (falcipain-1 and -2) of Plasmodium falciparum. Mol. Microbiol. 45, 
1245–1254 (2002). 
146 BIBLIOGRAPHY  
 
268. Eksi, S., Czesny, B., Greenbaum, D. C., Bogyo, M. & Williamson, K. C. Targeted 
disruption of Plasmodium falciparum cysteine protease, falcipain 1, reduces 
oocyst production, not erythrocytic stage growth. Mol. Microbiol. 53, 243–250 
(2004). 
269. Sijwali, P. S. et al. Plasmodium falciparum cysteine protease falcipain-1 is not 
essential in erythrocytic stage malaria parasites. Proc. Natl. Acad. Sci. 101, 
8721–8726 (2004). 
270. Sijwali, P. S., Koo, J., Singh, N. & Rosenthal, P. J. Gene disruptions demonstrate 
independent roles for the four falcipain cysteine proteases of Plasmodium 
falciparum. Mol. Biochem. Parasitol. 150, 96–106 (2006). 
271. Mohmmed, A., Dasaradhi, P. V. N., Bhatnagar, R. K., Chauhan, V. S. & Malhotra, P. 
In vivo gene silencing in Plasmodium berghei--a mouse malaria model. Biochem. 
Biophys. Res. Commun. 309, 506–11 (2003). 
272. Schwentke, A. et al. In vitro and in vivo silencing of plasmodial dhs and eIf-5a 
genes in a putative, non-canonical RNAi-related pathway. BMC Microbiol. 12, 
107 (2012). 
273. Feynman, R. P. Cargo Cult Science. (1974). 
274. Franke-Fayard, B. et al. A Plasmodium berghei reference line that constitutively 
expresses GFP at a high level throughout the complete life cycle. Mol. Biochem. 
Parasitol. 137, 23–33 (2004). 
275. Ma, H. et al. Pol III Promoters to Express Small RNAs: Delineation of 
Transcription Initiation. Mol. Ther. Nucleic Acids 3, e161 (2014). 
276. Herrera-Carrillo, E., Harwig, A. & Berkhout, B. Toward optimization of 
AgoshRNA molecules that use a non-canonical RNAi pathway: variations in the 
top and bottom base pairs. RNA Biol. 12, 447–456 (2015). 
277. Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via 
multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 
82, 5887–911 (2008). 
278. Glasmacher, E. et al. Roquin binds inducible costimulator mRNA and effectors of 
mRNA decay to induce microRNA-independent post-transcriptional repression. 
Nat. Immunol. 11, 725–733 (2010). 
279. Kooij, T. W. A. A., Rauch, M. M. & Matuschewski, K. Expansion of experimental 
genetics approaches for Plasmodium berghei with versatile transfection vectors. 
Mol. Biochem. Parasitol. 185, 19–26 (2012). 
280. Hliscs, M., Nahar, C., Frischknecht, F., Matuschewski, K. & Frischknecht, F. 
Expression Profiling of Plasmodium berghei HSP70 Genes for Generation of 
Bright Red Fluorescent Parasites. PLoS One 8, e72771 (2013). 
281. Meister, G. Argonaute proteins: functional insights and emerging roles. Nat. Rev. 
Genet. 14, 447–459 (2013). 
282. Vembar, S. S., Scherf, A. & Siegel, T. N. Noncoding RNAs as emerging regulators 
of Plasmodium falciparum virulence gene expression. Curr. Opin. Microbiol. 20, 
153–61 (2014). 
283. Engwerda, C., Belnoue, E., Gruner, A. C. & Renia, L. Experimental models of 
cerebral malaria. Curr Top Microbiol Immunol 297, 103–143 (2005). 
284. Iwanaga, S. et al. Functional identification of the Plasmodium centromere and 
generation of a Plasmodium artificial chromosome. Cell Host Microbe 7, 245–
255 (2010). 
 147 
 
285. van Dijk, M. R. et al. Replication, expression and segregation of plasmid-borne 
DNA in genetically transformed malaria parasites. Mol. Biochem. Parasitol. 86, 
155–162 (1997). 
286. Dieci, G., Conti, A., Pagano, A. & Carnevali, D. Identification of RNA polymerase 
III-transcribed genes in eukaryotic genomes. Biochimica et Biophysica Acta - 
Gene Regulatory Mechanisms 1829, 296–305 (2013). 
287. Bawankar, P., Shaw, P. J., Sardana, R., Babar, P. H. & Patankar, S. 5’ and 3’ end 
modifications of spliceosomal RNAs in Plasmodium falciparum. Mol. Biol. Rep. 
37, 2125–33 (2010). 
288. Sidik, S. M., Hackett, C. G., Tran, F., Westwood, N. J. & Lourido, S. Efficient 
Genome Engineering of Toxoplasma gondii Using CRISPR/Cas9. PLoS One 9, 
e100450 (2014). 
289. Shen, B., Brown, K. M., Lee, T. D. & Sibley, L. D. Efficient Gene Disruption in 
Diverse Strains of Toxoplasma gondii Using CRISPR / CAS9. MBio 5, e01114-14 
(2014). 
290. Lee, M. C. & Fidock, D. A. CRISPR-mediated genome editing of Plasmodium 
falciparum malaria parasites. Genome Med. 6, 63 (2014). 
291. Deligianni, E. et al. A perforin-like protein mediates disruption of the 
erythrocyte membrane during egress of Plasmodium berghei male gametocytes. 
Cell. Microbiol. 15, 1438–1455 (2013). 
292. Wirth, C. C. et al. Perforin-like protein PPLP2 permeabilizes the red blood cell 
membrane during egress of Plasmodium falciparum gametocytes. Cell. 
Microbiol. 16, 709–33 (2014). 
293. Drew, D. R. & Reece, S. E. Development of reverse-transcription PCR techniques 
to analyse the density and sex ratio of gametocytes in genetically diverse 
Plasmodium chabaudi infections. Mol. Biochem. Parasitol. 156, 199–209 (2007). 
294. Beetsma, A. L., van de Wiel, T. J., Sauerwein, R. W. & Eling, W. M. Plasmodium 
berghei ANKA: purification of large numbers of infectious gametocytes. Exp. 
Parasitol. 88, 69–72 (1998). 
295. O’Donnell, R. A. et al. An alteration in concatameric structure is associated with 
efficient segregation of plasmids in transfected Plasmodium falciparum 
parasites. Nucleic Acids Res. 29, 716–24 (2001). 
296. Tucker, K. et al. in Current Topics in Malaria (ed. Rodriguez-Morales, A. J.) 
(InTech, 2016). doi:10.5772/65592 
297. Hall, R. et al. Antigens of the erythrocytes stages of the human malaria parasite 
Plasmodium falciparum detected by monoclonal antibodies. Mol. Biochem. 
Parasitol. 7, 247–265 (1983). 
298. Simmons, D., Woollett, G., Bergin-Cartwright, M., Kay, D. & Scaife, J. A malaria 
protein exported into a new compartment within the host erythrocyte. EMBO J. 
6, 485–491 (1987). 
299. Sanchez, G. I., Rogers, W. O., Mellouk, S. & Hoffman, S. L. Plasmodium falciparum: 
Exported Protein-1, a Blood-Stage Antigen, Is Expressed in Liver Stage Parasites. 
Exp. Parasitol. 79, 59–62 (1994). 
300. Lisewski, A. M. et al. Supergenomic network compression and the discovery of 
exp1 as a glutathione transferase inhibited by artesunate. Cell 158, 916–928 
(2014). 
 
148 BIBLIOGRAPHY  
 
301. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas 
nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013). 
302. Bozdech, Z. et al. The Transcriptome of the Intraerythrocytic Developmental 
Cycle of Plasmodium falciparum. PLoS Biol. 1, e5 (2003). 
303. Janse, C. J., Ramesar, J. & Waters, A. P. High-efficiency transfection and drug 
selection of genetically transformed blood stages of the rodent malaria parasite 
Plasmodium berghei. Nat. Protoc. 1, 346–356 (2006). 
304. Modrzynska, K. et al. A Knockout Screen of ApiAP2 Genes Reveals Networks of 
Interacting Transcriptional Regulators Controlling the Plasmodium Life Cycle. 
Cell Host Microbe 21, 11–22 (2017). 
305. Mair, G. R. et al. Universal Features of Post-Transcriptional Gene Regulation Are 
Critical for Plasmodium Zygote Development. PLoS Pathog. 6, e1000767 (2010). 
306. Khan, S. M. et al. Proteome analysis of separated male and female gametocytes 
reveals novel sex-specific Plasmodium biology. Cell 121, 675–687 (2005). 
307. Helm, S. et al. Identification and Characterization of a Liver Stage-Specific 
Promoter Region of the Malaria Parasite Plasmodium. PLoS One 5, e13653 
(2010). 
308. Das, S. et al. Processing of Plasmodium falciparum Merozoite Surface Protein 
MSP1 Activates a Spectrin-Binding Function Enabling Parasite Egress from 
RBCs. Cell Host Microbe 18, 433–444 (2015). 
309. De Niz, M. et al. In vivo and in vitro characterization of a Plasmodium liver 
stage-specific promoter. PLoS One 10, e0123473 (2015). 
310. De Niz, M. et al. In Vivo and In Vitro Characterization of a Plasmodium Liver 
Stage-Specific Promoter. PLoS One 10, e0123473 (2015). 
311. Sapolsky, R. Belief and Biology. Freeth. Today 20, (2003). 
312. Pollack, Y., Katzen, A. L., Spira, D. T. & Golenser, J. The genome of Plasmodium 
falciparum. I: DNA base composition. Nucleic Acids Res. 10, 539–46 (1982). 
313. Otto, T. D. et al. A comprehensive evaluation of rodent malaria parasite genomes 
and gene expression. BMC Biol. 12, 86 (2014). 
314. Hu, X. et al. Relative gene-silencing efficiencies of small interfering RNAs 
targeting sense and antisense transcripts from the same genetic locus. Nucleic 
Acids Res. 32, 4609–17 (2004). 
315. Hong, S. W., Jiang, Y., Kim, S., Li, C. J. & Lee, D. Target gene abundance contributes 
to the efficiency of siRNA-mediated gene silencing. Nucleic Acid Ther. 24, 192–8 
(2014). 
316. Dornseifer, S. et al. RNAi revised--target mRNA-dependent enhancement of gene 
silencing. Nucleic Acids Res. 43, 10623–32 (2015). 
317. Larsson, E., Sander, C. & Marks, D. mRNA turnover rate limits siRNA and 
microRNA efficacy. Mol. Syst. Biol. 6, 433 (2010). 
318. Fellmann, C. & Lowe, S. W. Stable RNA interference rules for silencing. Nat. Cell 
Biol. 16, 10–8 (2014). 
319. Suarez, C. et al. The Malarial Serine Protease SUB1 Plays an Essential Role in 
Parasite Liver Stage Development. PLoS Pathog. 9, e1003811 (2013). 
 
 149 
 
320. Börner, K. et al. Robust RNAi enhancement via human Argonaute-2 
overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res. 41, 
e199 (2013). 
321. Silva, P. A. G. C. et al. Translational Control of UIS4 Protein of the Host-Parasite 
Interface Is Mediated by the RNA Binding Protein Puf2 in Plasmodium berghei 
Sporozoites. PLoS One 11, e0147940 (2016). 
322. Silvie, O., Briquet, S., Müller, K., Manzoni, G. & Matuschewski, K. Post-
transcriptional silencing of UIS4 in P lasmodium berghei sporozoites is 
important for host switch. Mol. Microbiol. 91, 1200–1213 (2014). 
323. Tomas, A. M. et al. P25 and P28 proteins of the malaria ookinete surface have 
multiple and partially redundant functions. EMBO J. 20, 3975–3983 (2001). 
324. Pujol, F. M. et al. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-
Mediated Exclusion from Virus Assembly Sites. J. Virol. 90, 6709–23 (2016). 
325. Mohr, S. E., Smith, J. A., Shamu, C. E., Neumüller, R. A. & Perrimon, N. RNAi 
screening comes of age: improved techniques and complementary approaches. 
Nat. Rev. Mol. Cell Biol. 15, 591–600 (2014). 
326. Deitsch, K., Driskill, C. & Wellems, T. Transformation of malaria parasites by the 
spontaneous uptake and expression of DNA from human erythrocytes. Nucleic 
Acids Res. 29, 850–853 (2001). 
327. Lamonte, G. et al. Translocation of sickle cell erythrocyte MicroRNAs into 
Plasmodium falciparum inhibits parasite translation and contributes to malaria 
resistance. Cell Host Microbe 12, 187–199 (2012). 
328. Martins, Y. C. et al. Endothelin-1 Treatment Induces an Experimental Cerebral 
Malaria–Like Syndrome in C57BL/6 Mice Infected with Plasmodium berghei 
NK65. Am. J. Pathol. 186, 2957–2969 (2016). 
329. Amani, V. et al. Cloned lines of Plasmodium berghei ANKA differ in their abilities 
to induce experimental cerebral malaria. Infect. Immun. 66, 4093–9 (1998). 
330. Ozgur, S. & Stoecklin, G. Role of Rck-Pat1b binding in assembly of processing-
bodies. RNA Biol. 10, 528–539 (2013). 
331. Suk, K. et al. Reconstitution of human RNA interference in budding yeast. Nucleic 
Acids Res. 39, e43 (2011). 
332. Bunnik, E. M. et al. The mRNA-bound proteome of the human malaria parasite 
Plasmodium falciparum. Genome Biol. 17, 147 (2016). 
333. Musiyenko, A., Majumdar, T., Andrews, J., Adams, B. & Barik, S. PRMT1 
methylates the single Argonaute of Toxoplasma gondii and is important for the 
recruitment of Tudor nuclease for target RNA cleavage by antisense guide RNA. 
Cell. Microbiol. 14, 882–901 (2012). 
334. Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-
specific control of gene expression. Cell 152, 1173–1183 (2013). 
335. Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of 
transcription in eukaryotes. Cell 154, 442–451 (2013). 
336. Larson, M. H. et al. CRISPR interference (CRISPRi) for sequence-specific control 
of gene expression. Nat. Protoc. 8, 2180–96 (2013). 
337. Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9-based 
transcription factors. Nat. Methods 10, 973–6 (2013). 
150 BIBLIOGRAPHY  
 
338. Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. 
Nat. Methods 10, 977–9 (2013). 
339. Chen, B. et al. Dynamic imaging of genomic loci in living human cells by an 
optimized CRISPR/Cas system. Cell 155, 1479–91 (2013). 
340. Tsuji, M., Mattei, D., Nussenzweig, R. S., Eichinger, D. & Zavala, F. Demonstration 
of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol. 
Res. 80, 16–21 (1994). 
341. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. 
Nat. Methods 9, 676–682 (2012). 
342. Planck, M. The Meaning and Limits of Exact Science. Science (80-. ). 110, (1949). 
343. de Koning-Ward, T. F., Thomas, A. W., Waters, A. P. & Janse, C. J. Stable 
expression of green fluorescent protein in blood and mosquito stages of 
Plasmodium berghei. Mol. Biochem. Parasitol. 97, 247–252 (1998). 
344. Schürmann, N., Trabuco, L. G., Bender, C., Russell, R. B. & Grimm, D. Molecular 
dissection of human Argonaute proteins by DNA shuffling. Nat. Struct. Mol. Biol. 
20, 818–826 (2013). 
345. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred 
kilobases. Nat. Methods 6, 343–5 (2009). 
346. Pfaffl, M. W. A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Res. 29, e45 (2001). 
347. Grimm, D. Production methods for gene transfer vectors based on adeno-
associated virus serotypes. Methods 28, 146–157 (2002). 
348. Orr, R. Y., Philip, N. & Waters, A. P. Improved negative selection protocol for 
Plasmodium berghei in the rodent malarial model. Malar. J. 11, 103 (2012). 
349. Hoeijmakers, W., Bártfai, R. & Stunnenberg, H. Transcriptome analysis using 
RNA-Seq. Malar. Methods Mol. Biol. 923, 221–239 (2013). 
350. Kensche, P. R. et al. The nucleosome landscape of Plasmodium falciparum 
reveals chromatin architecture and dynamics of regulatory sequences. Nucleic 
Acids Res. 44, 2110–2124 (2015). 
351. Newton, I. Letter from Sir Isaac Newton to Robert Hooke. Historical Society of 
Pennsylvania (1675). 
 Acknowledgements 
My PhD thesis would not have been possible without the support of many 
different people. First, I would like to thank my PIs, Dr. Ann-Kristin Mueller and 
Dr. Dirk Grimm, for the opportunity to work on this fascinating project, their 
joint supervision and their supportive and helpful advice. It was great to be able 
to combine the expertise of two different labs from different fields in one 
project. I am also thankful for all the opportunities they gave me during the 
time of my PhD, for the conferences I could travel to, for sending me off to the 
Biology of Parasitism Summer school (greatest idea ever), and for setting up all 
collaborations I needed for my work.  
I am also for the expert guidance I received from the other members of my 
thesis advisory committee: Prof. Dr. Michael Lanzer, who is also my primary 
examiner, and Prof. Dr. Freddy Frischknecht. Both have been very helpful 
during the meetings and provided lots of good input into the progress of the 
work. They gave me valuable suggestions, not only scientifically, but also for my 
future career opportunities in the academic world. Last but not least, I 
appreciate having with Dr. Julien Bethúne another expert on RNAi in my 
defense committee.  
Few projects can be done alone, and thus I am thankful for the 
collaboration with Dr. Richard Bartfái and Sabine Fraschka from Radboud 
University, The Netherlands, who performed the RNA-Seq analysis of PbAgo2. 
The data they gathered provided a valuable new insight into my parasite line 
and I would not have been able to get this without their help. In addition, I want 
to thank Dr. Jude Przyborski and his student Matthias Diehl at the Philips 
University in Marburg, Germany, for their support with the P. falciparum work. 
Even though it was not successful, it was great to gain insight into working with 
this parasite. I also would like to thank Dr. Ben Berkhout and Elena Herrera 
Carrillo for their advice regarding the design of AgoshRNAs.  
I was very fortunate that I had the opportunity to supervise three great 
students to help my project. Daria (Krzikalla) did a great job in her Master 
thesis to optimize the AgoshRNA design, and helped to generate the first 
PbAgo2 line. Annika (Binder) supported me during her rotation with analyzing 
the first GFP knockdown I ever observed. Vera (Mitesser) finally imaged the 
lines PbAgo2.scr and PbAgo2.GFP2c in mosquito- and liver stages and, most 
importantly, generated the line PbLISP2Ago2 during her Master thesis. All of 
them were smart, hardworking, and enjoyable students, and made the success 
of my project a lot easier.  
 153 
 
I was lucky enough to be able to work in two labs. All of the members of the 
Grimm lab and the Mueller lab were very supportive, helpful, and friendly, and I 
thank all of them for being fun to work with. In the Mueller lab, I would like to 
especially acknowledge Kirsten (Heiss), who never refused when I asked for a 
favor, which helped me a lot to manage experiments in two labs in parallel. In 
the Grimm lab, I have to thank Anne (Herrmann), who helped me with 
experiments and discussions, cheered me up when experiments did not work 
as expected and constantly supplied chocolate. I also want to express my 
thanks to Ellen (Wiedtke) for keeping the lab running and for always providing 
me with cells when I needed some. This list wouldn’t be complete without some 
of the old members of the Grimm lab, Stefanie (Grosse), Elena (Senis Herrero) 
and Nina (Schürmann), who helped me to get started, to find all reagents, 
protocols and equipments in the lab, to deal with this crazy thing called PhD 
and who danced with me to Barbed Wire. Without their advice I would have 
made much more mistakes than I already did. Thanks also to Flo (rian Schmidt) 
for tons of scientific discussions and sharing the passion for science. Without 
him I would have never figured out Gibson cloning for Plasmodium. It is really 
awesome that, even though all of you moved on to a new adventure in your life, 
we are still in touch and maintain the friendship! 
I have to thank Mirko Singer from the Frischknecht group for the ImageJ 
macro he provided me, and his patience when I repeatedly asked him countless 
questions about microscopy. I also have to thank Christian Sommerauer, who 
bravely enough took care of the bulk of the mosquito breeding work. I am also 
grateful to Moya, who was probably the most excited person ever to proof-read 
my thesis, even though we barely knew each other.  
Doing a PhD is stressful, and I could not have done it without my friends 
and family. Franziska and Miriam, my oldest friends, were patient with me 
when I again was late or spontaneously had to cancel our weekends because of 
sudden lab work, were always ready for a phone call (although we should have 
phone calls much more often), and even if we meet less often than we should, it 
always feels like we have never been apart. Kathrin – who started my PhD with 
me and became an awesome flatmate and friend – was always there for a 
“Feierabend-Bier”, listened to my endless complaints when experiments failed 
and celebrated every successful result with me. I also want to thank Fabi, for his 
love and care through all the ups and downs of my PhD, for his patience when I 
was once again stressed and annoyed, and for staying with me for almost 6 
years now. Let’s tackle the next 6 years (and the next, and the next…)! Finally, I 
have to thank my parents for all the support I had during my studies and for 
being there for me whenever I needed them. Papa, von dir habe ich gelernt, 
frickelige kleine Dinge mit großem Perfektionismus zu tun, und dass man NIE 
etwas wegwirft. Mama, du hast mir systematisches, strukturiertes und 
zielorientiertes Arbeiten beigebracht, aber genauso, das Leben außerhalb der 
Arbeit zu genießen. Genau das sind die Eigenschaften, die man braucht, um 
einen PhD erfolgreich zu meistern. Ohne euch hätte ich es nicht geschafft!  
